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Abstract 
The metabolism of microbial communities is extremely complex, having contributions 
from multiple species as well as the host. The metabolome (the complete set of detectable 
small molecules in a given environment) offers a window into the culmination of these 
events. The goal of this thesis was to apply metabolomics to improve our understanding of 
the metabolism of microbial communities, with specific focus on the vaginal microbiota. 
A combination of analytical chemistry techniques were employed to profile the vaginal 
metabolome of women with a dysbiotic vaginal microbiota, termed Bacterial Vaginosis 
(BV). The vaginal metabolome was closely associated with bacterial diversity and women 
with BV had a distinct metabolic profile compared to healthy women (N= 131). A number 
of novel biomarkers were identified, the most sensitive and specific being gamma-
hydroxybutyrate (GHB) and 2-hydroxyisovalerate (2HV). These biomarkers were 
validated in three independent cohorts of diverse geographical locations and ethnicities. 
Correlations between the microbiota and metabolome identified putative microbe-product 
relationships, including production of GHB by Gardnerella vaginalis which was 
confirmed in vitro. Combining these data with meta-transcriptome information, 
metabolites could be linked to specific transcripts and microbes with increased confidence. 
The fibronectin binding capabilities of Lactobacillus iners, the most prevalent species in 
the vagina, was also investigated and confirmed. 
To extend the tools developed during investigations of the vaginal microbiota to other 
systems, a study of stool and plasma samples from children with severe acute malnutrition 
(SAM) was conducted. Although the stool microbiota and metabolome did not discriminate 
children with SAM from controls, a number of metabolites differed significantly in plasma. 
Most of these metabolites had not been associated with SAM previously, including 
oxylipins, 2C6-disaccharides, truncated fibrinopepetides, and heme. These metabolic 
perturbations provide novel insight into the pathogenesis of SAM, and could serve as 
predictors of mortality/recovery and enteropathy. This study also led to the development 
of a novel method to filter out salt cluster artefacts in LC-MS metabolomics data using 
mass defect filtering.  
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Collectively, these studies have demonstrated how analytical chemistry, computational 
biology and microbiology can be integrated to advance our understanding of the 
metabolism of the microbiome and identify novel biomarkers of disease.  
Keywords 
Metabolomics, microbiome, bacterial vaginosis, LC-MS, GC-MS, 16S rRNA gene 
sequencing, malnutrition 
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Chapter 1 
1 General Introduction 
1.1 The human microbiome  
The human microbiome can be considered our largest endocrine organ, with the 
abundance of approximately 10% of metabolites detected in blood significantly altered by 
microbial colonization1. Indeed, the number of microbial cells by far outnumbers the 
number of human cells, and the microbiome possess ~150 times more genes than 
humans2. Due to recent advances in next generation sequencing and analytical chemistry 
techniques, we are just now beginning to understand the contribution of microbial 
metabolism towards human health.  
1.2 Tools for studying microbial communities 
The most used tool to survey microbial community composition is 16S rRNA gene 
sequencing. The 16S ribosomal RNA is a component of the 30S small ribosomal subunit 
in bacteria and archaea. Woese and Fox3 were the first to use the rRNA gene to infer the 
phylogenetic relationship between organisms, using this approach to define the three 
domains of life. Due to its slow rate of evolution, this gene is highly conserved between 
species4 and therefore can be amplified via universal 16S primers. The presence of 
hypervariable regions within the 16S gene allows microbes to be distinguished from one-
another, most commonly down to the genus level, with speciation possible in some cases. 
Thus 16S primers universally amplify bacterial and archaeal DNA, while allowing some 
level of taxonomic classification of the microbes in a given community.  
 
The choice of hypervariable region depends upon the environment being surveyed. The 
V6 region is commonly applied to the vaginal environment as speciation of 
Lactobacillus, the most common genus in the vagina, is possible5–8. Conversely, the V4 
region has been shown to most accurately capture the microbial diversity of the gut 9,10. 
Alternative approaches attempt to amplify two variable regions across a constant region 
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such as V4-V5, however these approaches are not ideal due to a high rate of chimeric 
reads composed of two different genomes 11.  
 
There are numerous next-generation sequencing (NGS) platforms suitable for 16S 
sequencing purposes, with improvements being made continuously. The Illumina series 
of machines have recently become leaders in the field due to their unparallelled read 
depth, low error rate and ever increasing read length capabilities12. The Illumina 
platforms amplify DNA by incorporating adaptor sequences into their primer design, 
which are complementary to sequences on the Illumina flow cells13. Once DNA has 
annealed to the flow cells, PCR is then conducted by bridge amplification and sequences 
determined by incorporation of fluorescent nucleotides. To allow a large number of 
communities to be sequenced in a single NGS run, sample specific barcodes are also 
incorporated into the primer design14. With the advancement of this multiplexing 
technique, the number of samples that can be analyzed in a single run is limited only by 
read depth (the number of DNA amplicons that can be sequenced in a single run). 
 
Analyzing the data resulting from 16S experiments requires considerable computational 
expertise, and therefore a number of software packages have been developed specifically 
for 16S data. The most widely used  is QIIME (Quantitative Insights into Microbial 
Ecology)15. QIIME is a Python-based tool that provides a workflow for taxonomy 
assignment, statistical analysis and plotting of 16S data. Alternatively, many groups 
choose to develop in house pipelines to suit their specific needs. 
 
After data are acquired and sample specific barcodes have been removed, sequences are 
conventionally clustered by similarity into operational taxonomic units or OTUs. The 
percent cutoff for two sequences to be considered a single OTU is user defined, and is 
often set to 97% to allow speciation16. Taxonomy is then assigned based on sequence 
similarity using a variety of databases including the Ribosomal database project 
(https://rdp.cme.msu.edu/)17, Greengenes (http://greengenes.lbl.gov/)18, and/or Silva 
(http://www.arb-silva.de/)19, in addition to in-house curated databases.  
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To describe the composition of the microbiome, the concepts of alpha and beta diversity 
are commonly applied. Alpha diversity describes the diversity within a sample, and can 
be calculated by a number of different methods, the most common being the Shannon 
index, which takes into account both the number of OTUs present in a community and 
their eveness20. Conversely, beta diversity describes the diversity between microbial 
communities. Again there are a variety of methods employed to calculate beta diversity. 
The method used most often, developed and available in QIIME, is UniFrac. UniFrac is a 
distance metric that relies on both the taxonomic relationships between OTUs and the 
relative abundance of taxa within a sample (weighted UniFrac) to calculate the distances 
of samples from one another21. These distances can be visualized in 2D space in the form 
of phylogenetic trees, or in 3D space through the use of principal coordinate plots 
(PCoA). The separation of samples based on these trees or PCoA plots can then be used 
to infer the relationship between microbial composition and a given parameter, for 
example a disease state.  
 
Although UniFrac provides a useful way to visualize microbiome data, it is a relatively 
qualitative tool and provides little information about the specific organism(s) differing 
between a healthy and diseased state, for example. To answer this question, univariate 
statistics are required. This aim is non-trivial due to the compositional nature of NGS 
data, to which classical univariate statistics cannot be applied22–24. Compositional data is 
by definition constrained by an arbitrary constant sum, and therefore can only be 
expressed as proportions of this sum22. For example, a given NGS run will return a 
certain number of reads for each sample. This number on its own provides no biological 
information, as read number can be influenced by a variety of factors including the PCR 
efficiency and NGS platform read depth in addition to the original concentration of DNA 
in the sample24,25. Because all OTUs can only be expressed as a proportion of the total 
reads, no OTU is truly independent from another, rendering classical statistical methods 
invalid22. Various approaches have been undertaken to circumvent the compositional 
issue in microbiome data. The most widely used method is rarefaction, which normalizes 
the per sample read count to that of the sample with the fewest reads. In addition to 
discarding much of the reliable information from the experiment, this method results in a 
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high number of false positives26. Because most microbiome studies do not treat NGS as 
compositional, the literature is rife with irreproducible association between the 
microbiome and disease 24,27. 
 
An alternative approach is to apply methods developed specifically for compositional 
data stemming from geology where much of the data is also compositional24,28. Gloor et 
al 24 have adapted these methods specifically for NGS data to create a multi-purpose tool 
for statistical analysis of compositional sequencing data called ALDEx2 (ANOVA-Like 
Differential Expression)29,30. ALDEx2 applies the centered log ratio (clr) transformation ( 
[ln(x/g(x)] ), which renders values independent from one another and therefore 
appropriate for classical univariate statistics. It also treats the data as probability 
distributions rather than point estimates as the data in actuality represents only a random 
sampling of sequences in an environment, which vary upon replication. Finally, ALDEx2 
incorporates corrections for multiple testing, which are often overlooked by other 
methods. The ALDEx2 approach is applied throughout this thesis to identify differences 
in microbial communities between disease states as well as to evaluate correlations 
between the metabolome and NGS data. 
1.3 The vaginal microbiome 
1.3.1 Healthy vaginal microbiota 
A healthy vaginal microbiota is dominated by Lactobacillus species5–8, which possess a 
number of properties that benefit the host. Lactic acid, the main end product of anaerobic 
respiration by these organisms, lowers the pH of the vagina and protects against infections 
by pathogens31,32. In addition these bacteria can produce bacteriocins33 and hydrogen 
peroxide34,35 to further combat invading organisms, although the in vivo plausibility of the 
latter has been disputed32. Unlike the gut, where low microbial diversity is associated with 
diseases such as inflammatory bowel disease and obesity36–38, in the vagina low diversity 
is a hallmark of health5–7. Indeed, most women are dominated by a single Lactobacillus 
species, the most common being L. iners followed by L. crispatus. These species are 
uniquely adapted to the human vaginal tract and predominate irrespective of ethnicity, 
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geographical location, or pregnancy status5–8. L. iners is particularly unique, having the 
smallest genome of any Lactobacillus species reported to date, and possessing several 
components which make it ideally suited to the vaginal niche39. Despite its small genomic 
capacity, L. iners is able to persist fluctuations in community composition that occur during 
a condition known as bacterial vaginosis (BV), while L. crispatus does not5–8.   
1.3.2 Bacterial vaginosis 
Bacterial vaginosis is the most common vaginal condition in women, affecting an estimated 
30% at any given time40. This condition is characterized by an increase in microbial 
diversity with a concomitant decrease in the proportion and absolute abundance of 
lactobacilli5–8,41. The loss of lactic acid producing bacteria results in increased pH of the 
vagina along with increased risk of sexually transmitted infections such as HIV, gonorrhea, 
and chlamydia42–45. Women with BV are also more likely to experience pre-term labor, 
believed to be due in part to the immune response to these organisms46,47. Although some 
but not all women experience symptoms such as malodor due to production of biogenic 
amines48–50, many women with BV are asymptomatic5,7,40,51, making detection reliant on 
signs or symptoms unreliable.  
BV is a polymicrobial disease, meaning no single organisms causes the condition, rather it 
is the complex interaction of multiple species that causes dysbiosis. The most common 
bacteria associated with BV belong to the genus Gardnerella, Prevotella, Atopobium, 
Megasphaera, Sneathia, and Dialister 5–8. As mentioned previously, L. iners is also found 
in many patients with BV, raising questions of whether some clones may play a role in the 
condition, while others may align more with health.  The presence of L. iners may be 
important for recovery from BV, by being the lactobacilli that helps re-create a healthy 
environment39.  
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Figure 1-1.  The vaginal microbiota assessed by 16S rRNA gene sequencing.  
Each bar represents a single sample from a single woman and each color a different 
bacterial taxa. Samples were clustered by the similarity of the relative organism 
abundance and their similarity was visualized using a neighbor-joining tree. The major 
clusters are named after a taxa with a relative even abundance across samples in the 
cluster. The sample numbers are colored according to Nugent categories with BV = red, 
intermediate = green, normal = blue. Amsel criteria are shown for each sample with 
present = grey, absent = white and missing data = black. Figure taken from Hummelen 
et al 20107. 
Despite the prevalence of BV, the cause remains unknown. Furthermore, the diagnostic 
methods are imprecise, time consuming and have poor reliability. The current gold 
standard for BV diagnosis is known as the “Nugent Score”. This microscopy-based 
Figure 1. Relative abundance of taxa across samples. The composition of the microbiota was visualized by bar-plots. Samples were clustered
by the similarity of the relative organism abundance and their similarity was visualized using a neighbor-joining tree. The major clusters (.10
samples) are named after a taxa with a relative even abundance across samples in the cluster. The sample numbers are coloured according to Nugent
categories with BV= red, intermediate = green, normal = blue. Amsel criteria are shown for each sample with present = grey, absent = white and
missing data = black. The complete legend is given in figure S2.
doi:10.1371/journal.pone.0012078.g001
Figure 2. Association of vaginal pH and odor with members of the vaginal microbiota. The flow chart explaining the relationship between
microbiota and diagnostic criteria were generated using data mining techniques (Materials and Methods). To obtain the prediction about a clinical
sample, follow the arrows like a flow chart from the organisms (rectangular boxes) to the prediction (ovals). Each decision in the tree is split on the
proportion of the organism above; thus, if a clinical sample has proportions less than 13.6% L. crispatus and less than 48.8% of L. iners it is predicted
that the sample is taken from a vaginal environment with a pH$4.5. The accuracy of the decision tree is reported for the entire dataset and for 10-
folds cross validation, which is an attempt to estimate the accuracy of the decision tree on new clinical samples.
doi:10.1371/journal.pone.0012078.g002
Vaginal Microbiota in HIV
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technique defines BV as a score of 7-10 when low numbers of lactobacilli morphotypes 
are observed, and high numbers of short rods are present, which are presumed to represent 
BV associated bacteria52. Nugent Normal (N) is defined as a score of 1-3, indicating almost 
exclusively Lactobacillus morphotypes. Intermediate samples are given a score of 4-6 and 
do not fit into either group. As demonstrated in Figure 1-2, the high morphological 
variability of lactobacilli makes the identification of BV associated bacteria a non-trivial 
task. These analyses are also time consuming as they must be shipped to a central lab for 
processing.  
 
 
 
 
 
 
Figure 1-2. The morphology of lactobacilli are highly variable. Adapted from 
Veehelst et al 200553. 
An alternative diagnostic approach was developed by Amsel et al54 and is known as the 
Amsel criteria. This method relies on the presence of at least three of the following: i) 
vaginal pH > 4.5, ii) presence of “clue cells” (epithelial cells covered in dense biofilm 
of bacteria), iii) positive amine “whiff” test and iv)  abnormal discharge. The Amsel 
criteria is equally poor in identifying BV as a large proportion of women with BV are 
asymptomatic5,7,40,51.  
Given the stark contrast in microbial composition of women with with BV compared to 
healthy women, one would expect the metabolic by-products of these communities to differ 
significantly. This has been further emphasized by meta-transcriptomic studies 
demonstrating significant differences in gene expression of the community in BV55, 
suggesting the resulting small molecules could serve as accurate diagnostic biomarkers for 
the condition.     
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total of 136 isolates remained unidentified, since no cor-
responding tDNA-PCR fingerprint could be found in the
database or because no amplification was obtained. A
total of 72 species were identified, of which 17 belonged
to the genus Lactobacillus and six to the genus Bifidobacte-
rium (Table 1). The most common species recovered from
grade Ia, Ib and Iab specimens were lactobacilli. L. crispa-
tus (87.0%) and L. jensenii (22.2%) were the most abun-
dant bacteria in grade Ia samples, whereas L. gasseri
(32.0%) and L. iners (39.8%) were the most frequently
present species in grade Ib specimens. Grade I-like speci-
mens were found to contain mostly bifidobacteria
(54.9%) and L. gasseri (52.8), while L. crispatus was almost
absent (2.8%). In 19.8% of grade I-like specimens bifido-
bacteria were present while lactobacilli were absent. Bifi-
dobacteria were more frequent in grade I-like samples
than in other samples (χ2 = 120.6, p < 0.001, Table 2).
L. crispatus was present in 87.0% of grade Ia, 76.7% of
grade Iab and 37.5% of grade IV samples but in less than
13.3% in all other grades. L. crispatus was the only Lacto-
bacillus species that was linked to a single grade, namely
grade Ia (χ2 = 186.3, p < 0.001), while the other lactoba-
cilli were more evenly distributed over all samples (Table
3, 4, 5, 6). L. jensenii was the second most abundant spe-
cies in grade Ia (22.2%), but was also frequent in most
other grades, for example in 47.8% of grade II. L. vaginalis,
the third most abundant species in grade Ia (9.3%) was
absent from grade III and present in less than 20% of all
other grades. L. gasseri and L. iners were more abundant in
grade Ib (32.0 and 39.8%), grade I-like (52.8 and 19.4%),
grade II (54.3 and 26.1%) and grade III (9.1 and 31.8%)
than in grade Ia (6.8 and 3.7%).
The most characteristic cultured organisms in grade II and
grade III specimens were G. vaginalis (respectively 21.7%
and 72.7%) (χ2 = 120.6, p < 0.001, Table 7), Actinomyces
neuii (respectively 6.5% and 9.1%), Aerococcus christensenii
(respectively 4.3% and 22.7%), A. vaginae (respectively
4.3% and 13.6%), Finegoldia magna (respectively 2.2%
and 9.1%) and Varibaculum cambriense (respectively 2.2%
and 13.6%). These were virtually absent from grade I and
grade IV, although G. vaginalis was present in approxi-
mately 2.0% of grade I samples. L. jensenii (47.8%) and L.
gasseri (54.3%) were the most common lactobacilli in
grade II specimens. Furthermore, whereas L. crispatus and
L. vaginalis were never cultured from grade III specimens,
L. iners (31.8%) was the lactobacillus mostly present in
grade III. Mobiluncus curtisii and Peptostreptococcus sp. were
cultured from grade III specimens only (both 4.5%). Dial-
ister sp. (22.7%) and Prevotella spp. (22.6%) were
frequently cultured from grade III specimens and only
sporadically from other specimens.
Microscopic image (100 ×) of Gram-stained vaginal smears illustrating the different categories of v ginal microflora desc ibed:Figu e 1
Microscopic imag  (100 ×) f Gram-stained vaginal 
smears illustrating the different categories of vaginal 
microflora described:. a, b: grade Ia, i.e. mainly Lactobacil-
lus crispatus cell types, plump quite homogeneous lactobacilli. 
c, d: grade Ib, i.e. non-L. crispatus cell types, long or short, 
thin lactobacilli. e, f: grade Iab, i.e. containing mixtures of L. 
crispatus and non-L. crispatus cell types. g, h: grade I-like, i.e. 
irregular-shaped Gram positive rods. i, j: grade II, i.e. mixture 
of Lactobacillus cell types and bacterial vaginosis-associated 
bacteria (Gardnerella, Bacteroides-Prevotella and Mobiluncus cell 
types). k, l: grade III, i.e. bacterial vaginosis.
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1.4 Metabolomics 
The complete set of detectable small molecules in a given environment is known as the 
metabolome, and it’s study coined ‘metabolomics’ in alignment with other ‘omics’ 
technologies56. There are a number of different analytical tools to survey the metabolome, 
the most common being nuclear magnetic resonance (NMR) and mass-spectrometry 
(MS)57,58. The latter is usually coupled to a separation technique such as gas or liquid 
chromatography. Each method has its own advantages and disadvantages, and therefore a 
combination of techniques is ideal for most complete metabolite coverage58.  
 
NMR has been widely used for metabolomics due to its reproducibility and relative ease 
of compound identification57,58. Also, unlike MS based platforms, NMR is non-
destructive to the sample. However, the number of metabolites which can be resolved 
from a complex mixture by NMR is low in comparison to other technologies. This 
method also lacks the sensitivity of MS-based platforms, providing a survey of only the 
most abundant compounds in a sample.  
 
Gas-chromatography mass spectrometry (GC-MS), like NMR, is also prevalent due to the 
fact that compound identification is fairly straightforward57,58. GC-MS is also generally 
more sensitive than NMR. The caveat is that derivatization is usually required, which 
leads to degradation of samples over time. Sample preparation and data acquisition time 
for GC-MS is also quite long in comparison to its liquid chromatography counterpart. 
 
The final platform employed most often in metabolomics is liquid-chromatography mass-
spectrometry (LC-MS). This platform undoubtedly holds the most promise due to its 
unparalleled metabolite coverage and sensitivity57,58. Many different classes of 
metabolites can be detected by this method, from small organic acids, to lipids and even 
small peptides. Due to advances in ultra-high performance liquid chromatography 
(UHPLC), the data acquisition time is also quite short in comparison to GC-MS, and 
derivatization is usually not required. However, the bottleneck in analysis of LC-MS data 
is compound identification. Due to the diversity of molecules, limited databases, and poor 
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reproducibility between different methods and platforms, identification remains a very 
challenging and time consuming task.  
 
Regardless of the platform used, the workflow for data processing is similar between 
technologies, with the exception of the software, which differ between platforms and 
vendors (Figure 1-3). Briefly, samples are collected via a standardized approach and 
stored preferably at -80 °C. Metabolites are then extracted with various solvents 
depending on the classes of metabolites of interest. After extraction, data is acquired via 
NMR, GC-MS or LC-MS and a spectra (NMR) or chromatogram with corresponding MS 
spectra (GC-MS and LC-MS) is acquired for each sample. Data processing software are 
then used to combine files into a feature matrix containing the abundance of every feature 
in every sample. The definition of a “feature” differs for each platform. For NMR, spectra 
are usually divided into spectral bins, so each feature represents a ‘slice’ of the NMR 
spectra. For GC-MS, each feature represents a unique retention time and MS spectra, 
which equates to a single feature for each metabolite with some exceptions. For LC-MS, 
each feature represents a unique ion and retention time in the MS spectra. A given 
metabolite will have multiple isotopic peaks and can form adducts with salts such as 
sodium, and therefore the number of features by far exceeds the number of metabolites in 
an LC-MS experiment. After spectral processing, multivariate modelling methods such as 
principle component analysis (PCA) are used to visualize the relationships between 
samples based on the metabolome. Univariate statistics are then employed to determine 
features of interest, for example metabolites significantly altered by a disease state. 
Although many forms of software are available for these purposes, the majority of 
statistical analyses and plotting performed in this thesis were executed using the 
statistical computing programming language R (www.r-project.org)59. The final step in 
the pipeline is compound identification. Again identification differs by platform and 
usually takes advantage of several databases and software, including but not limited to 
the NIST (National Institute of Standards and Technology) (GC-MS)60, METLIN (LC-
MS)61, Chenomx (NMR)62, and many others. Of course, once metabolites have been 
identified they must put into biological context. Online pathway mapping tools such as 
Kegg (www.kegg.jp)63, Metacyc (www.metacyc.org)64, the Human Metabolome 
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Database (www.hmdb.ca)65 and others can be useful for this purpose. These databases are 
far from complete, especially for non-model organisms, and often review of the literature 
is the best method of determining the biological relevance of a metabolite.  
Although many variations of NMR, GC-MS and LC-MS exist, for the purposes of the 
thesis, the focus will be on the Agilent 7890A GC-5975 inert MSD GC-MS and Agilent 
1290 Infinity HPLC-Thermo Q-Exactive Orbitrap LC-MS systems as these were the main 
platform employed throughout the various chapters that follow. 
 
 
Figure 1-3. An overview of the steps involved in analysis of metabolomics data57.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Alonso et al. Analytical methods in untargeted metabolomics
In the present review, we will describe the processing and
analysis workflows that are commonly used in high-throughput
untargeted metabolomic studies. Untargeted metabolomic stud-
ies are characterized by the simultaneous measurement of a large
number of metabolites from each sample. This strategy, known
as top-down strategy, avoids the need for a prior specific hypoth-
esis on a particular set of metabolites and, instead, analyses the
global metabolomic profile. Consequently, these studies are char-
acterized by the generation of large amounts of data. This data
is not only characterized by its volume but also by its complexity
and, therefore, there is a need for high performance bioinformatic
tools. Conversely, targeted metabolomic studies are hypothesis-
driven experiments and are characterized by the measurement of
predefined sets of metabolites with a high level of precision and
accuracy. This low level of metabolite analysis is not in the scope
of this review, and interested readers are referred to other excellent
specific reviews (Roberts et al., 2012; Putri et al., 2013).
In Figure 2, we show the typical methodological pipeline of
an untargeted metabolomic study. This methodological pipeline
starts with the processing of the spectral data to generate the sam-
ple metabolic information (i.e., metabolic features). The different
methods available to process spectral data are revised in Section
“Spectral Processing.” Together with metabolite-identification
methods, spectral processingmethods are highly dependent on th
analytical technique used (e.g., NMR, LC-MS, or GC-MS). Once
the complete set of metabolomic features has been generated, uni-
variant and multivariant data analysis methods can be applied
to investigate: (a) the general structure of the metabolomics data
in the dataset and (b) how t different metabolic features are
related with the phenotypic data associated with the samples.
These analysis methods are reviewed in Section “Data Analysis.”
The analysis of metabolomic data can often be used to build mod-
els that attempt to describe the observed data. Section “Biomarker
Discovery in Metabolomics” of the present review describes the
different strategies for assessing the performance of these models.
In Section “Metabolite Identification and Spectral Databases,” we
address the important technical issue that is the identification of
the metabolites underlying the observed metabolic features (i.e.,
peak areas and spectral bins). The bioinformatic methods that are
actually available for the integration of metabolomic data accord-
ing with biological knowledge are reviewed in Section “Pathway
and Network Analysis of Metabolomic Data.” Finally, the differ-
ent methodologies that allow the integration of metabolomics
data with other omics data (e.g., genomics or transcriptomics) are
reviewed in Section “Integration of Omics Data.” Table 1 shows
a list of the freely available tools that are most commonly used
in metabolomic analysis. These tools provide different method-
ological options for spectral processing, data analysis, or pathway
analysis.
SPECTRAL PROCESSING
Spectral processing is a methodological approach aimed at accu-
rately identifying and quantifying the features in the sample spec-
tra of a metabolomics study (Figure 3). Metabolomic spectra
are sequentially or jointly processed until a final set of feature
quantifications is obtained. Spectral processing is also necessary
to guarantee that each final measurement will refer to the same
metab lomic f ature in all samples. The data resulting from spec-
tral processing is generally arranged in a feature quantification
matrix (FQM) that contains the quantification of the metabolic
features of all the analyzed samples and that will be used as input
for subsequent statistical analysis.
SPECTRAL PRE-PROCESSING
In order to improve the signal quality and reduce possible biases
present in the raw data, several pre-processing steps are usually
applied. In NMR- and MS-based spectra, baseline correction is
used to remove low frequency artifacts and differences between
FIGURE 2 | Analysis workflow in untargeted metabolomic studies. This figure shows the different steps of the metabolomic analysis pipeline.
www.frontiersin.org March 2015 | Volume 3 | Article 23 | 3
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1.4.1 GC-MS 
1.4.1.1 Hardware 
The Agilent 5975 GC-MS series consists of a 7890A GC coupled to as 5975 MSD mass 
spectrometer. A schematic of the system is illustrated in Figure 1-4. Samples are usually 
derivatized prior to injection to allow detection of compounds which are non-volatile in 
their native form. The most common derivatization reagents are alkylation, acylation and 
silylation reagents66. These chemicals replace hydrogens on N-H, O-H, and S-H groups 
with a non-polar group such as a trimethylsilyl. This reduction in polarity increases the 
volatility of compounds, allowing them to be detected by GC-MS. In solution, molecules 
with ketone or aldehydes such as carbohydrates undergo tautomerization (conversion 
between keto and enol form), resulting in a peak for each tautomer67. To simplify analysis 
of these kinds of molecules reagents which prevent tautomerization are often used in 
conjunction with a silylation reagent.  
 
After derivatization, samples are injected onto the GC column which is stored in a 
temperature controlled oven to allow volatilization of the molecules68. An inert carrier 
gas, most often helium, serves as the mobile phase and an adsorbent silica coated column 
as the stationary phase. Gaseous compounds are separated based on adsorption to the 
column and also based on their boiling point. By applying a temperature ramp to the 
column, chemicals with high boiling points such as disaccharides will elute later, whereas 
low boilers will elute earlier. After separation, gaseous molecules enter the ion source 
where they are ionized by electrons emitted from a heated filament69. This is known as 
electron ionization (EI), also known as electron impact. EI is a form of ‘hard’ ionization, 
in reference to the fact that fragmentation induced by this method is extensive, with the 
parent ion often undetectable in the resulting mass spectra. The ions then enter the 
quadrupole mass analyzer, which selects the mass range. The quadrupole consists of four 
parallel metal rods to which alternating and direct currents are applied to select a specific 
window of mass-to-charge ratios (m/z). Masses outside this window will collide with the 
quadrupole and not reach the detector. The type of detector employed by the Agilent 
model is known as an electron multiplier (EM). Specifically, the model used in this thesis 
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contains a triple axis detector which bends the ion beam at three axes to maximize the 
signal-to-noise ratio. When an ion hits the EM, it releases secondary electrons, 
amplifying (or multiplying) the original signal69. The current created by this amplification 
of electrons can then be measured, allowing for ion quantification. 
 
Figure 1-4 Schematic of the Agilent MSD GC-MS system70. 
1.4.1.2 Software 
There are various forms of software available to view raw data and combine individual 
GC-MS files into a feature list. The most widely used for viewing raw chromatograms 
and spectra is AMDIS (Automated Mass spectral Deconfolution and Identification 
System)71. AMDIS is a free, vendor-independent software for viewing GC-MS 
chromatograms and corresponding spectra. It also integrates and extracts GC-MS 
features, allowing the user to define the signal-to-noise ratio as well as other aspects of 
feature detection. Due to integration with the NIST database, the most widely used 
database for metabolite identification in GC-MS, metabolites can be easily identified 
within the AMDIS interface.  
 
Once features have been detected in AMDIS they need to be aligned across samples and 
converted into a feature list. Again there are multiple software available for this purpose. 
SpectConnect (http://spectconnect.mit.edu/)72 was chosen for its ease of use, and ability 
to be run independently through a command line interface, allowing for rapid analysis of 
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a large number of samples. The integration of this software with AMDIS also gives 
SpectConnect a considerable advantage over other software as each resulting feature 
represents a unique retention time and mass spectra. Other software most commonly 
return a separate feature for each ion within a spectra, exponentially increasing the 
amount of data generated and complicating feature identification. 
1.4.1.3 Compound identification 
Compounds detected by GC-MS are putatively identified based on MS spectra alone and 
then confirmed by authentic standards using both MS and retention time. The most 
widely used library of GC-MS spectra is the NIST Spectral Database. Due to the 
reproducible fragmentation of compounds by EI, and the relatively limited classes of 
molecules which can be ionized by this method, most compound can be confidently 
identified based on library comparison. Figure 1-5 shows an example of metabolite 
identification by comparison to the NIST database. The query spectra (red) is compared 
to the library spectra in blue. Attempts have been made to quantify the score of this 
library match, however they are often inaccurate. Currently, visual inspection of the 
match, combined with biological plausibility and validation with authentic standards 
remains the most reliable method of identification.   
 
Figure 1-5. Example of metabolite (gamma-aminobutyrate) identification by GC-MS 
using the NIST database.  
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The query spectra is on top in red, with the database spectra beneath in blue. 
Trimethylsilyl (TMS) groups are introduced during derivatization.  
 
1.4.2 LC-MS 
1.4.2.1 Hardware 
Unlike GC-MS, most molecules do not require derivatization to be detected by LC-MS, 
allowing for faster sample preparation and more stable extractions. Another key 
difference is that the LC and MS segments are manufactured independently in LC-MS, 
and therefore mixing segments from different vendor is common. The run times for LC-
MS can also be quite short in comparison to GC-MS (5 min vs 60 min respectively for 
methods used in this thesis). This is due to in part to advancements in HPLC/UHPLC. By 
combining small particle (< 2µm) packing material with high pressure (> 200 bar), 
superior resolution can be achieved in a short amount of time73. HPLC columns are 
coated with a packing material or stationary phase, the most widely used being octadecyl, 
also known as “C18”. C18 is a non-polar stationary phase, and is best suited to detect 
non-polar compounds, although detection of polar compounds is also possible. This is 
conventionally referred to as “reverse-phase” chromatography. In reverse phase, a polar 
mobile phase such as water is applied, followed by an organic phase, for example 
acetonitrile. In contrast, polar stationary phases such as HILIC (hydrophilic interaction 
liquid chromatography) are referred to as normal phase, but are less commonly used.  
 
Once molecules have been separated by HPLC, they enter the source where they are 
ionized by electrospray ionization (ESI). Ions are formed by applying high voltage to 
liquid passing through a capillary tube69. The resulting charged droplet will eventually 
break, creating the ‘electrospray’. By changing the voltage of the applied charge, 
positively or negatively charged ions are created. In contrast to EI, ESI is a known as a 
‘soft’ ionization technique because it does not usually induce fragmentation of the 
molecular ion.  
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The most common form of ionization are protonation [M+H] and deprotonation [M-H], 
however chemicals may ionize in a number of different ways, sometimes in an 
unpredictable manor. For positive ESI, the most common form of alternative ions are salt 
adducts such as [M+Na], [M+NH4] or [M+K]. For negative ESI, acids present in the 
mobile phase, such as formic acid, form the most common adducts ([M-HCOO]), as well 
as [M-Cl]. Additionally, molecules can be multiply charged if they possess multiple 
ionizable sites, such is the case with most peptides. In this case the observed ion will be 
smaller than the parent, as only the mass-to-charge ratio (m/z) of an ion can be measured 
by the mass spectrometer. 
 
Once the electrospray has been created, ions enter the mass spectrometer. A schematic of 
the Thermo Q-Exactive Orbitrap mass spectrometer, the model used throughout this 
thesis, is shown in Figure 1-6. Briefly, ions are guided into the quadrupole by a bent 
flatapole. The quadrupole then selects the range of m/z to be analyzed in the same fashion 
as was described for GC-MS. After mass selection, ions enter the C-trap which guides the 
ions into the orbitrap for mass detection. The orbitrap is a relatively new form of mass 
analyzer, having first been described in the year 2000 by Alexander Makarov74. It is 
composed of a barrel-shaped outer electrode and an inner spindle-shaped electrode. The 
ions oscillate around this spindle at a frequency that is proportional to their m/z, enabling 
mass detection with high accuracy. The orbitrap’s superior resolution and mass accuracy 
make it an ideal choice for untargeted metabolomics.     
 
The Q Exactive is capable of performing both ‘full MS’ and/or ‘MS/MS’ analyses, the 
choice of which is pre-set by the user. In full MS analysis, molecules are ionized and 
detected intact without fragmentation. This mode maximizes the sensitivity of the 
instrument and is therefore most useful for relative quantification of ions, but gives little 
information about the structure of compounds. Alternatively, MS/MS, also known as 
tandem mass spectrometry, provides information about the structure of the molecule at 
the expense of sensitivity. For MS/MS, ions selected by the C-Trap are sent into a 
collision cell (HCD cell) where they collide with neutral molecules of nitrogen gas, 
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inducing fragmentation of the molecular ion69. These fragments can then be used the 
piece together the structure of the parent molecule.  
 
Figure 1-6. Thermo Q-Exactive Orbitrap configuration75. 
1.4.2.2 Software 
As with GC-MS, a number of vendor-derived and open source software have been 
developed to view and analyze LC-MS metabolomics data. To view raw chromatograms 
and spectra, a vendor provided software is most commonly used. The Thermo Scientific 
software for LC-MS spectral viewing is called Xcaliber. This program allows one to view 
all ions in a given mass spectrum, as well as MS/MS of metabolites of interest. It is also 
useful for calculating molecular formulas, as well as adduct and neutral loss 
determination. Xcaliber is a low throughput program and is best suited to viewing a 
single or at most a handful of samples at a time. For this reason, other programs have 
been created to align and integrate multiple LC-MS files into a feature list which can then 
be used for multivariate modelling and statistical analysis. One of the most widely used 
tools for LC-MS feature alignment is XCMS76,77. XCMS is an open source software, and 
is compatible with a wide range of LC-MS platforms. One of the main advantages of 
XCMS over other software is that it is available as both an online point and click 
interface as well as a command line R package. The R version allows for rapid processing 
of a large number of samples and is highly adaptable compared to the online version. 
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XCMS also excels at identifying signal from noise in comparison to other available 
programs.   
1.4.2.3 Compound identification 
Compound identification remains the most challenging and time consuming aspect of 
untargeted LC-MS analysis. Even if a molecular formula can be assigned based on the 
m/z alone, there can be hundreds if not thousands of molecular species with the same 
formula. For this reason, the mass alone provides little information about the structure of 
the molecule. To confidently identify a metabolite, an MS/MS spectra must be acquired. 
This spectra can then be searched against an MS/MS databases, the largest being 
METLIN61. Although these databases can be extremely useful, they are far from 
complete, and an MS/MS spectra for the vast majority of known molecules cannot be 
found in any database. In these cases, molecules must be identified ‘de novo’ from the 
fragments present in the mass spectra. To help address this issue, fragmentation 
prediction tools such as CFM-ID78 have been created. These programs use machine 
learning algorithms to predict the MS/MS spectra of a known compound, or alternatively 
to predict the compound identity from an experimental MS/MS spectra. In many cases, 
neither of these approaches yield plausible identities and more advanced methods such as 
neutral loss and fragment matching must be used to piece together the putative structure. 
Ultimately, an MS/MS spectra of an authentic standard must be run to confirm the 
predicted identity, only then can one be confident in the annotation. 
1.5 Using metabolomics to characterize microbial communities 
The metabolome represents the end-products of both mammalian and microbial 
metabolism in a given community, providing a snapshot of all cellular processes in an 
environment. Given the complex interaction between bacterial species and with the host, 
metabolomics offers a unique window into the culmination of these interactions. Recent 
advances in processing of metabolomics and NGS data has now made it possible to 
combine these data to obtain a picture not only of “who is there”, but also “what they are 
producing”. Despite the capabilities of performing such experiments, these studies are 
still relatively rare due to their multidisciplinary nature, requiring biology, chemistry, and 
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computational expertise. Access to analytical chemistry platforms remains a formidable 
barrier, as metabolomics core facilities are still scarce, unlike their NGS counterpart. For 
this reason, most metabolomics analyses are contracted out on a fee for service basis. 
While this approach is attractive to groups lacking chemistry expertise, it is extremely 
costly. Furthermore, analysis is mainly restricted to targeted profiling as the time required 
to elucidate structures of unknown compounds would be far too expensive.  
 
Despite the infancy of the field, a number of studies have successfully applied 
metabolomics to improve our understanding of disease mechanisms, the microbiome, and 
to identify diagnostic biomarkers. A prime example is the discovery of the microbial-
mammalian co-metabolite trimethylamine N-oxide (TMAO) and its involvement in 
cardiovascular disease. In this work an untargeted study of metabolites linked to 
cardiovascular disease revealed a causal association between TMAO and atherosclerosis, 
elucidating a novel role for the microbiome in cardiovascular disease79–81. Another 
remarkable application for metabolomics is in surgery. Work by Takats and colleagues82 
have developed a mass spectrometry based surgical knife capable of accurately 
deciphering cancerous tissue from healthy in real time.  Finally, metabolomics has also 
been used to identify biomarkers that predict future disease onset such as development of 
mild cognitive impairment or Alzheimer’s disease83.  
1.6 Scope and objectives  
Upon commencement of my PhD studies, the concept of using metabolomics to 
characterize the function of microbial communities was relatively new. Indeed, there 
were few if any publications attempting this feat. The purpose of this thesis was therefore 
to develop the tools to analyze the metabolome of biological samples and integrate this 
data with microbiota profiles. The chapters that follow use these tools to advance 
understanding of the diseases under investigation and/or identify diagnostic biomarkers, 
with a focus on the vaginal microbiota and BV. 
 
Chapter 2 describes a clinical study of the vaginal metabolome and microbiota of 
Rwandan women. By combining mass spectrometry, NGS and in vitro analyses of 
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bacterial isolates I demonstrated that the vaginal microbiota shapes the chemical 
composition of the vagina, and identified highly specific biomarkers for BV. By 
correlating metabolites with the microbiota I was able to pinpoint the species responsible 
for producing one of these biomarkers and validated production in vitro. This work 
provides novel insight into the metabolism of the vaginal microbiota and identifies 
candidate biomarkers for BV. It is also one of the first to demonstrate that metabolomics 
can be used to identify previously unknown microbe-product relationships. 
 
Chapter 3 expands upon the second chapter, exploring what the bacteria are doing  in 
addition to which organisms are present by relating the bacterial meta-transcriptome and 
metabolome. Combining these data (the meta-transcriptome portion performed by Jean 
Macklaim, a former PhD student in our lab), we demonstrated that while both methods 
effectively separate women with BV from health, the information provided by each 
method is unique and complementary. This is the first study to combine meta-
transcriptomics and metabolomics, and provides valuable information about the kinds of 
questions that can and cannot be addressed using these approaches.  
 
In chapter 4, the persistence of L. iners is explored. Based on previous genome 
sequencing of an isolate of L. iners39, I hypothesized that this species had fibronectin 
binding capabilities. I demonstrated that L. iners is able to bind to fibronectin with high 
affinity and that this binding is protein mediated. Fibronectin binding is unique to L. iners 
in the vaginal environment, suggesting this may be one of the factors which allows it to 
persist under conditions of BV.  
 
The vaginal microbiota is a relatively simple community compared to the gut, as it is a 
closed system and contains fewer species. The goal of chapter 5 was therefore to apply 
the tools developed in the previous chapters to more complex biological matrices. This 
chapter describes a study of the stool microbiota and stool/plasma metabolome of 
Nigerian children with severe acute malnutrition (SAM). I demonstrated that the plasma 
metabolome, but not the stool metabolome or microbiota, discriminates children with 
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SAM from controls. Numerous metabolic perturbations in children with SAM were 
elucidated, providing novel insight into disease mechanisms and management. 
The final chapter stems from data generated in chapter 5 and details a method to filter out 
noise resulting from salts in LC-MS based human metabolomics data. Applying this filter 
will allow for more accurate annotation of the metabolome and decrease reporting of 
unknowns. 
 
Throughout this thesis I demonstrate the value of an untargeted metabolomics approach. 
Identifying novel associations between metabolites and disease, I illustrate how an 
untargeted metabolomics can be used to identify diagnostic biomarkers and generate new 
hypotheses regarding the microbiome and mechanisms of disease. 
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Chapter 2 
2 A multi-platform metabolomics approach identifies highly 
specific biomarkers of bacterial diversity in the vagina of 
pregnant and non-pregnant women 
This chapter is reproduced with permission (Appendix A) from:  
McMillan, A, Rulisa, S, Sumarah, M, Macklaim, JM, Renaud, J, Bisanz JE, Gloor JB, and 
G, Reid. (2015). A multi-platform metabolomics approach identifies highly specific 
biomarkers of bacterial diversity in the vagina of pregnant and non-pregnant women. 
Scientific Reports, 5: 14174. 
Supplemental material available for download at 
http://www.nature.com/articles/srep14174. 
2.1 Introduction 
The vaginal microbiota is dominated by Lactobacillus species in most women, 
predominantly by L. iners and L. crispatus1-3. When these lactobacilli are displaced or 
outnumbered by a group of mixed anaerobes, belonging to the genus Gardnerella, 
Prevotella, Atopobium and others, this increase in bacterial diversity is associated with 
bacterial vaginosis (BV)1-3. BV is the most common vaginal condition, affecting an 
estimated 30% of women at any given time4. While many women remain asymptomatic2-
5, when signs and symptoms do arise they include an elevated vaginal pH>4.5, discharge, 
and malodor due to amines6-8. BV is also associated with a number of comorbidities, 
including increased transmission and acquisition of HIV and other sexually transmitted 
infections9, and increased risk of preterm labour10. 
In most instances, diagnosis is dependent upon microscopy of vaginal samples to identify 
BV-like bacteria by morphology alone (Nugent Scoring11), or in combination with clinical 
signs (Amsel Criteria12). The precision and accuracy of these methods are poor due to the 
diverse morphology of vaginal bacteria, the observation that many women with BV are 
asymptomatic, and subjectivity in microscopic examination13-15. Misdiagnosis creates 
stress for the patient, delays appropriate intervention and places a financial burden on the 
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health care system. A rapid test based on stable, specific biomarkers for BV would improve 
diagnostic accuracy and speed, and reduce costs through improved patient management.  
The metabolome, defined as the complete set of small molecules in a given environment, 
has been studied in a variety of systems to identify biomarkers of disease16,17, and advance 
our understanding of how the microbiota contributes to host metabolism18. Using an 
untargeted multiplatform metabolomics approach, combined with 16S rRNA gene 
sequencing, we demonstrate that the vaginal metabolome is driven by bacterial diversity, 
and identify biomarkers of clinical BV that can be reproduced in a blinded validation 
cohort. We further demonstrate that Gardnerella vaginalis, which has long been thought 
to be an important contributor to BV, is the likely source of one of the most specific 
compounds, GHB. This work provides a foundation for improved detection of disease and 
demonstrates how metabolomics can be utilized to identify validated sources of metabolites 
in microbial communities. 
2.2 Materials and methods  
2.2.1 Clinical samples 
Premenopausal women between the ages of 18 and 55 were recruited at the University of 
Kigali Teaching Hospital (CHUK) and the Nyamata District Hospital in Rwanda. The 
Health Sciences Research Ethics Board at Western University, Canada, and the CHUK 
Ethics Committee, Rwanda granted ethical approval for all experiments involved in the 
study. The methods were carried out in accordance with the approved guidelines and all 
women provided written informed consent. Participants were excluded if they had reached 
menopause, had a current infection of gonorrhea, Chlamydia, genital warts, active genital 
herpes lesions, active syphilis, HIV, urinary tract infections, received drug therapy that 
may affect the vaginal microbiome, had unprotected sexual intercourse within the past 48 
hours, used a vaginal douche, genital deodorant or genital wipe in past 48 hours, had taken 
any probiotic supplement in past 48 hours, or were menstruating at time of clinical visit. 
As materials for sample collection were limited, we set out to obtain an equal number of 
women with and without Nugent BV to ensure the study would be powered to test for BV 
biomarkers. To accomplish this, only women with suspected BV were recruited after the 
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quota of Nugent N women was met. After reviewing details of the study, participants gave 
their signed consent before the start of the study. For metabolome analysis, sterile Dacron 
polyester-tipped swabs (BD) were pre-cut with sterilized scissors and weighed in 1.5 ml 
microcentrifuge tubes prior to sample collection. Using sterile forceps to clasp the pre-cut 
swabs, a nurse obtained vaginal samples for metabolomic analysis by rolling the swab 
against the mid-vaginal wall. A second full-length swab was obtained for Nugent Scoring 
and 16S rRNA gene sequencing using the same method. Nugent Scoring was performed at 
CHUK by Amy McMillan. Vaginal pH was measured using pH strips. Samples were frozen 
within 2 hours of collection and stored at -20 °C or below until analysis.  
2.2.2 Microbiome profiling 
Vaginal swabs for microbiome analysis were extracted using the QIAamp DNA stool mini 
kit (Qiagen) with the following modifications: swabs were vortexed in 1 mL buffer ASL 
before removal of the swab and addition of 200 mg of 0.1 mm zirconia/silica beads 
(Biospec Products). Samples were mixed vigorously for 2 x 30 seconds at full speed with 
cooling at room temperature between (Mini-BeadBeater; Biospec Products). After heating 
to 95 °C for 5 minutes, 1.2 ml of supernatant was aliquoted into a 2ml tube and one-half 
an inhibitEx tablet (Qiagen) was added to each sample. All other steps were performed as 
per the manufacturers’ instructions. Sample amplification for sequencing was carried out 
using the forward primer 
(ACACTCTTTCCCTACACGACGCTCTTCCGATCTnnnn(8)CWACGCGARGAACC
TTACC) and the reverse primer 
(CGGTCTCGGCATTCCTGCTGAACCGCTCTTCCGATCTn(12)ACRACACGAGCT
GACGAC) where nnnn indicates four randomly incorporated nucleotides, and (8) was a 
sample nucleotide specific barcode. The 5’ end is the adapter sequence for the Illumina 
MiSeq sequencer and the sequences following the barcode are complementary to the V6 
rRNA gene region. Amplification was carried out in 42 µL with each primer present at 0.8 
pMol/mL, 20 µL GoTaq hot start colorless master mix (Promega) and 2 µL extracted DNA. 
The PCR protocol was as follows: initial activation step at 95 °C for 2 minutes and 25 
cycles of 1 minute 95 °C, 1 minute 55 °C and 1 minute 72 °C. 
36 
 
All subsequent work was carried out at the London Regional Genomics Centre (LRGC, 
lrgc.ca, London, Ontario, Canada). Briefly, PCR products were quantified with a Qubit 2.0 
Flourometer and the high sensitivity dsDNA specific fluorescent probes (Life 
Technologies). Samples were mixed at equimolar concentrations and purified with the 
QIAquick PCR Purification kit (QIAGEN). Samples were paired-end sequenced on an 
Illumina Mi-Seq with the 600 cycle version 3 reagents with 2x220 cycles. Data was 
extracted from only the first read, since it spanned the entirety of the V6 region including 
the reverse primer and barcode 
Resulting reads were extracted and de-multiplexed using modifications of in-house Perl 
and UNIX-shell scripts with operational taxonomic units (OTUs) clustered at 97% identity, 
similar to our reported protocol48. Automated taxonomic assignments were carried out by 
examining best hits from comparison to the Ribosomal Database Project 
(rdp.cme.msu.edu) and manually curated by comparison to the Green genes database 
(greengenes.lbl.gov) and an in house database of vaginal sequences (Macklaim 
unpublished). Taxa with matches at least 95% similarity to query sequences were annotated 
as such. OTUs were summed to the genus level except for lactobacilli, and rare OTUs 
found at less than 0.5% abundance in any sample removed. Supplementary Table S1 
displays the nucleotide barcodes and their corresponding samples. Reads were deposited 
to the Short Read Archive (BioProject ID: PRJNA289672). To control for background 
contaminating sequences, a no-template control was also sequenced. Barplots were 
constructed with R {r-project.org } using proportional values.  
To avoid inappropriate statistical inferences made from compositional data, centered log-
ratios (clr), a method previously described by Aitchison49 and adapted to microbiome data 
was used with paired t-tests for comparisons of genus and species level data 27,28. The 
Benjamini Hochberg (False Discovery rate) method was used to control for multiple testing 
with a significance threshold of 0.1. All statistical analysis, unless otherwise indicated, was 
carried out using R (r-project.org). 
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2.2.3 Sample preparation GC-MS 
Vaginal swabs were pre-cut into 1.5 mL tubes and weighed prior to and after sample 
collection to determine the mass of vaginal fluid collected. After thawing, swabs were 
eluted in methanol-water (1:1) in 1.5 mL microcentrifuge tubes to a final concentration of 
50 mg vaginal fluid/mL, which corresponded to a volume ranging from 200-2696 µL, 
depending on the mass of vaginal fluid collected. A blank swab eluted in 800 µL methanol-
water was included as a negative control. All samples were vortexed for 10 s to extract 
metabolites, centrifuged for 5 min at 10 621 g, vortexed again for 10 s after which time the 
brushes were removed from tubes. Samples were centrifuged a final time for 10 min at 10 
621 g to pellet cells and 200 µL of the supernatant was transferred to a GC-MS vial. The 
remaining supernatant was stored at -80 °C for LC-MS analysis. Next, 2 µL of 1 mg/mL 
ribitol was added to each vial as an internal standard. Samples were then dried to 
completeness using a SpeedVac. After drying, 100 µL of 2% methoxyamine-HCl in 
pyridine (MOX) was added to each vial for derivatization and incubated at 50 °C for 90 
min. 100 µL N- Methyl-N-(trimethylsilyl) trifluoroacetamide (MSTFA) was then added 
and incubated at 50 °C for 30 min. Samples were then transferred to micro inserts before 
analysis by GC-MS (Agilent 7890A GC, 5975 inert MSD with triple axis detector). 1 µL 
of sample was injected using pulsed splitless mode into a 30 m DB5-MS column with 10 
m duraguard, diameter 0.35mm, thickness 0.25 µm (JNW Scientific). Helium was used as 
the carrier gas at a constant flow rate of 1 ml/min. Oven temperature was held at 70 °C for 
5 min then increased at a rate of 5 °C/min to 300 °C and held for 10 min. Solvent delay 
was set to 13 min to avoid solvent and a large lactate peak, and total run time was 61 min. 
Masses between 25 m/z and 600 m/z were selected by the detector. All samples were run 
in random order and a standard mix containing metabolites expected in samples was run 
multiple times throughout to ensure machine consistency. 
2.2.4 Data processing GC-MS 
Chromatogram files were deconvoluted and converted to ELU format using the AMDIS 
Mass Spectrometry software50, with the resolution set to high and sensitivity to medium. 
Chromatograms were then aligned and integrated using Spectconnect51 
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(http://spectconnect.mit.edu), with the support threshold set to low. All metabolites found 
in the blank swab, or believed to have originated from derivatization reagents were 
removed from analysis at this time. After removal of swab metabolites, the IS matrix from 
Spectconnect was transformed using the additive log ratio transformation (alr)49 and ribitol 
as a normalizing agent (log2(x) / log2(ribitol)). Zeros were replaced with two thirds the 
minimum detected value on a per metabolite basis prior to transformation. All further 
metabolite analysis was performed using these alr transformed values.  
Metabolites were initially identified by comparison to the NIST 11 standard reference 
database (http://www.nist.gov/srd/nist1a.cfm). Identities of metabolites of interest were 
then confirmed by authentic standards if available. 
2.2.5 Global metabolomic analysis 
In order to visualize trends in the metabolome as detected by GC-MS, principal component 
analysis (PCA) was performed using pareto scaling. To determine the percentage of 
variation in the metabolome that could be explained by a single variable we performed a 
series of partial least squares (PLS) regressions where each variable was used as a 
continuous latent variable. We tested every taxa, pH, Nugent score, pregnancy status, 
Shannon’s diversity index and sample ID and compared the percent variation explained by 
the first component of each PLS. The variable with the highest value was determined to be 
most closely associated with the metabolome (Shannon’s Diversity). Analysis was 
conducted in R using the PLS package and unit variance scaling. Jackknifing with 20% 
sample removal and 10 000 repetitions was then applied to determine 95% confidence 
intervals for each metabolite. Metabolites with confidence intervals that did not cross zero 
in both cohorts (pregnant and non-pregnant) were considered significantly associated with 
diversity. Heatmaps of significant metabolites were constructed using the heatmap.2 
function in R with average linkage hierarchical clustering and Manhattan distances. Unless 
specified otherwise, all tests for differential metabolites between groups were performed 
using unpaired t-test with a Benjamini-Hochberg (False Discovery Rate) significance 
threshold of p < 0.01 to account for multiple testing and multiple group comparisons.  
16S rRNA microbial gene profiles generate compositional data that interferes with many 
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standard statistical analyses, including determining correlations26-28. We used the 
aldex.corr function from the ALDEx2 package to calculate the Spearman’s rank correlation 
between each OTU abundance in 128 inferred technical replicates and that were 
transformed by center log-ratio transform27,28,49. Spearman’s rho values were converted to 
P values and corrected by the Benjamini-Hochberg procedure52 using the cor.test function 
in R. This approach is conceptually similar to that adopted by SPARCC26, but calculates 
the correlation between the OTU abundances and continuous metadata variables. Heatmaps 
of correlation p values were constructed using the heatmap.2 function in R with complete 
linkage hierarchical clustering and Euclidean distances. 
Odds ratios of metabolites to identify Nugent BV from Normal were calculated from 
conditional logistic regressions performed on all metabolites using the glm function in R 
with 10 000 iterations and a binomial distribution. Metabolites with 95 % CI > 1 and p < 
0.01 (unpaired t-test, Benjamini-Hochberg corrected) were determined to be significantly 
elevated in Nugent BV. “Nugent BV” was defined by the clinical definition of a score of 
7-10, with a score of 0-3 being “Nugent Normal”.  ROC curves and forest plots were built 
in R using the pROC and Gmisc packages respectively.   
2.3 Sample preparation LC-MS 
To confirm GC-MS findings, samples which had at least 100 µL remaining after GC-MS 
were also analyzed by LC-MS (N=107). 100 µL of supernatant was transferred to vials 
with microinserts and directly injected into an Agilent 1290 Infinity HPLC coupled to a Q-
Exactive Orbitrap mass spectrometer (Thermo Fisher Scientific) with a HESI source. For 
HPLC, 2 µL of each sample was injected into a ZORBAX Eclipse plus C18 2.1 x 50mm x 
1.6 micron column. Mobile phase (A) consisted of 0.1% formic acid in water and mobile 
phase (B) consisted of 0.1% formic acid in acetonitrile.  The initial composition of 100% 
(A) was held constant for 30 s and decreased to 0% over 3.0 min. Mobile phase A was then 
held at 0% for 1.5 minutes and returned to 100% over 30s for a total run time of 5 min.  
Full MS scanning between the ranges of m/z 50-750 was performed on all samples in both 
positive and negative mode at 140 000 resolution.  The HESI source was operated under 
the following conditions: respectively nitrogen flow of 25 and 15 arbitrary units for the 
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sheath and auxiliary gas, probe temperature and capillary temperature of 425 °C and 260 
°C,  and spray voltage of 4.8 kV and 3.9 kV in positive and negative mode.  The AGC 
target and maximum injection time were 3e6 and 500 ms respectively.  For molecular 
characterization, every tenth sample was also analyzed with a data dependent MS2 method 
where a 35 000 resolution full MS scan identified the top 10 signals above an 8.3e4 
threshold which were subsequently selected at a 1.2 m/z isolation window for MS2. 
Collision energy for MS2 was 24, resolution 17 500, AGC target 1e5 and maximum 
injection time was 60ms. Blanks of pure methanol were run between every sample to limit 
carryover, and a single sample was run multiple times with every batch to account for any 
machine inconsistency. A blank swab extract was also run as a negative control.  
For increased sensitivity, a separate LC-MS method was used for relative quantification of 
GHB in human samples. This was accomplished by selected ion monitoring in the mass 
range of 103.1 – 107.1 m/z in positive mode, and integrating the LC peak area of the 
[M+H+] ion (± 5 ppm). 
2.3.1 Data processing LC-MS 
After data acquisition Thermo .RAW files were converted to .MZML format using 
ProteoWizard53 and imported into MZmine 2.1154 (http://mzmine.sourceforge.net) for 
chromatogram alignment and deconvolution. Masses were detected using the Exact Mass 
setting and a threshold of 1E5. For Chromatogram Builder, minimum time was 0.05 min, 
minimum height 3E3, and m/z threshold set to 0.025 m/z or 8 ppm. Chromatogram 
deconvolution was achieved using the Noise Amplitude setting with the noise set to 5E4 
and signal to 1E5 for negative mode. Due to an overall greater signal and noise in positive 
mode, the noise was adjusted to 6E5 and signal to 6.5E5 for positive mode. Join aligner 
was used to combine deconvoluted chromatograms into a single file with the m/z threshold 
set to 0.05 m/z or 10 ppm, weight for m/z and RT set to 20 and 10 respectively, and a RT 
tolerance of 0.4 min.  After chromatograms were aligned, a single .CSV file was exported 
and all further analysis was carried out in R.  
To confirm metabolites identified as significant by GC-MS in the LC-MS data set, the 
masses of metabolites of interest were searched in the LC-MS data set, and identities 
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confirmed by MS2 using METLIN 55 and the Human Metabolome Database56 online 
resources. Standards of metabolites of interest were also run to confirm identities when 
available. An unpaired t-test with Benjamini-Hochberg correction was used to determine 
metabolites significantly different between Nugent BV and Normal in the LC-MS data set. 
Metabolites with corrected p < 0.05 were considered statistically significant.  Metabolites 
detected exclusively by LC-MS that have previously been associated with BV or health 
(lactate, trimethylamine) were also included in this analysis. Data was log base 10 
transformed prior to data analysis and zeros replaced by two thirds the minimum detected 
value on a per metabolite basis. To determine optimal cut points of biomarkers for 
diagnostic purposes, cut points were computed from LC-MS data using the 
OptimalCutpoints package in R57 and the Youden Index method.58  
2.3.2 Validation in blinded replication cohort 
Women between the ages of 18 and 40 were recruited from an antenatal clinic at the 
Nyerere Dispensary in Mwanza, Tanzania as part of a larger study on the effect of 
micronutrient supplemented probiotic yogurt on pregnancy. The Medical research 
Coordinating Committee of the National Institute for Medical Research (NIMR), as well 
as the Health Sciences Research Ethics Board at Western University granted approval for 
all experiments involved in the study. The methods were carried out in accordance with 
the approved guidelines and all women provided written informed consent. The study was 
registered with clinicaltrials.gov (NCT02021799). Samples were collected using the 
methods mentioned above, and Nugent scores performed by research technicians at NIMR 
in Mwanza, Tanzania. A subset of samples was selected based on these Nugent scores by 
a third party, who ensured there was not repeated sampling of any women. Amy McMillan, 
who performed metabolite analysis, was blinded to the Nugent scores for the duration of 
sample processing and data analysis. Biomarkers were quantified in samples by LC-MS 
using the protocols mentioned above. The study was unblinded after the submission of BV 
status based on the ratio cut points established in the Rwandan data set.  
2.3.3 Identification of putative GHB dehydrogenases in G. vaginalis  
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The protein sequence of a bona fide 4-hydroxybutyrate (GHB) dehydrogenase isolated 
from Clostridium kluyveri 29 (GI:347073) was blasted against all strains of G. vaginalis in 
the NCBI protein database. Blast results identified multiple isolates containing a putative 
protein with 44-46% identity to the GHB dehydrogenase from C. kluyveri. The strain used 
for in vitro experiments (G.vaginalis ATCC 14018) was not present in the NCBI protein 
database, however a nucleotide sequence in 14018 with 100% nucleotide identity to a 
putative 4-hydroxybutyrate dehydrogenases in strain ATCC 14019 (GI:311114893) was 
identified, indicating potential for GHB production by strain 14018. 
2.3.4 In vitro extraction of GHB from vaginal isolates 
Bacteria isolated from the vagina were difficult to grow consistently in liquid media. To 
circumvent this, a lawn of bacteria was plated and metabolites were extracted from agar 
punches. All strains were grown on Columbia Blood Agar (CBA) plates using 5% sheep’s 
blood for 96h under strict anaerobic conditions, with the exception of L. crispatus, which 
was grown on de Man Rogosa Sharp (MRS) agar for 48 h. To extract metabolites, 16 agar 
punches 5 mm in diameter were taken from each plate and suspended in 3 mL 1:1 Me:H20. 
Samples were then sonicated in a water bath sonicater for 1h, transferred to 1.5 ml tubes 
after vortexing and spun in a desktop microcentrifuge for 10 min at 10 621 g to pellet cells. 
200 µl of supernatant was then aliquoted for GC-MS described above. The area of each 
peak was integrated using ChemStation (Agilent) by selecting m/z 233 in the range of 14-
16 min. Initial peak width was set to 0.042 and initial threshold at 10. An authentic standard 
of GHB was run with samples to confirm identification. Succinate production by vaginal 
isolates was measured from the same GC-MS run, and quantified using Spectconnect as 
described above. Un-inoculated media was used as a control and experiments were 
repeated three times with technical duplicates.  
2.4 Results 
2.4.1 The vaginal metabolome is most correlated with bacterial diversity 
We completed a comprehensive untargeted metabolomic analysis of vaginal fluid in two 
cross-sectional cohorts of Rwandan women: pregnant (P, n=67) and non-pregnant (NP, 
43 
 
n=64) (Supplementary Table S1). To normalize the amount of sample collected, vaginal 
swabs were weighed prior to and after collection and normalized to equivalent 
concentrations. This enabled us to collect precise measurements of metabolites in vaginal 
fluid. Metabolite profiling was carried out using both gas chromatography-mass 
spectrometry (GC-MS) and liquid chromatography-mass spectrometry (LC-MS), and 
microbiota composition by 16S rRNA gene sequencing.  
The metabolome determined by GC-MS contained 128 metabolites (Supplementary Table 
S2). We conducted a series of partial least squares (PLS) regression analyses to determine 
the single variable that could best explain the variation in the metabolome. In both cohorts, 
the diversity of the microbiota, as measured using Shannon’s Diversity19, was the factor 
that explained the largest percent variation in the metabolome (Supplementary Table S3), 
demonstrating that the vaginal metabolome is most correlated with bacterial diversity 
(Figure 2-1). Metabolites robustly associated with this diversity (95% CI < or > 0)(Figure 
2-1) were determined by jackknifing, and within this group, metabolites associated with 
extreme diversity tended to have less variation in the jackknife replicates, and were 
common to both pregnant and non-pregnant women. This identified a core set of 
metabolites associated with diversity. 
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Figure 2-1. The vaginal metabolome is most correlated with bacterial diversity. 
 All analyses were carried out independently for non-pregnant (left) and pregnant (right) 
cohorts. Row (A) Partial least squares regression (PLS) scoreplot built from 128 
metabolites detected by GC-MS using bacterial diversity as a continuous latent variable. 
Each point represents a single woman (n=131). The position of points display 
similarities in the metabolome, with samples closest to one another being most similar. 
Circles are colored by diversity of the microbiota measured using Shannon’s diversity, 
where darker circles indicate higher diversity. Row (B) PLS regression loadings. Each 
point represents a single metabolite. Shaded circles indicate metabolites robustly 
associated with diversity in either cohort (Jackknifing, 95% CI < 0 > ). Shading of 
circles corresponds to the size of the confidence interval (CI) for each metabolite, where 
darker circles indicate narrower CIs. Venn diagram depicts overlap between metabolites 
associated with diversity in either cohort. Cad:Cadaverine, Tya:Tyramine, 
Put:Putrescine, MPh:Methylphosphate, 5AV:5-aminovalerate, HIC:2-
hydroxyisocaproate, HMV:2-hydroxy-3-methylvalerate, HV:2-hydroxyisovalerate, 
GHB: γ-hydroxybutyrate. Ser:serine, Asp:aspartate, Glu:glutamate, Gly:glycine, 
Tyr:tyrosine. NAcLys:n-acetyl-lysine, Phe:phenylalanine, Orn:ornithine. 
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The two cohorts overlapped by principal component analysis (PCA) (Supplementary Fig. 
S1), and no metabolites were significantly different between pregnant and non-pregnant 
women (unpaired t-test, Benjamini-Hochberg p > 0.01). Thus, the cohorts were combined 
for all further analysis. 
2.4.2 Metabolites and taxa associated with diversity 
A single PLS regression was performed on all samples with Shannon’s diversity as a 
continuous latent variable (Supplementary Fig. S2). Samples were then ordered by their 
position on the 1st component of this PLS. The diversity indices, microbiota and 
metabolites associated with diversity of PLS ordered samples are shown in Figure 2-2. The 
vaginal microbiota of Rwandan women were similar to women from other parts of the 
world, with the most abundant species being L. iners followed by L. crispatus1-3,20 (Figure 
2-2, Supplementary Table S4). Women with high bacterial diversity were dominated by a 
mixture of anaerobes, including Gardnerella, Prevotella, Sneathia, Atopobium, Dialister, 
and Megasphaera species. 
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Figure 2-2. Bacterial taxa and metabolites correlated with bacterial diversity in the 
vagina.  
Cohorts (non-pregnant and pregnant) were combined prior to analyses. Samples are 
ordered by their position on the first component (x-axis) of a partial least squares 
regression (PLS) built from metabolites using bacterial diversity as a continuous latent 
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variable (Supplementary Fig. S2). Diversity was calculated using Shannon’s diversity 
(A). Red dots indicate samples clearly misclassified by Nugent. Barplots (B) display the 
vaginal microbiota profiled using the V6 region of the 16S rRNA gene. Each bar 
represents a single sample from a single woman, and each colour a different bacterial 
taxa. (C) Nugent Score (black=7-10 (BV), dark grey=4-6 (Int), light grey=1-3 (N), 
white=ND) and pregnancy status (black=P, grey=NP). (D) Heatmap of GC-MS detected 
metabolites which were robustly associated with diversity in both cohorts (Jackknifing, 
95% CI <0>). Metabolites are clustered using average linkage hierarchical clustering. 
(E) Lactate and succinate abundance. Grey = ND. (*) indicates metabolites confirmed 
by authentic standards. 
2.4.3 Succinate is not associated with diversity or clinical BV, and is 
produced by L. crispatus 
Succinate and lactate abundance are shown in panel E of Figure 2-2.  Succinate levels, and 
the succinate:lactate ratio have historically been associated with BV21-23, and succinate has 
been postulated to play an immunomodulatory role23. Here we show that succinate is not 
associated with bacterial diversity, nor is it significantly elevated in clinical BV as defined 
by Nugent scoring. This trend was independent of the detection method used. In addition, 
succinate was elevated in women dominated by L. crispatus compared to L. iners-
dominated women (unpaired t-test, Benjamini-Hochberg p < 0.01) (Figure 2-3), indicating 
L. crispatus may produce succinate in vivo, a phenomenon that has been demonstrated in 
vitro24. We extracted metabolites from vaginal isolates grown on agar plates and confirmed 
that succinate is produced by L. crispatus in vitro, but not by L. iners ( 
). Succinate was also produced by Prevotella bivia, and Mobiluncus curtisii, but not by G. 
vaginalis. 
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Figure 2-3. Relative abundance of succinate in women dominated by L. crispatus, L. 
iners, or Nugent BV detected by GC-MS. 
 ( * ) p < 0.01, unpaired t-test, Benjamini-Hochberg corrected. 
 
Figure 2-4. Succinate production by vaginal isolates.  
Bacteria were grown on agar plates and succinate detected by GC-MS. Three biological 
replicates are shown in technical duplicate. CBA: Columbia Blood Agar, MRS: de Man 
Rogosa Sharpe Agar.  
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Supplementary Fig. S3. Relative abundance of succinate in women 
dominated by L. crispatus, L. iners or Nugent BV detected by GC-MS. 
( * ) p < 0.01, unpaired t-test, Benjamini-Hochberg corrected.
Supplementary Fig. S4. Succinate production by vaginal isolates. Bacteria 
were grown on agar plates and succinate detected by GC-MS. Three biological 
replicates are shown in technical duplicate. CBA: Columbia Blood Agar, MRS: de 
Man Rogosa Sharp Ag r. 
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Supplementary Fig. S3. Relative abundance of succinate in women 
dominated by L. crispatus, L. iners or Nugent BV detected by GC-MS. 
( * ) p < 0.01, unpaired t-test, Benjamini-Hochberg c rrected.
Supplementary Fig. S4. Succi ate production by vaginal isolates. Bact ria 
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Man Rogosa Sharp Agar. 
L. 
ine
rs
L. 
cr
isp
atu
s
P. 
biv
ia
M
. c
ur
tis
ii
G.
 va
gin
ali
s
CB
A 
co
nt
ro
l
M
RS
 co
nt
ro
l
1 2 3 4 5 6 7 8
0e
+0
0
2e
+0
8
4e
+0
8
Pe
ak
 A
re
a
1 2 3 4 5 7 8
0e
+0
0
2e
+0
8
4e
+0
8
6e
+0
8
R
el
at
iv
e 
A
bu
nd
an
ce
 (p
ea
k 
ar
ea
)
49 
 
2.4.4 Metabolites associated with diversity are sensitive and specific for 
clinical BV 
We defined clinical BV by the Nugent method, which is the current gold standard for BV 
diagnosis11. This microscopy-based technique defines BV as a score of 7-10 when low 
numbers of lactobacilli morphotypes are observed, and high numbers of short rods are 
present, which are presumed to represent BV associated bacteria. Nugent Normal (N) is 
defined as a score of 1-3, indicating almost exclusively Lactobacillus morphotypes. 
Intermediate samples are given a score of 4-6 and do not fit into either group. Although 
Nugent scores correlated well with bacterial diversity in our study, it was apparent from 
the microbiota and metabolome profiles that two samples (41 and 145) had clearly been 
misclassified by Nugent (Figure 2-2, red dots). The Nugent status of these samples was 
therefore corrected prior to further analyses.  
In total we identified 49 metabolites that were significantly different between clinical BV 
and N (unpaired t-test, Benjamini-Hochberg p < 0.01, Supplementary Table S2). We 
determined the odds ratio (OR) for BV based on conditional logistic regressions of all 
individual metabolites detected by GC-MS (Supplementary Table S2) to determine if the 
metabolites we associated with high bacterial diversity could accurately identify clinical 
BV as defined by Nugent scoring. Metabolites significantly elevated in Nugent BV 
(unpaired t-test, Benjamini-Hochberg p < 0.01) with OR > 1 are shown in Figure 2-5A. 
Succinate was included as a comparator, although it did not reach significance. Both GHB 
and 2HV were significantly higher in women with BV, and had OR > 2.0, demonstrating 
they are indicators not only of high bacterial diversity, but also clinical BV. Receiver 
operating characteristics (ROC) curves built from LC-MS data determined that high 2HV, 
high GHB, low lactate and low tyrosine were the most sensitive and specific biomarkers 
for BV, with the largest area under the curve (AUC) achieved using the ratio of 
2HV:tyrosine (AUC=0.993)(Figure 2-5B-D). ROC curves of GC-MS data identified 
similar trends, with the largest AUC achieved by the ratio of GHB:tyrosine (AUC=0.968) 
(Supplementary Table S6).  
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Figure 2-5. Comparison of biomarkers to identify Nugent BV from Nugent N. 
 (A) Odds ratios (OR) of metabolites with positive predictive value to identify Nugent 
BV. Bars represent 95% Confidence Intervals. Metabolites were detected by GC-MS 
and P values generated from unpaired t-tests with a Benjamini-Hochberg correction to 
account for multiple testing (p < 0.01). (*) indicates metabolites confirmed by authentic 
standards. (B) Receiver operating characteristic (ROC) curves of metabolite ratios to 
identify Nugent BV from Nugent N. Ratios with largest area under the curve (AUC) are 
shown, along with succinate:lactate as a comparator. (C) AUC of selected metabolite 
ratios to identify Nugent BV. (D) AUC of metabolites alone to identify Nugent BV. 
Panels B-D were built from LC-MS data. GHB:γ-hyroxybutyrate, 2-HV:2-
hydroxyisovalerate. 
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The optimal cut points for the GHB:tyrosine (0.621) and 2HV:tyrosine (0.882) ratios were 
determined by selecting values which maximized the sensitivity and specificity for BV. 
These cut points were generated excluding Nugent intermediate samples, however when 
cut points were applied to intermediates, they grouped equally with N or BV, and samples 
with smaller proportions of lactobacilli tended to group with BV (Figure 2-6). PCA of 
metabolite data verified that Nugent intermediate samples do not cluster separately from 
BV or N (Supplementary Fig. S1 C), indicating they are not a metabolically distinct group. 
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Figure 2-6. Biomarker cut points effectively group Nugent Intermediate samples as 
BV or N.  
Barplots display the vaginal microbiota of Rwandan women sorted by (A) 
GHB:tyrosine or (B) 2HV:tyrosine. Each bar represents a single sample from a single 
woman and each colour a different bacterial taxa. Nugent scores are indicated below 
barplots. Black lines indicate ratio cut point for Nugent BV. Ratios were calculated from 
LC-MS data. 
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2.4.5 Validation of biomarkers in a blinded replication cohort from 
Tanzania 
We validated these biomarkers in a blinded cohort of 45 pregnant women from Mwanza, 
Tanzania.25 Using the 2HV:tyrosine cut point identified in the Rwanda data set, we 
identified Nugent BV with 89% sensitivity and 94% specificity in the validation set 
(AUC=0.946), demonstrating our findings are reproducible in an ethnically distinct 
population (Figure 2-7, Supplementary Table S7). The GHB:tyrosine ratio cut point was 
slightly less specific (88%), with an AUC of 0.948. We confirmed that succinate was not 
significantly different between Nugent N and BV in the validation set, nor was the 
succinate:lactate ratio. 
 
Figure 2-7. Biomarker validation in a blinded replication cohort of 45 women from 
Tanzania.  
(A) BV status as defined by Nugent Score or ratio cut points identified in the Rwandan 
discovery data set. Black=BV,  Gray=N. (B) Heatmap of ratio values. (C) ROC curves 
and AUC of ratios to identify Nugent BV from N in the validation set. 2HV: 2-
hydroxyisovalerate, GHB: γ-hydroxybutyrate, Tyr: tyrosine. 
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2.4.6 Identification of G. vaginalis as a producer of GHB 
Correlations between metabolites and the OTU abundances were performed using a 
method that took into account both the compositional nature of 16S rRNA gene survey data 
and the technical variation26-28. Metabolites and taxa which contained any correlation 
below a Benjamini-Hochberg corrected p < 0.01 are displayed as a heatmap in Figure 2-8. 
Tyramine, putrescine, and cadaverine were most correlated with Dialister (Spearman’s R 
= 0.54, 0.51, 0.61, p < 0.001) (Supplementary Table S8), indicating this genus may 
contribute to malodor. GHB was most correlated with G. vaginalis (Spearman’s R = 0.56, 
p < 0.001), while 2HV was most correlated with Dialister, Prevotella, and Gardnerella 
(Spearman’s R = 0.55, 0.48, 0.47, p < 0.001). 
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Figure 2-8. Correlations between metabolites and taxa which are robust to random 
sampling of the underlying data.  
P values (Benjamini-Hochberg corrected) of Spearman’s correlations are plotted on a 
log scale. The sign of each p value corresponds to the directionality of the correlation. 
Only metabolites and taxa for which any p values are < 0.01 are displayed. 
The correlation between GHB and G. vaginalis was investigated since this was an 
unexpected metabolite that was predictive for both Shannon’s diversity and Nugent BV. 
Examination of available genomes showed that many strains of G. vaginalis possess a 
putative GHB dehydrogenase (annotated as 4-hydroxybutyrate dehydrogenase). 
Metabolites were extracted from bacterial colonies grown on agar plates and reproducibly 
detected GHB in G. vaginalis extracts well above control levels (unpaired t-test, p< 0.05), 
but did not detect GHB from other species commonly associated with BV (Figure 2-9, 
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Supplementary Table S9). These data suggest that G. vaginalis is the primary source of 
GHB detected in vivo. 
 
Figure 2-9. GHB is produced by Gardnerella vaginalis.  
GHB was extracted from bacteria grown on agar plates and detected by GC-MS. Values 
from three independent experiments are shown where each point was generated from an 
average of technical duplicates. * p < 0.05, unpaired t-test. 
2.5 Discussion 
We have demonstrated that alterations in the vaginal metabolome are driven by bacterial 
diversity in both pregnant and non-pregnant Rwandan women, and identified 2HV and 
GHB as highly specific biomarkers of clinical BV, the latter of which we attribute to 
production by G. vaginalis. Extremely accurate results were obtained by controlling for the 
mass of vaginal fluid collected, however we recognize this may not be logistically possible 
in a clinical setting. To circumvent this need, biomarkers were expressed as ratios to the 
amino acid tyrosine, which we identified as the most differential amino acid in health 
(Supplementary Table S2). Using optimal cut points of these ratios we predicted 91% of 
Nugent BVs in a blinded replication cohort, demonstrating the reproducibility of our 
findings. These cut points also accurately classified Nugent intermediate samples into 
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groups with similar microbiota profiles dominated by either lactobacilli (N) or anaerobes 
(BV). 
Although we demonstrated production of GHB by G. vaginalis, it is important to note that 
no single organism has been identified as the cause of BV, and G. vaginalis is present in 
many women with a lactobacilli-dominated microbiota. However, GHB is metabolized 
from succinate in other bacteria29,30, suggesting a similar pathway could exist in G. 
vaginalis. Succinate-producing genera may therefore be required, making G. vaginalis 
essential, but not sufficient for GHB production in the vagina. This remains to be tested. 
The predominant pathway for succinate production in bacteria is from pyruvate via 
anaerobic respiration. The genes for this pathway are expressed in vivo and differentiate 
BV from N31. Srinivasan et al32recently proposed an alternate pathway whereby succinate 
is produced from putrescine via gamma-aminobutyric acid (GABA). Although this 
pathway is plausible, it is unlikely given many of the enzymes are either not expressed in 
vivo or are absent from the genomes of common vaginal organisms31.  
Despite previous findings that succinate is elevated in BV21-23,32 , it was not differential in 
our study. This unexpected outcome is likely a result of normalizing sample weights prior 
to analysis, used to ensure the most consistent measurements of metabolites. Succinate was 
one of the most abundant metabolites detected in vaginal fluid in our study (Supplementary 
Table. S2), and was present in nearly all samples regardless of BV status. The universal 
presence of succinate make it more susceptible to dilution effects compared to GHB and 
2HV, which were less abundant and below our detection limit in many non-BV samples. 
Other groups have reported large ranges in succinate abundance in women with BV21,22, or 
used pooled samples22, which could account for additional disparities in results. 
Differences in succinate abundance may have been more pronounced in previous studies 
if there were a lack of L. crispatus-dominated women, which our data demonstrate is a 
succinate producer (Figure 2-3 
). L. crispatus contains all the enzymes necessary to produce succinate from malate with 
the exception of malate dehydrogenase (MDH). However, the pathway is annotated as 
complete at http://biocyc.org/LCRI491076-HMP/missing-rxns.html, with the closely 
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related enzyme lactate dehydrogenase (LDH). As there is increased expression of 
succinate-producing pathways during BV30, it is probable that large amounts are produced 
initially, but then rapidly converted to other compounds, such as GHB, by the microbiota 
and/or host.  
In addition to GHB, 2HV was identified as a highly specific biomarker for BV. 2HV is 
produced from breakdown of branched chain amino acids in humans34 and some bacteria35-
37. When the trend for amino acid depletion in BV is considered, these findings suggest 
increased amino acid catabolism in this condition. Some of these amino acids are converted 
to the amines cadaverine, tyramine, and putrescine, which are also associated with BV. 
These odor-causing compounds were most correlated with Dialister. Yeoman et al.38 also 
linked amines to Dialister species, and the decarboxylating genes required for amine 
production are expressed by this genus in vivo30. These data strongly suggest that Dialister 
is one of the genera responsible for malodor in the vagina. Given the small proportion of 
this genus in women with BV (0.2-8% in our study), this emphasizes the need for functional 
characterizations of the microbiome using metabolomic and transcriptomic approaches. 
The taxa that constitute the vaginal microbiota are highly conserved across different 
populations 1-3,20,39, although prevalence of certain taxa differs between ethnicities 1,39. 
These observations lead us to believe that GHB, 2HV and their tyrosine ratios will be 
globally applicable for the diagnosis of BV. Our ability to replicate findings in a distinct 
population strongly supports this theory. Srinivasan et al.32 concurrently identified elevated 
GHB in the vaginal fluid of American women with BV33, however they were not able to 
replicate this result in a second cohort. This could be due in part to the use of cervicovaginal 
lavages for sample collection or the use of different detection methods between cohorts. 
2HV (annotated as alpha-hydroxyisovalerate) was also identified as differential in their 
study, but was not tested in the replication cohort. These observations further validate our 
findings and demonstrate these biomarkers are robust to the effects of dilution.  
The exact role, if any, of GHB and 2HV in the etiology of BV is unknown. Systemically 
GHB has both inhibitory and excitatory effects through activation of the GABA(B) and 
perhaps GABA(A) receptors in the brain, resulting in stimulatory and sedative effects if 
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taken at high doses40-42. The effects of GHB at other sites remain elusive. Future work 
should attempt to elucidate biological function of GHB and other novel metabolites to 
determine what effect (if any) they have on lactobacilli and the vaginal environment. 
Although we did not identify any metabolites that differed significantly between pregnant 
and non-pregnant women, it should be noted that patient selection was biased to include an 
even number of women with and without Nugent BV. Our study was not designed to test 
if the metabolome differed during pregnancy, but rather if the metabolic signatures of BV 
were similar between pregnant and non-pregnant women. Other groups have noted 
decreased bacterial diversity during pregnancy and across gestational age43-45. These 
observations suggest differences in the metabolome of pregnant women would be 
observable in a larger randomly sampled population, and may include elevated levels of 
metabolites associated with low diversity such as amino acids. 
In summary, we have demonstrated using an untargeted, multiplatform approach that 
differences in the vaginal metabolome are driven by bacterial diversity. Other metabolomic 
studies have focused on symptom-associated metabolites32,38, changes after treatment46, or 
longitudinal changes in a few subjects47, and included exclusively non-pregnant women. 
Several highly specific biomarkers were identified for clinical BV that are independent of 
pregnancy status, and we replicated this result in a blinded cohort. By combining high-
throughput sequencing with advanced mass spectrometry techniques we have shown how 
in vivo metabolite information can be used to identify validated sources of metabolic end 
products in bacterial communities. These techniques can be applied to many systems where 
organisms may be fastidious or difficult to culture, and provide a much-needed link 
between microbial composition and function. 
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Chapter 3 
3 Integration of the vaginal metabolome and bacterial meta-
transcriptome of Canadian women 
3.1 Introduction 
A number of approaches are employed to characterize the function of microbial 
communities. This includes classical microbiology methods where organisms are studied 
in isolation, as well as in vivo investigations of communities using 16S sequencing, meta-
genomics, meta-transcriptomics, proteomics and/or metabolomics. Each of these 
techniques provides unique and complementary information, however they are rarely 
examined together. We have demonstrated previously in two independent studies that the 
bacterial meta-transcriptome and metabolome of women with BV are distinct from healthy 
women1,2. How these two datasets relate to one another in the context of the vaginal 
microbiota, or any microbial community for that matter, is not well understood.  
The purpose of this chapter was two-fold. Firstly, we wished to replicate the Rwandan 
study in Canadian women to determine if GHB and 2HV are consistent markers of BV 
across geographical locations and ethnicities. Secondly, we attempted to, for the first time 
relate the bacterial meta-transcriptome and metabolome, and demonstrate how these very 
distinct types of data can be integrated to gain improved insight into microbial 
communities. 
3.2 Materials and methods 
3.2.1 Study design and sample collection 
This study was approved by the Health Sciences Research Ethics Board (REB) at The 
University of Western Ontario, REB number 18203E. Vaginal samples were collected from 
two clinics in London, Ontario, Canada: Victoria Family Medicine, and the 
Middlesex-London Health Unit. Participants were excluded from the study if they had 
reached menopause, had a urogenital infection other than BV in the past 6 months, were 
pregnant, had a history of gonorrhea, chlamydia, estrogen-dependent neoplasia, abnormal 
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renal function or pyelonephritis, were taking prednisone, immunosuppressives or 
antimicrobial medication, or had undiagnosed abnormal vaginal bleeding. Participants 
were asked to refrain from oral or vaginal intercourse and consuming probiotic 
supplements or foods for 48 hours prior to the clinical visit. No participants were 
menstruating at time of the clinical visit. After reviewing details of the study, participants 
gave their signed informed consent before the start of the study. Four Cytobrush swabs 
(Cooper Surgical) were collected from each participant by rolling against the mid-vaginal 
wall and used as follows: 1) immediately smeared onto a glass slide and left to dry for 
Gram staining and Nugent scoring, 2) immediately suspended in RNAprotect (Qiagen) 
containing 100 ug/ml rifampicin, 3 and 4) swabs were placed in an empty 1.5ml Eppendorf 
tube and frozen at -20 for later DNA and metabolite isolation.  
3.2.2 DNA isolation, PCR amplification, and sequencing  
Vaginal swabs for DNA microbiome analysis were extracted using the QIAamp DNA stool 
mini kit (Qiagen) with the following modifications: swabs were vortexed in 1 mL buffer 
ASL before removal of the swab and addition of 200 mg of 0.1 mm zirconia/silica beads 
(Biospec Products). Samples were shaken vigorously (Mini-BeadBeater; Biospec 
Products) for 2 x 30 seconds at full speed with cooling at room temperature between. After 
heating to 95 °C for 5 minutes, 1.2 ml of supernatant was aliquoted into a 2ml tube and 
one-half an inhibitEx tablet (Qiagen) was added to each sample. All other steps were 
performed as per the manufacturer's instructions. DNA amplification for sequencing was 
carried out using the forward primer 5’ C 
CATCTCATCCCTGCGTGTCTCCGACTCAGn 
nnnnC[W]ACGCGA[R]GAACCTTACC 3’ and the reverse primer 5’ C 
CTCTCTATGGGCAGTCGGTGATA C[R]ACACGAGCTGACGAC 3’. The forward 
primer contained an Ion Torrent adapter (bolded), followed by a 5-mer unique sequence 
barcode (specific to each sample), and then sequence complementary to the V6 rRNA gene 
region. The reverse primer contains the Ion Torrent adapter (bolded), followed by sequence 
complementary to the V6 rRNA gene region.Amplification was carried out in 42 µL with 
each primer present at 0.8 pMol/mL, 20 µL GoTaq hot start colorless master mix (Promega) 
and 2 µL extracted DNA. The PCR protocol was as follows: initial activation of Taq 
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mastermix at 95°C for 2 minutes, followed by the addition of template and primers, then 
25 cycles of 1 minute 95°C, 1 minute 55°C and 1 minute 72°C.  
PCR products were quantified with a Qubit 2.0 Fluorometer and the high sensitivity 
dsDNA specific fluorescent probes (Life Technologies). Samples were mixed at equimolar 
concentrations and purified with the QIAquick PCR Purification kit (QIAGEN).Library 
preparation and sequencing was performed at the London Regional Genomics Institute 
(LRCG), in London, Canada. Samples were sequenced across 3 different runs (316 chips), 
and computationally pooled for analysis.  
3.2.3 16S sequence analysis  
De-multiplexed and pooled reads (using in-house BASH and Perl scripts) were clustered 
into operational taxonomic units (OTUs) at a 97% ID using UClust 
(uclust3.0.617_i86darwin32). OTUs were kept if they represented >1% of the reads in any 
one sample. Taxonomic assignment was completed by comparing the representative 
sequence for each OTU to our curated V6 vaginal database via BLAST, and confirmed by 
the ribosomal database project (RDP) seqmatch tool3.  
3.2.4 Meta-transcriptome analysis 
Sample preparation and data analyses were performed according to the methods of 
Macklaim et al 20131. Briefly, RNA was extracted by TRIzol (Invitrogen), and rRNA 
depleted using MICROBEExpress (Ambion). Extracted RNA was then DNAse treated and 
sent to the Toronto Center for Applied Genomics (TCAG) for library preparation and 
sequencing by Illumina Hi-seq.  
Sequences were clustered into representative sequences (refseqs) by sequence identity 
(95% nucleotide identity over 90% sequence length) and mapped to a reference database 
which included all partial or complete genomes from vaginal isolates in the NCBI database. 
Amino acid translations of predicted coding sequences were then used to assign SEED 
subsystems or Kegg Orthology (KO) functions. Differential expression was assessed by 
ALDEx2 Wilcoxon tests. A Benjamini-Hochberg corrected (FDR) p value < 0.05 was 
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considered statistically significant. Compositional biplots were constructed as reported by 
Gloor et al 20164,5.  
3.2.5 Sample preparation GC-MS. 
Samples were collected from the mid-vaginal wall using the Cytobrush vaginal brush and 
sterile forceps, and stored at -80 C until analysis. Vaginal brushes were pre-cut into 1.5 mL 
tubes and weighed prior to and after sample collection to determine the mass of vaginal 
fluid collected. After thawing, brushes were eluted in methanol-water (1:1) to a final 
concentration of 0.05 g/mL. This corresponded to a volume of 200-1500 µL, depending on 
the mass of vaginal fluid collected. Four control swabs were included which consisted of 
blank swabs eluted in 200, 400, 800, or 1500 µL of methanol-water. Samples and controls 
were vortexed for 10 sec to extract metabolites, centrifuged for 5 min at 10 000 rpm, 
vortexed again for 10 sec after which time the brushes were removed from tubes. Samples 
were centrifuged a final time to pellet cells and 150 µL of supernatant transferred to GC-
MS vials. Remaining supernatant was transferred to a new 1.5 mL tube, frozen at -80 C 
and shipped to the University of Reading for NMR analysis. Next, 25 µL of 0.2 mg/ml 
ribitol standard was added to each GC-MS vial. Samples were then dried to completeness 
using a SpeedVac. After drying 100 µL of 2% methoxyamine•HCl in pyridine (MOX) was 
added to each sample for derivatization and samples were incubated at 500C for 90 min. 
100 µL N-Methyl-N-(trimethylsilyl) trifluoroacetamide (MSTFA) was then added to each 
vial and incubated at 500C for 30 min. After derivatization, an equal aliquot of each sample 
was combined to make the quality control (QC). Samples were then transferred to micro 
inserts before analysis by GC-MS (Agilent 7890A GC, 5975 inert MSD with triple axis 
detector). 1 µL of sample was injected using pulsed splitless mode into a 30 m DB5-MS 
column with 10 m duraguard, diameter 0.35mm, thickness 0.25 µm (JNW Scientific). 
Helium was used as the carrier gas at a constant flow rate of 1 mL/min. Oven temperature 
was held at 70 °C for 5 min then increased at a rate of 5 °C/min to 300 °C and held for 10 
min. Solvent delay was set to 13 min to avoid solvent and a large lactate peak, and total 
run time was 61 min. Masses between 25 m/z and 600 m/z were selected by the detector. 
All samples were run in random order and the QC was run multiple times throughout the 
run to ensure machine consistency.  
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3.2.6 Data analysis GC-MS. 
Chromatogram files were de-convoluted and converted to ELU format using the AMDIS6 
mass spectrometry software with the sensitivity set to medium. Chromatograms were then 
aligned and integrated using Spectconnect7 software with the support threshold set to low. 
All metabolites found in the blank swab, or believed to have originated from derivatization 
reagents were removed from analysis at this time. After removal of swab metabolites, the 
IS matrix from Spectconnect was transformed using the additive log ratio transformation 
(alr)8 and ribitol as a normalizing agent (log2(x) / log2(ribitol)). Zeros were replaced with 
two thirds the minimum detected value on a per metabolite basis prior to transformation. 
All further metabolite analysis was performed using these alr transformed values.  
A total of 90 metabolites were detected by GC-MS. Upon manual inspection it was 
determined that 50 of these metabolites were either redundant, background noise or present 
in controls, and therefore they were removed from analysis. For redundant peaks, the sum 
of each peak was combined resulting in a single value for each metabolite. Metabolites 
were initially identified by comparison to the NIST 11 standard reference database 
(http://www.nist.gov/srd/nist1a.cfm). Identities of metabolites of interest were then 
confirmed by authentic standards if available.  
Independent Wilcoxon tests with a Benjamini-Hochberg false discovery rate (FDR)9 
correction to account for multiple testing were used to determine metabolites that differed 
significantly between healthy and BV (p < 0.10.). Groups were defined as healthy or BV 
using a percentage Lactobacillus cutoff of 75 %. 
3.2.7 Sample preparation NMR. 
Spectra were processed according to the methods of Swann et al 201110 with the following 
modifications. 1H NMR spectra were manually corrected for phase and baseline distortions 
and then referenced to the TSP resonance δ 0.0. Spectra were digitized using an in-house 
MATLAB(version R2009b, The Mathworks, Inc.; Natwick, MA) script. To prevent 
baseline effects that arise from imperfect water saturation the region containing the water 
resonance was excised. An in-house peak alignment algorithm was then performed on each 
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spectrum in MATLAB to adjust for shifts in peak position due to small pH differences 
between samples and then each spectrum was normalized using a sum normalization 
approach.  Principal components analysis (PCA) using pareto scaling was applied in 
SIMCA (Umetrics, Umea). Orthogonal projection to latent structure discriminant analysis 
(OPLS-DA) models were constructed using unit variance scaling to aid the interpretation 
of the model and distinguish the metabolites that differed between the groups. Here, 1H 
NMR spectroscopic data were used as the descriptor matrix and class information (N or 
BV) as the response variable. The contribution of each variable (metabolite) to sample 
classification was visualized by back-scaling transformation, generating a correlation 
coefficient plot. These coefficient plots are colored according to the significance of 
correlation to “class” (e.g. N or BV), with red indicating high significance and blue 
indicating low significance. The direction and degree of the signals relate to covariation of 
the metabolites with the classes in the model. For all models, one orthogonal component 
was used to remove systematic variation unrelated to class. Predictive performance was 
assessed using the Q2^Y parameter.  
3.2.8 Correlations between transcriptome and metabolome 
The expected value of Kendall’s Tau was used when reporting the correlation between 
transcript abundance and metabolite abundance since it is not expected that the 
metabolome and meta-transcriptome tables share even passingly similar units or scaling11. 
Spearman’s correlations were used when reporting correlations between between 16S 
proportions and transcripts (refseqs or KOs). All analyses were conducted in R using clr 
transformed values for compositional data (16S and transcriptome) with Benjamini-
Hochberg corrections to account for multiple hypothesis testing.  
3.3 Results 
3.3.1 The vaginal microbiota of Canadian women 
Forty-one women were recruited to the study initially, for which 16S and metabolome data 
was obtained (data not shown). From these 41 original samples, 24 were selected for meta-
transcriptome analysis. Selection aimed to obtain an equal representation of biota types and 
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also included several unique profiles, for example subject 013B who was dominated nearly 
completely by Atopobium vaginae (Error! Reference source not found.A). Four samples 
from previously published work, for which transcriptome but not 16S data was obtained1, 
were also included (Samples 30S, 4S, 31S and 27S, Figure 3-1B). 
Consistent with previous studies, the vaginal microbiota of healthy Canadian woman was 
dominated by either L. iners or L. crispatus (Error! Reference source not found.A). There 
was also one women dominated by L. jensenii. Women with BV were dominated by 
mixture of anaerobes including members of the genera Gardnerella, Prevotella, 
Megasphaera, Atopobium, 
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Dialister, Sneathia, as well as a recently identified taxa putatively designated BV 
associated bacteria 1 (BVAB1)12,13 (Error! Reference source not found.A).  Although all 
of these taxa were identified in Rwandan dataset, women with BV from Rwanda tended to 
have a larger proportion of Sneathia compared to Canadian women, while women with BV 
from Canada tended to be dominated more often by Megasphaera. BVAB1 was also more 
prevalent in Canadian women compared to Rwandan (data not shown).  
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Figure 3-1. Taxonomic barplots and clustered heatmap of meta-transcriptome 
expression.  
Taxonomic distribution by genus of each sample as a fraction of total reads are shown 
for V6 16S rDNA (panel A) and for the mapped mRNA reads (panel B). Reads 
belonging to the Lactobacillus genus are plotted by species-level assignment where 
possible. Nugent status and presence of corresponding metabolite samples (used for 
later analysis) are indicated. 16S sequence data are not available for the samples from 
the previous dataset, indicated with an “S” designation in the sample ID1. Samples were 
clustered based on their relative SEED subsystem 4 (subsys4) expression, where a 
subsystem represents a set of functional roles that together implement a specific 
biological process or structural complex (panel C, heatmap and dendrogram). Complete 
linkage clustering was then used to draw the dendrogram based on Euclidean distances 
between the zero-replaced, clr-transformed subsys4 counts (the relative expression). 
The four major groups are identified on the plot as health-associated group 1 (H1) and 
group 2 (H2), and BV-associated group 1 (BV1) and group 2 (BV2). Data and figure 
generated by Jean Macklaim. 
 
3.3.2 The vaginal metabolome of Canadian women 
To determine if the biomarkers of health and BV identified in the Rwandan dataset could 
be replicated in Canadian women, we performed an untargeted metabolomic analysis of 
vaginal fluid using GC-MS (Error! Reference source not found.A) and NMR (Figure 
3-3). LC-MS was not available at the time of study commencement. The majority of 
metabolites discriminating BV from health were consistent with the Rwandan study, 
including GHB, 2HV, 2-hydroxyisocaproate, 2-hydroxyglutarate, cadaverine, 
trimethylamine, and tyramine. Succinate was weakly associated with BV by NMR (Figure 
3-3), but was not significant by GC-MS (Error! Reference source not found.A). 
Metabolites associated with health included amino acids and lactate, as was found in 
Rwandan women. Due to differences in sampling methods between studies, samples were 
less concentrated in the Canadian study, and therefore some of the low level biomarkers 
identified in Rwandan women, such as tyrosine, were not detected in Canadian samples.  
Although the majority of the metabolites differing significantly between women with BV 
and health were consistent between studies, there were some inconsistencies. Mainly, a 
number of sugars were significantly increased in women with BV from Canada, including 
glucose, maltose, and fructose, and were confirmed by both GC-MS (Figure 4-1A) and 
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NMR (Figure 3-3). This was not the case for Rwandan women.
 
Figure 3-2. The vaginal metabolome of Canadian women analyzed by GC-MS.  
A. Heatmap depicting abundance of metabolites in samples. Dendrogram above shows 
distances (dissimilarity) between samples based on complete linkage hierarchical 
clustering of metabolites. B. Barplots of relative abundance of bacterial species, genera, 
or families in each corresponding sample as determined by 16S rRNA gene sequencing.
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Figure 3-3. The vaginal metabolome of Canadian women analyzed by NMR.  
Correlation coefficient plot was extracted from orthogonal projection to latent 
structures-discriminatory analysis (OPLS-DA). Metabolites pointing upwards or 
downwards are elevated in BV or H respectively. Peak color reflects the correlation 
between each peak and the condition, with red indicating stronger correlations. The 
direction and degree of the signals relate to covariation of the metabolites with the 
classes (BV or H) in the model. (Q2Ŷ=0.82). 
 
3.3.3 The bacterial meta-transcriptome identifies subtypes of BV and health 
To visualize the relationship between samples based on the meta-transcriptome, samples 
were clustered based on SEED subsystem 4 (subsys4) expression profiles, where a 
subsystem represents a set of functional roles that together implement a specific biological 
process or structural complex14. Analysis of expression profiles (performed by Jean 
Macklaim) identified four distinct microbiota subtypes, two associated with health and two 
associated with BV (Figure 3-1C). The first H1 group was composed largely of L. crispatus 
by both the 16S rRNA gene sequencing and the mRNA fraction mapping. The second 
group, H2, was composed largely of a mixed set of Lactobacillus species, often dominated 
by L. iners in total abundance, but with a substantial gene expression contribution from L. 
jensenii, L. gasseri or unknown Lactobacillus sp. The BV1 group contained a substantial 
amount of the unclassified BVAB1 organism by 16S rRNA gene sequencing and had a 
large gene expression contribution from Sneathia sp, and also contained the largest 
contribution of expression from de-novo assembled contigs. These contigs were assigned 
to the BVAB1 group color in the figure. The final group, BV2, had only a small amount of 
BVAB1, and a generally larger amount of Atopobium sp. by 16S rRNA gene profiling, and 
a very small or absent contribution to gene expression by Sneathia and BVAB1. Samples 
that did not fit into these groups mostly exhibited atypical profiles and were therefore 
removed from further meta-transcriptome and metabolome analysis. One of these outliers, 
sample 019A, was particularly interesting as this subject was classified as clinically BV by 
Nugent scoring despite being completely dominated by L. iners (Figure 3-1). The 
metabolome of this sample also clustered with BV samples by both NMR and GC-MS 
(data not shown). 
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3.3.4 Integrating the meta-transcriptome and metabolome 
To determine if microbiota subtypes identified through meta-transcriptome analysis were 
also metabolically distinct, the relationship between samples based on principle 
component analysis (PCA) of the metabolome were examined (Figure 3-4A). A clear 
separation was observed between BV and H by both methods, confirming the 
metabolome of women with BV is distinct from healthy women. Unlike the SEED 
subsys4 meta-transcriptome data, the microbiota subtypes did not separate clearly by 
metabolome, nor were there any metabolites that differed significantly between BV 
subtypes as measured by GC-MS (Wilcox test, Benjamini-Hochberg p > 0.1).  
 
To visualize the relationship between the meta-transcriptome and metabolome, 
correlations between metabolite abundance and the position of samples on biplots built 
from SEED subsys4 meta-transcriptomic data were calculated. These correlations were 
then scaled by the axis of the biplots and metabolites plotted according to their scaled 
positions (Figure 3-4B). As expected, amino acids and lactate were correlated with the 
positions of healthy samples, while organic acids, amines and monosaccharides were 
correlated with positions of BV samples.  
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Figure 3-4. Correlation between metabolite abundance and microbial function.  
A. Principal component analysis (PCA) scoreplots of vaginal metabolome as detected 
by GC-MS (left) or NMR (right). Each point represents a single sample from a single 
women colored according to their microbiota subtype. Positions of points display 
dissimilarities in the metabolome, with points furthest from one another being most 
dissimilar. B. Correlations between metabolite abundance and positions of samples on 
compositional biplots built from meta-transcriptomic data. Each point represents a 
single SEED subsys4 function, with the positions of samples based on the relative 
abundance of these functions within samples. Correlations between metabolites and 
sample positions were scaled by the first and second component of the biplots, and 
metabolites plotted according to their scaled position. Only metabolites that differed 
significantly between BV and health are shown. GHB: gamma-hydroxybutyrate, 2HG: 
2-hydroxyglutarate, 2HIC: 2-hydroxyisocaproate, PhLa: phenyllactate, Tyr: tyramine, 
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Cad: cadaverine, Pip: pipecolate, Gluc: glucose, Malt: maltose, Fruc: fructose, U: 
unknown, TMA: trimethylamine, Lact: lactate, Acet: acetate, Form: formate, 2HV: 2-
hydroxyisovalerate, Chol: choline, Succ: succinate. 
 
We next attempted to correlate individual metabolites and transcripts (Kegg Orthology 
(KO))15 to identify transcripts and taxa which could be involved in metabolite production. 
Cadaverine was chosen to investigate further as the bacterial gene responsible for 
production (lysine decarboxylase) has been characterized extensively16,17, although not in 
vaginal organisms specifically. As expected, the relative abundance of lysine 
decarboxylase (K01582) differed significantly between BV and health (Wilcoxon test, 
FDR corrected p =7.2E-4, Figure 3-5 middle panel). The majority of transcripts for this 
KO mapped to Megasphaera species, indicating this organism may be the main producer 
of cadaverine in the vagina (Figure 3-5 top panel). Despite the co-occurrence of lysine 
decarboxylase and cadaverine in BV, the correlation between lysine decarboxylase and 
cadaverine was not amongst the strongest (Spearman’s R=0.53, FDR corrected p=0.07, 
Figure 3-5 bottom panel). In fact, there were 442 KOs with larger Spearman’s rho values 
than that of lysine decarboxylase. The KO correlating most strongly with cadaverine was 
a sulfertransferase, an enzyme with no clear link to cadaverine metabolism. 
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Figure 3-5. Relative abundance of bacterial genus (Megasphaera) and transcript 
(lysine decarboxylase) predicted to be responsible for cadaverine synthesis in women 
with BV compared to health.  
The top, middle, and bottom panels display the proportion of Megasphaera, relative 
abundance of lysine decarboxylase, and absolute abundance of cadaverine within each 
sample respectively. “R” refers to the Spearman’s rho value between Megasphaera and 
lysine decarboxylase, as well as lysine decarboxylase and cadaverine. All correlations 
were performed using clr transformed sequencing data. Metabolite data was acquired 
by GC-MS. 
 
GHB was a secondary metabolite of interest as it is one of the most sensitive and specific 
biomarkers for BV, and has been shown to be produced by G. vaginalis2. The bacterial 
enzyme involved in GHB synthesis (GHB dehydrogenase18) is not in the Kegg database, 
and therefore the relationship between GHB and its putative transcript could not be 
investigated using the KO system. To circumvent this, we performed a protein BLAST 
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search of a validated GHB dehydrogenase from Clostridium kluyveri18, specifically 
targeting sequences in the meta-transcriptome belonging to G. vaginalis. This analysis 
identified two translated refseqs (reference sequences, defined as sequences with >90% 
nucleotide similarity) from G. vaginalis with ~46% amino acid similarity to the GHB 
dehydrogenase of C. kluyveri. Both were annotated as GHB dehydrogenases. The 
correlation between these refseqs was strong (Spearman’s R=0.88, p=3.22 E-6), and the 
translated amino acid sequences differed by only a single Serine-Alanine repeat. Due to 
limitations in computing power stemming from the large number of variables in the 
refseq table (n=49 885), an FDR correction could not be computed for the comparison of 
GHB dehydrogenase abundance in BV and health. However, the uncorrected p values for 
the two GHB dehydrogenase refseqs were low (Wilcoxon test, p=0.001 and 0.003), and 
effect sizes were large (1.77 and 1.90 respectively), indicating the between group 
variation was larger then that of within.  
 
When the 16S proportion of G. vaginalis,  relative abundance of G. vaginalis GHB 
dehydrogenase refseq1, and measured abundance of GHB were plotted across samples, it 
is clear they are highly correlated (Figure 3-6). Despite this fact, GHB was not most 
correlated with the GHB dehydrogenase refseqs (refseq 1 R=0.69, p=0.002, refseq 2 
R=0.73, p=0.0009), and there were >500 refseqs with greater correlation values than that 
of the putative GHB dehydrogenases (data not shown). 
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Figure 3-6. Relative abundance of bacterial species (Gardnerella vaginalis) and 
transcript (GHB dehydrogenase) predicted to be responsible for GHB synthesis in 
women with BV compared to health. 
The top, middle, and bottom panels display the proportion of G. vaginalis, relative 
abundance of GHB dehydrogenase, and absolute abundance of GHB within each sample 
respectively. “R” refers to the Spearman’s rho value between G. vaginalis and GHB 
dehydrogenase, as well as GHB dehydrogenase and GHB. All correlations were 
performed using clr transformed 16S and transcript data. Metabolite data was acquired 
by GC-MS. 
 
3.4 Discussion 
This work confirms that GHB and 2HV are reproducible biomarkers of BV, irrespective of 
geographical location or ethnicity. It also represents the first study to relate the bacterial 
meta-transcriptome and metabolome. Through the examples of cadaverine and GHB, we 
have demonstrated how the metabolome and transcriptome can be leveraged to identify 
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putative genes and taxa involved in metabolite production within a community. In the case 
of GHB, production by G. vaginalis was first reported by us recently2. Unfortunately, we 
were unable to grow Megasphaera isolates in vitro and therefore could not confirm 
cadaverine production by this genus. However, the near complete dominance of the lysine 
decarboxylase KO by Megasphaera provides good circumstantial evidence for production 
by this genus. 
Despite the stark contrast in the transcriptome and metabolome of women with BV 
compared to health, we found that correlations between these datasets were not sufficient 
to identify clear gene-product relationships without prior knowledge of the enzymes 
involved. Multiple factors likely contribute to this. Firstly, in contrast to sequence-based 
methods, metabolites may be of bacterial or host origin or both. Many metabolites may 
therefore be generated fully or partially by mammalian metabolism, which is not captured 
by the bacterial meta-transcriptome. The strong correlation between BV associated 
bacteria, and therefore their transcripts and products, may also be a large contributor. This 
leads to spurious correlations, whereby transcripts and products involved in unrelated 
pathways are highly correlated. Whether this observation holds true for communities with 
less microbial co-occurrence, such as the gut, remains to be determined.  
Another contributing factor is the non-specific nature of many enzymes. For example, 
although the KO for lysine decarboxylase is specific to lysine, the Megasphaera refseq 
assigned to this KO is annotated as a Orn/Lys/Arg decarboxylase 
(gi|335049912|ref|NZ_AFIJ01000038.1|:c21078-19624). This enzyme could therefore 
perform decarboxylation of substrates other than lysine, or may not act on lysine at all. 
This is true of many enzymes, which may contribute to the weaker than expected 
correlation between transcripts and products. 
Finally, the most overlooked factor may be the fact that metabolomic data, unlike 
sequencing data, is not compositional in nature. Metabolites are measured in absolute 
abundance; that is, a change in the abundance of one metabolite will not affect that of 
another. As the absolute abundance of gene expression cannot be measured by meta-
transcriptomics, there is a considerable amount of disconnect between sequence-based and 
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metabolomic data, which has only just begun to be addressed. Our work highlights this fact 
and suggests using metabolomics to guide transcriptome analysis, as measured by RNA-
seq or more quantitative methods such as RT-qPCR, may be a more fruitful approach for 
characterization of microbial communities and their relation to disease processes. Of 
course, this approach is only useful when the transcripts responsible from metabolite 
production are known. As a large proportion of RNA-seq reads have no known function 
and/or cannot be mapped to any sequenced genome19,20, identifying the source of 
metabolites of unknown origin, such as 2HV, remains a formidable challenge.   
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Chapter 4 
4 Adhesion of Lactobacillus iners AB-1 to human fibronectin: a 
key mediator for persistence in the vagina? 
This chapter is reproduced with permissions (Appendix B) from:  
McMillan, A, Macklaim, JM, Burton, JP, and G Reid. (2012). Adhesion of Lactobacillus 
iners AB-1 to human fibronectin: a key mediator for persistence in the vagina? 
Reproductive Sciences 20 (7), 791-796.  
4.1 Introduction 
The vaginal microbiota plays an important role in maintaining female and fetal health, with 
over 250 bacterial species identified1-3. It has been known for some time that a healthy 
vagina is dominated by Lactobacillus species, in particular Lactobacillus iners and 
Lactobacillus crispatus. A shift from this state can result in aberrant conditions such as 
bacterial vaginosis (BV)1-4 and aerobic vaginitis (AV)5, as well as urinary tract infection 
(UTI) 6,7. 
The predominant species in the vagina as determined by 16S rRNA gene sequencing is 
Lactobacillus iners2,8-10. Due to its demanding nutritional and growth requirements, this 
species has been largely overlooked in past bacteriologically based studies. In a deep 
sequencing study of women with BV, L. iners was the only species to increase in numbers 
following metronidazole treatment, demonstrating its unique ability to persist in fluctuating 
vaginal environments2. L. iners has also been shown in vitro to displace biofilms of 
Gardnerella vaginalis11, a bacterium associated with BV2,10. Others have suggested that 
because L. iners can be found in women with infection, the species is not protective 4,12, 
but recent studies show that L. iners changes its gene expression to adapt to BV conditions 
by increasing metabolic activity against carbohydrates (manuscript being submitted). This 
suggests that L. iners may provide a nidus for recovery from BV and restoration of 
homeostasis.  
Adhesion is the first step in bacterial colonization of a surface, and in the gastrointestinal 
tract Lactobacillus adhesion is commonly mediated by mucus-binding protein13. Adhesion 
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is also believed to play a role in pathogen exclusion via blockage of their binding sites on 
the mucosa14. The ability to produce adhesion proteins has been shown in the genome of 
L. iners AB-1, potentially providing it with a means to colonize the vagina15. Genomic 
sequencing of the strain L. iners AB-1 revealed that it has the smallest Lactobacillus 
genome known to date (1.3Mbp), and lacks better known adhesion molecules common to 
other Lactobacillus species, none of which have the persistence capability of L. iners.  This 
suggests that L. iners contains somewhat of a unique mechanism to persist in the host. 
A predicted fibronectin binding protein in L. iners AB-1 was of interest as it contains a 
motif (fbpA) common to pathogenic strains of Staphylococcus aureus, where it mediates 
adhesion and internalization into host cells16. Although there is no evidence that L. iners 
internalizes into host cells15, protein predictions suggest L. iners may adhere to the vaginal 
epithelium via fibronectin. Fibronectin (Fn) is a 454 kDa glycoprotein found in a soluble 
form in plasma, and an insoluble form in the extracellular matrix and attached to the surface 
of host cells. We demonstrate here that L. iners AB-1 binds strongly to human fibronectin 
and that this process is protein mediated.  
4.2 Materials and methods 
The overall design of the experiments was to determine the extent of binding of L. iners 
to fibronectin, to compare it to a well known binder, S. aureus, in order to better 
understand how the lactobacilli might utilize the glycoprotein for persistence in the 
vagina.   
4.2.1 Strains and growth conditions 
The strains used in this study are listed in Table 4-1. Lactobacillus crispatus was selected 
as it is the second most common vaginal lactobacilli after L. iners1-3,30. Lactobacillus 
rhamnosus GR-1 and L. reuteri RC-14 are used in a combination probiotic therapy for 
Bacterial Vaginosis, but do not themselves colonize the vagina28. Lactobacillus 
rhamnosus GG is a common gut probiotic and was chosen to represent a species not 
native to the vagina29. Staphylococcus aureus was used as a positive control as its 
fibronectin binding properties have been well documented16,31.  
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L. rhamnosus GR-1, L. rhamnosus GG, L. reuteri RC-14, and L. crispatus ATCC 33820 
were grown in de Man, Rogosa and Sharpe (MRS) agar and broth (Difco, MD), 
anaerobically at 37°C under static conditions. L. iners AB-1 was grown on Columbia 
blood agar (Difco), then sub cultured in 10ml MRS broth and grown anaerobically at 
37°C overnight under static conditions. Growth of L. iners AB-1 in MRS broth is shown 
in Figure 4-1. Staphylococcus aureus MN8 was grown in brain heart infusion (BHI, 
Difco) agar and broth at 37°C aerobically with agitation. 
Table 4-1. Bacterial strains used in this study  
Strain Source/relevant characteristics 
Lactobacillus iners AB-1 Vaginal isolate; from healthy woman 15 
Lactobacillus rhamnosus GR-1 Distal urethral isolate; from a healthy woman 28 
Lactobacillus rhamnosus GG Human feces isolate 29 
Lactobacillus reuteri RC-14 Vaginal isolate; from a healthy woman 28 
Lactobacillus crispatus ATCC 
33820 
Vaginal isolate 30 
Staphylococcus aureus MN8 Clinical isolate from patient with menstrual toxic 
shock syndrome (TSS) 31 
 
Figure 4-1. L. iners AB-1 grown in 10 ml MRS broth for 7 days.  
The bars represent standard deviation. The OD600 is a measurement of the density of 
the L. iners growth. 
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4.2.2 Fibronectin adhesion assay 
Binding of bacteria to immobilized fibronectin was measured according to the methods of 
Munoz-Provencio et al., 200917. Briefly, 96-well Polysorp plates (Nunc, Rochester, NY) 
were coated with 50 µg/ml human fibronectin (Fn) (Sigma Chem. Co, St Louis, MO) in 
carbonate/bicarbonate buffer 50 mmol/l pH 9.6 and incubated at 4°C overnight. Wells were 
washed three times with 100 µl PBS (pH 7.4), then blocked with 100 µl PBS + 1% Tween 
20 for 1 h. All strains were grown to late exponential phase (54 h for L. iners AB-1, 5-6 h 
for all other strains tested), washed three times with PBS, and re-suspended in PBS to an 
optical density that represented 107 CFU/ml as determined previously by growth curves. 
100 µl of each strain was then added to each well and incubated at 37°C for 2 hours. After 
incubation non-adherent cells were removed by three washes with 200 µl PBS + 0.05% 
Tween 20. Adhered cells were stained with 100 µl of 1 mg/ml crystal violet for 45 minutes. 
After washing, colorant was released with 100 µl citrate buffer (50 mmol/l, pH 4.0), and 
the absorbance at 600 nm was measured in a Multiskan Ascent plate reader (Thermo-
Scientific, Rockford, U. S.). Drop dilution plates using 10 ul of culture and series of 10 
times dilutions were performed simultaneously with binding assays to enumerate bacterial 
numbers upon addition to Fn-coated plates. Experiments were repeated three times and in 
triplicate. 
The effect of protease treatment was assayed by incubating cells with 100 µg/ml proteinase 
K for 1 h at 37 °C followed by 1 h incubation with 1 mmol/L 
phenylmethanesulfonylfluoride (PMSF) to inactivate proteinase K. Cells were then 
transferred to Fn-coated plate. Experiments were repeated twice and in duplicate. Wells 
without Fn were run as controls in all experiments and their absorbance values subtracted 
from Fn-coated wells. PBS alone was included in all experiments to account for any Fn 
binding by PBS.  
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4.2.3 Bacterial binding to fibronectin coated cover slips 
Binding of bacteria to fibronectin coated cover slips was determined by coating glass 
cover slips overnight with 50 ug/mL fibronectin in PBS + 0.05 % Tween 20 at 4°C. Slips 
(VWR 18 mm glass) were washed three times with 1 mL PBS, and blocked with 1 mL 
PBS + 1 % Tween 20 for 1 h. Cells were grown to late exponential phase, washed twice 
with PBS and diluted to a concentration of 107 CFU/mL with PBS. Numbers were 
confirmed by drop plating. One mL of these cultures was added to separate cover slips 
and incubated for 2 h at 37°C. Non-adherent cells were removed by three washes with 
PBS + 0.05 % Tween 20. Cover slips were then Gram-stained and adherent cells viewed 
under a Zeiss Axioscop HBO50 light microscope under 100 x objective. Cover slips 
without fibronectin were run as controls in all experiments. Five fields of view were 
recorded for each cover slip and biological replicates were repeated three times to 
confirm results. 
4.2.4 Statistical analysis 
Statistical analysis was performed on all data from binding assays using the GraphPad 
Prism ® 4 program. The data fitted a normal distribution and was therefore appropriate for 
ANOVA testing. Differences between the normally distributed means were compared 
using a one-way ANOVA analysis with a Tukeys post hoc test. Differences in binding were 
considered significant with p values of < 0.05.  
4.3 Results 
Lactobacillus iners AB-1 bound to fibronectin coated polystyrene plates in significantly 
greater amounts than all strains tested (Fig. 2). The effect of proteinase K, a serine protease, 
was determined by incubating bacteria with proteinase K followed by the protease inhibitor 
PMSF before addition of cells to fibronectin coated plates. Proteinase K treatment 
significantly reduced binding of L. iners AB-1 to fibronectin (p<0.05) (Figure 4-3).  
Photomicrograph images of cells adhering to fibronectin coated and uncoated cover slips 
are shown in Figure 4-4, and bacterial cells counts in Table 4-2. Adhesion of L. iners AB-
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1 and S. aureus MN8 was enhanced by coating slips with fibronectin. There was no 
difference in adhesion to Fn of L. iners AB-1 compared with S. aureus (p> 0.05). The 
addition of Fn had no effect on adhesion of L. crispatus (p> 0.05). 
 
Figure 4-2. Bacterial binding to immobilized fibronectin as measured by optical 
density at 600 nm (OD600).  
All strains were added to fibronectin-coated plates at a concentration of 107 CFU/mL 
unless indicated and bacterial numbers were confirmed by drop plating. Binding by L. 
iners AB-1 is significantly greater than all strains (p<0.05). n = 9. The bars represent 
standard deviation.  
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Figure 4-3. Effect of proteinase K pre-treatment on adhesion to immobilized 
fibronectin by L. iners AB-1.  
PMSF (phenylmethanesulfonylfluoride) is a proteinase K inhibitor. L. iners AB-1 
binding was significantly reduced by proteinase K pre-treatment (p<0.05). n = 4. The 
bars represent standard deviation. 
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Figure 4-4. Bacterial adhesion to fibronectin coated cover slips.  
A. L. iners + fibronectin B. L. iners no fibronectin C. S. aureus + fibronectin D. S. 
aureus no fibronectin. E. L. crispatus + fibronectin. F. L. crispatus no fibronectin.  
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Table 4-2. Bacterial adhesion to fibronectin coated cover slips cell counts.  
Counts represent an average of 3 fields of view ± SD. Adhesion of MN8 and AB-1 to 
fibronectin was statistically higher (p<0.01), while that of 33820 was not altered 
(p>0.05).  
Strain Fibronectin No Fibronectin 
S. aureus MN8 299 ±28.2 54 ±19.7 
L. iners AB-1 341 ±27.7 33 ±19.2 
L. crispatus 33820 8 ±3.1 20 ±11.0 
 
4.4 Discussion 
The concentration of Fn in the vagina has been reported from as high as 90-140 pg/ml 
during menses to 3-5 pg/ml at the end of the menstrual cycle18. As L. iners possesses a 
predicted fibronectin binding protein and adhesion is the first step in colonization of a 
surface, we hypothesized that strong adhesion to Fn could be contributing to its persistence 
in the human vagina15. L. iners AB-1 bound significantly greater to human Fn compared 
to other Lactobacillus strains tested, including vaginal probiotic L. rhamnosus GR-1 and 
L. reuteri RC-14, and gut probiotic L. rhamnosus GG (Figure 4-2), none of which are able 
to persist long term in the vagina. However, since strains L. rhamnosus GR-1 and L. reuteri 
RC-14 help restore the vaginal microbiota back to a healthy state19,20 they must use 
different adhesion mechanisms, such as extracellular polysaccharides, or metabolic 
pathways, in the vagina. L. iners bound Fn significantly better than the S. aureus positive 
control as assessed by crystal violet microplate assay, however this binding was more 
comparable when assessed on a per cell basis via light microscopy. These results indicate 
that differences in cell surface area and/or size may account for the apparent difference in 
Fn binding between S. aureus and L. iners as detected by crystal violet staining alone.  
In relation to pregnancy, fetal fibronectin found in the amniotic fluid, placental tissue, and 
the decidua basalis, but its presence in the cervicovaginal secretions between 22 and 37 
weeks may be due to disruption of the chorionic-decidual interface secondary to 
infection21. Hypothetically, L. iners could bind to fibronectin and potentially counter 
pathogenesis thereby extending the duration of the pregnancy. Since L. iners has only 
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relatively recently been discovered and detected using molecular methodologies, no studies 
have looked for its presence during elevated fibronectin and infection. Investigations of 
this nature perhaps warrant undertaking.  
This is the first report of L. iners having such strong adhesion to a mucosal protein. This 
trend was confirmed by viewing cells bound to Fn coated cover slips under a light 
microscope (Figure 4-4). Interestingly, L. iners AB-1 bound equally or stronger to Fn 
compared to S. aureus MN8, a species well studied for its Fn binding properties16. L. 
crispatus, another member of the core vaginal microbiota, lacks Fn binding properties, 
indicating that L. iners and L. crispatus use different adhesion mechanisms to colonize the 
same environment. This is particularly interesting since L. crispatus strains do not appear 
to persist to the extent of L. iners, and their displacement coincides with onset of BV1.  
When candidate probiotic strain L. crispatus CTV-05 did colonize hosts who lacked 
indigenous L. crispatus, a healthy state was maintained22. It is not clear how BV organisms 
induce L. crispatus and not L. iners displacement, but the avidity of adhesion to Fn of the 
latter likely plays a role. A recent study using atomic force microscopy highlighted the 
weaker adhesion of L. crispatus and L. jensenii and suggested that for Lactobacillus species 
to displace pathogens, they need to display strong adhesion forces23. This is not ubiquitous 
across Lactobacillus, and Nagy et al.,24 found only 9/54 (16.7%) of vaginal Lactobacillus 
isolates bound Fn at pH 7.2, however, L. iners was not included as it had not yet been 
discovered. They also observed that adhesion to Fn increased when the pH was lowered to 
4.0. This may help explain the loss of some Lactobacillus species during BV, where the 
pH is elevated. It also suggests that L. iners is able to persist during incidences of BV due 
in part to its ability to bind Fn at a more neutral pH as shown in our study. The fluctuations 
in vaginal Fn during episodes of BV have not yet been elucidated. Future work should 
determine if free Fn increases during BV, which might offer L. iners a competitive 
advantage over other vaginal lactobacilli. 
To determine if Fn adhesion by L. iners was protein-mediated we pre-treated cells with the 
serine protease, proteinase K. This treatment significantly reduced binding to Fn (p<0.05), 
confirming that Fn adherence by L. iners AB-1 is protein-mediated. A predicted Fn binding 
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protein (LINAB1_0564) in L. iners AB-1 could be contributing to this interaction. This 
protein has 34% amino acid similarity to a Fn binding protein of S. aureus MN8. 
Furthermore, analysis of the transcriptome of L. iners has revealed that this gene is 
expressed in both healthy patients and those with BV (manuscript submitted), indicating 
the protein may be used during both conditions to adhere to the vaginal mucosa and 
colonize the vagina.  
In summary, the persistence of L. iners in the vagina despite the presence of other 
lactobacilli and pathogens or antibiotics could be due to its strong adhesion to Fn. If clones 
of this species do indeed form an environment that allows restitution of a Lactobacillus 
microbiota that protects against disease, future probiotic strains, such as those used against 
HIV25,26 or ones devised to compete with Fn binding Trichomonas27 could benefit from 
cloning of the L. iners Fn binding protein.  
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Chapter 5 
5 Metabolic derangements identified through untargeted 
metabolomics in a cross-sectional study of Nigerian children 
with severe acute malnutrition 
A. McMillan, A.E. Orimadegun, M.W. Sumarah, J. Renaud, M. Muc, G.B. Gloor, O.O. 
Akinyinka, G. Reid, and S.J. Allen. 
Supplemental Tables 5-(1-6) are available for download as additional files (.xlsx) 
5.1 Introduction 
Severe acute malnutrition (SAM) is a leading cause of global child mortality, is associated 
with growth faltering, and results in impaired cognitive development1. SAM is most 
frequently defined by a weight-for-length/height Z-score (WHZ) < -3 and/or presence of 
edema 2. Middle upper arm circumference (MUAC) < 11.5 cm is also commonly used in 
children aged 6-59 months2. Despite its prevalence, the metabolic changes that occur 
during malnutrition are poorly understood. Identification of these metabolites could i) lead 
to improved interventions through identification of nutrient deficiencies, ii) advance our 
understanding of the metabolic adaptations to malnutrition and shed light on 
pathophysiology, and iii) identify biomarkers of nutritional status for diagnostic and 
monitoring purposes. 
 
Amino acids are known to be depleted in children with SAM3, but untargeted studies 
pertaining to other metabolites are limited. Bartz et al4  applied a targeted and untargeted 
approach to identify biomarkers associated with recovery and mortality in Ugandan 
children with SAM. The concentrations of a number of metabolites were significantly 
altered upon rehabilitation, including amino acids, acylcarnitines and leptin. However, 
non-malnourished controls were not included, and the untargeted analysis was limited to 
gas chromatography-mass spectrometry (GC-MS) which covers only a small portion of the 
metabolome. Malnutrition in juvenile pigs has also revealed alterations in the metabolome, 
including changes in amino acids, choline metabolites, and products of microbial-
mammalian co-metabolism5, suggesting the gut microbiota may be playing a role. 
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Differences in gut microbial composition of children with SAM compared to healthy co-
twins and unrelated controls have been described in Malawian and Bangladeshi children6,7. 
Additionally, specific taxa capable of causing enteropathy when combined with a low 
protein diet have been identified in mice8. Enteropathy resulting in malabsorption and 
increased intestinal permeability is associated with SAM in humans, as indicated by 
intestinal biopsies and dual sugar permeability tests9. This phenomenon may be a more 
severe form of environmental enteric dysfunction (EED), previously referred to as “tropical 
enteropathy”, which occurs almost universally in people exposed to poor hygiene and 
sanitation. The etiology of enteropathy in SAM is not well understood, but may involve 
repeated exposure to fecal enteropathogens combined with a low protein diet8,10. There is 
currently no widely accepted non-administered biomarker for enteropathy, and therefore 
the role of enteropathy in malnutrition is difficult to determine. 
 
The aim of this study was to identify conserved changes in the metabolome of children 
with SAM, both to identify biomarkers and to improve our understanding of the 
pathophysiology of the condition. We aimed to undertake a pragmatic study of unselected 
children admitted to a health facility in a region with endemic malnutrition, to maximise 
the relevance of our findings to clinical practice. Given the association with enteropathy 
and recent studies linking changes in the microbiota to SAM6,7, we also measured 
biomarkers of intestinal inflammation and profiled the gut microbiota of these children. 
5.2 Materials and methods 
5.2.1 Study design and sample collection  
Children aged 6 – 59 months with SAM (WHZ <-3 or MUAC <11.5 cms and/or 
nutritional edema) admitted to the Federal Medical Centre, Gusau, Zamfara State, Nigeria 
during July-September 2012 were enrolled in the study. The hospital serves both urban 
and rural populations and recruitment occurred during the rainy season when malnutrition 
is most common. Written information about the study and a verbal explanation in the 
appropriate local language was provided to parents/carers and signed or thumb-printed 
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consent secured. Clinical management was performed according to usual practice based 
on WHO guidelines including those for the management of SAM (WHO 1999). Well-
nourished children (MUAC >12.5 cms or WHZ score ≥ -1 and no nutritional edema) 
were recruited from the paediatric ward or outpatient clinics as controls. HIV positive 
individuals were excluded from the study. In both groups, baseline demographic and 
clinical information was collected on standard forms by one of five clinicians trained in 
the research methods (Supplemental Table 5-1). The first available stool sample was 
collected and its consistency and the presence of visible blood and mucus were recorded. 
At the time of clinical sampling, approximately 2.5 mL of venous blood was collected 
into EDTA tubes for the purposes of the study. Ethical approval was provided by the 
Joint Ethical Review Committees of the University of Ibadan / University College 
Hospital, Ibadan, Nigeria. 
5.2.2 Metabolite extraction from stool and plasma 
Approximately 250 mg of wet stool was lyophilized overnight. After drying, 40 mg was 
weighed into microcentrifuge tubes and extracted with 8:2 methanol:H2O to a final 
concentration of 40 mg/mL. Samples were then vortexed for 30 sec, followed by 
centrifugation for 15 min at 10 000 rpm. 50 µL of this supernatant was dried in a 
speedvac for GC-MS analysis and the remaining stored at -80°C for LC-MS. 
Metabolites were extracted from plasma according to the methods of Dunn et al, 201111. 
Briefly, plasma samples were thawed on ice for 30 min. Once thawed, 805 µL of 8:2 
methanol:H2O was added to 230 µL of plasma to make a 4.5 fold dilution. Samples were 
vortexed for 15 sec and centrifuged at 15 000 rpm for 15 min to pellet precipitated 
proteins. 370 µL of supernatant was then transferred to separate vials and dried down for 
GC-MS and LC-MS using a speedvac with no heat. 
5.2.3 Untargeted GC-MS analyses 
For stool, samples were derivatized with 40 µL of 2% methoxyamine-HCl in pyridine 
(MOX) incubated at 50 °C for 90 min, followed by 20 µL of N- Methyl-N-(trimethylsilyl) 
trifluoroacetamide (MSTFA) for 30 min at 50°C. Samples were then transferred to micro-
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inserts before analysis by GC-MS. For plasma, 50 µL of MOX was added to dried samples 
and incubated for 90 min at 50°C. Fifty microlites of MSTFA was then added and 
incubated for 30 min at 50°C. Samples were then transferred to 1.5 ml microcentrifuge 
tubes and centrifuged at 15 000 rpm for 5 min to pellet debris. This supernatant was then 
transferred to HPLC vials containing inserts for analysis. 
 
One µL of sample was injected into an Agilent 7890A GC, 5975 inert MSD with triple axis 
detector. Samples were injected using pulsed splitless mode using a 30 m DB5-MS column 
with 10 m duraguard, diameter 0.35mm, thickness 0.25µm (J&W Scientific, Folsom, 
USA). Helium was used as the carrier gas at a constant flow rate of 1 mL/min. Oven 
temperature was held at 70°C for 5 min then increased at a rate of 5 °C/min to 300°C and 
held for 10 min. Solvent delay was set to 7 min, and total run time was 61 min. Masses 
between 25 m/z and 600 m/z were selected by the detector. All samples were run in random 
order and a single sample was run with every batch as a quality control to ensure machine 
consistency. 
 
Chromatogram files were deconvoluted and converted to ELU format using AMDIS Mass 
Spectrometry software12 with the sensitivity set to low, resolution to medium, and support 
threshold to high. Chromatograms were aligned using Spectconnect 
(http://spectconnect.mit.edu)13 with the support threshold set to low. The integrated signal 
(IS) matrix output was used for all further analysis. Zeros were replaced with two thirds 
the minimum detected value on a per metabolite basis14, followed by a log base 2 
transformation. All further analyses were performed using these log-transformed values.  
 
Metabolites were initially identified by comparison to the NIST 11 standard reference 
database (http://www.nist.gov/srd/nist1a.cfm). Identities of metabolites of interest were 
then confirmed by authentic standards if available. 
5.2.4 Untargeted LC-MS analyses 
For stool, 2.5µL of 1 µg/mL 13C6 phenylalanine internal standard (Cambridge Isotopes, 
Tewksbury, USA) was added to 47.5µL of extracted stool. For plasma, dried samples were 
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reconstituted in 85.5µL of ddH2O. 4.5µL of 1 ug/mL 13C6 phenylalanine in ddH2O was 
then added to each vial as an internal standard. Samples were vortexed for 15 sec, then 
transferred to microinserts and directly injected into an Agilent 1290 Infinity HPLC 
coupled to a Q-Exactive Orbitrap mass spectrometer (Thermo Fisher Scientific, Waltham, 
USA) with a HESI (heated electrospray ionization) source. For HPLC, 2µL of each sample 
was injected into a ZORBAX Eclipse plus C18 2.1 x 50mm x 1.8 micron column. Mobile 
phase (A) consisted of 0.1% formic acid in water and mobile phase (B) consisted of 0.1% 
formic acid in acetonitrile. The initial composition of 0% (B) was held constant for 30s and 
increased to 100% over 3.0 min. For stool, mobile phase B was held at 100% for 1 minute 
and returned to 0% over 30s for a total run time of 5 min. For plasma, mobile phase B was 
held at 100% for 2 minutes and returned to 0% over 30s for a total run time of 6 min. 
 
Full MS scanning between the ranges of m/z 50-750 was performed on all samples in both 
positive and negative mode at 140 000 resolution. The HESI source was operated under 
the following conditions: nitrogen flow of 30 and 8 arbitrary units for the sheath and 
auxiliary gas respectively, probe temperature and capillary temperature of 450°C and 
250°C respectively and spray voltage of 3.9 kV and 3.5 kV in positive and negative mode 
respectively. The automatic gain control (AGC) target and maximum injection time were 
1e6 and 500 ms respectively. For molecular characterization, every tenth sample was also 
analyzed with a data dependent MS/MS method where a 35 000 resolution full MS scan 
identified the top 12 signals above a 1e5 threshold which were subsequently selected at a 
1.2 m/z isolation window for MS/MS. Normalized collision energy for MS/MS was 28, 
resolution 17 500, AGC target 1E5 and maximum injection time was 60ms. Blanks of pure 
methanol were run between every sample to limit carryover, and a single sample was run 
multiple times with every batch to account for any machine inconsistency. After data 
acquisition Thermo .RAW files were converted to .MZML format and centroided using 
jjjProteoWizard15. Files were then imported into R using the XCMS package16 for 
chromatogram alignment and deconvolution. Features were detected with the “xcmsSet” 
function using the “centWave” method and a ppm tolerance of 1. Prefilter was set to 3-
5000, noise 1E5, and signal to noise threshold was set to 5. Due to a lower overall noise 
and signal in negative mode, noise was set to 1E3 for this mode. Retention time correction 
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was conducted using the “obiwarp” method, grouping included features present in at least 
25% of samples, allowable retention time deviation was 5 seconds, and m/z width set to 
0.015. Areas of features below the signal to noise threshold in the data were integrated 
using the “fillPeaks” function with default settings. Any remaining zeros in the data were 
then replaced with two-thirds the minimum value on a per mass basis14 before log base 2 
transformation. The log-transformed mass list was then exported as a single .txt file and 
used for all further analyses. All further analyses were carried out in R unless otherwise 
specified. Positive and negative mode data were treated as two independent datasets for all 
analyses. 
 
Metabolites were putatively identified based on accurate mass and LC-MS/MS 
fragmentation patterns (Error! Reference source not found.). Predictions were made mainly 
by de novo compound identification from in depth investigation of individual MS/MS 
spectra, utilizing the METLIN database (http://metlin.scripps.edu)17, Human Metabolome 
Database (www.hmdb.ca) 18, and CFM-ID (http://cfmid.wishartlab.com)19 whenever 
possible to aid in identification. Metabolites of interest were confirmed by authentic 
standards when available based on accurate mass, retention time and MS/MS spectra 
(Supplemental Table 5-2).  
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Figure 5-1. LC-MS/MS spectra for metabolites elevated in plasma of children with SAM.  
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5.2.5 Statistical analysis of metabolome data 
Principal Component Analysis (PCA) was conducted in R using the “FactoMineR” 
package with pareto scaling. Components 1 and 2, representing approximately 15% and 
9% of the variation respectively, could not be explained by any of the metadata collected. 
We therefore selected the lowest components which maximized separation between SAM 
and controls (components 3 and 4) for qualitative analysis of the metabolome. 
Metabolites that differed between SAM and controls were determined independently of 
PCA analysis using unpaired Wilcoxon tests with Benjamini-Hochberg (False Discovery 
Rate (FDR)) corrections to account for multiple hypothesis testing20. Metabolites with a 
corrected P < 0.1 and average fold change > 2 in either group (SAM or control) were 
selected for further investigation. Fold changes were calculated using the geometric mean 
to limit inflation of fold change values due to outliers. Boxplots and stripcharts were 
constructed in R using the ggplot2 package. Odds ratios of metabolites to identify SAM 
from controls were calculated from conditional logistic regressions performed on all 
metabolites using the glm function in R with 10 000 iterations and a binomial 
distribution. Receiver operating characteristic (ROC) curves and forest plots were built in 
R using the pROC and forestplot packages respectively. In the case of Des ADS-FPA, the 
13C isotope was used for statistical analyses and plotting due to a large singly-charged 
interfering peak with mass similar to the 12C Des ADS-FPA. All raw data files were 
manually inspected to ensure the data was accurately represented by the 13C peak.   
5.2.6 Calprotectin and lactoferrin ELISAs 
Calprotectin was measured using the IDK® Calprotectin ELISA Kit along with the IDK 
Extract® stool extraction kit (Immundiagnostik, Bensheim, Germany). Lactoferrin was 
measured using the Lactoferrin Scan™ ELISA kit (Techlab®, Blacksburg, USA). All 
protocols were followed as per the manufacturer’s instructions. 
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5.2.7 Microbiome profiling 
DNA was extracted from stool samples using the PowerSoil-htp 96 Well Soil DNA 
isolation kit from MoBio (Carlsbad, CA) according to the manufacturer’s protocol, with 
modifications as outlined by the Earth Microbiome Project (version 4_13). Approximately 
250 mg of fecal sample was used for the extractions. Samples were sequenced by 
amplifying the V4 hypervariable region of the 16S rRNA gene. Sample amplification for 
sequencing was carried out using the forward primer 
(ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNN(8)GTGCCAGCMGCCG
CGGTAA) and the reverse primer 
(CGGTCTCGGCATTCCTGCTGAACCGCTCTTCCGATCTNNNN(8)GGACTACHV
GGGTWTCTAAT) where nnnn indicates four randomly incorporated nucleotides, and (8) 
was a sample-specific nucleotide barcode where the barcodes differed by an edit distance 
of at least 4. The 5’ end is the adapter sequence for the Illumina MiSeq sequencer and the 
sequences following the barcode are complementary to the V4 rRNA gene region. 
Amplification was carried out in 42µL with each primer present at 3.2 pmol/µL, 20µL 
GoTaq hot start colorless master mix (Promega) and 2µL extracted DNA. The PCR 
protocol was as follows: initial activation step at 95°C for 2 minutes and 25 cycles of 1 
minute 95°C, 1 minute 50°C and 1 minute 72°C. 
 
All subsequent work was carried out at the London Regional Genomics Centre (LRGC, 
lrgc.ca, London, Ontario, Canada). Briefly, PCR products were quantified with a Qubit 2.0 
Flourometer and the high sensitivity dsDNA specific fluorescent probes (Life 
Technologies). Samples were mixed at equimolar concentrations and purified with the 
QIAquick PCR Purification kit (QIAGEN). Samples were paired-end sequenced on an 
Illumina Mi-Seq with the 600 cycle version 3 reagents with 2x220 cycles. 
 
Resulting reads were extracted and de-multiplexed using modifications of in-house Perl 
and UNIX-shell scripts with operational taxonomic units (OTUs) clustered at 97% identity, 
similar to our reported protocol21. Automated taxonomic assignments were carried out by 
comparison to the SILVA database (http://www.arb-silva.de/). Supplemental Table 5-1 
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displays the nucleotide barcodes and their corresponding samples. To control for 
background contaminating sequences, a no-template control was also sequenced. Barplots 
were constructed with R (r-project.org) using proportional values. Rare OTUs found at less 
than 1% abundance in all samples were grouped in the remainder for barplots only. All 
other analyses were conducted with all OTUs. Principal Coordinate Analysis (PCoA) plots 
were constructed in Qiime22 (qiime.org) using weighted UniFrac distances. 
 
To avoid inappropriate statistical inferences made from compositional data, centred log-
ratios (clr), a method previously described by Aitchison23, and adapted to microbiome data 
was used with unpaired Wilcoxon tests for comparisons of OTU level data24,25. The 
Benjamini Hochberg (FDR) method was used to control for multiple testing with a 
significance threshold of 0.1. All statistical analysis, unless otherwise indicated, was 
carried out using R (r-project.org). 
5.3 Results 
5.3.1 Study population 
We recruited 58 children aged 6 -59 months: 47 children with SAM (WHZ < -3 and/or 
MUAC < 11.5 and/or edema) and 11 well-nourished hospital controls. Demographic and 
clinical characteristics at recruitment are shown in Table 5-1. The distribution of ethnicity 
and area of residence differed significantly between cases and controls. 
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Table 5-1. Demographic and clinical characteristics of cases and controls.(1) 
 
Variable 
Severe	acute	malnutrition 
(N=47) 
Non-malnourished	
controls 
(N=11) 
 
P	value 
 
Male:	No	(%) 
 
30	(63.8) 
 
7	(63.6) 
 
1.00 
 
Age	(months;	median,	range) 
 
22.0	(6	to	48) 
 
14.0	(6	to	44) 
 
0.76 
 
Ethnicity:	No.	(%) 
• Hausa 
• Fulani 
• Ibo 
• Yoruba 
• Bugaje 
 
 
43	(91.5) 
3	(6.4) 
1	(2.1) 
0	(0) 
0	(0) 
 
 
9	(81.8) 
0	(0) 
0	(0) 
1	(9.1) 
1	(9.1) 
 
 
 
 
0.048 
 
Residence:	No.	(%) 
• Urban 
• Peri-urban 
• Rural 
 
 
21	(44.7) 
1	(2.1) 
25	(53.2) 
 
 
7	(63.6) 
2	(18.2) 
2	(18.2) 
 
 
 
0.024 
 
Weight-for-length/height	 z	 score	
(median;	IQR) 
 
-5.08	(-10.74	to	-2.32) 
 
-0.61	(-1.64	to	0.73) 
 
<0.001 
 
Mid-upper	 arm	 circumference	
(cms:	median;	IQR) 
 
10.0	(7.0	to	12.0) 
 
14.0	(13.5	to	18.0) 
 
<0.001 
 
Pedal	edema:	No.	(%) 
 
 
21	(44.7) 
 
0	(0) 
 
- 
Stool	 appearance	 (Bristol	 Stool	
Form	Scale): 
• 2 
• 3 
• 4 
• 5 
• 6 
• 7  
 
 
0	(0) 
9	(19.1) 
2	(4.3) 
9	(19.1) 
18	(38.3) 
9	(19.1) 
 
 
3	(27.3) 
4	(36.4) 
0	(0) 
2	(18.2) 
2	(18.2) 
0	(0) 
 
 
 
 
0.003 
 
Ever	 received	 formula	 milk:	 No.	
(%) 
 
 
23	(48.9) 
 
2	(18.2) 
 
0.093 
(1) P values were calculated using the Wilcoxon test with the exception of ethnicity, 
residence, ever received formula, for which the Chi squared or Fisher’s exact test was 
used. 
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Amongst the cases, 26 (55.3%) were diagnosed with kwashiorkor. Apathy was present in 
34 (72.3%), anorexia in 42 (89.4%), thin hair in 42 (89.4%), glossitis in 27 (57.4%), one 
or more Bitot spots in 9 (19.1%), dermatitis in 22 (46.8%), stomatitis in 27 (57.4%) and 
18 (38.3%) had oral ulceration. Abdominal distension was present in 11 (23.4%), 
hepatomegaly in 28 (59.6%) and splenomegaly in 26 (55.3%). Loose or watery stools 
(Bristol Stool Form Scale 5-7) occurred in 36 (76.6%) of the SAM cases compared with 4 
(36.4%) controls (Table 1). None of the children had bloody stools.  
5.3.2 The fecal microbiota of Nigerian children 
To determine if the composition of the gut microbiota differed between Nigerian children 
with SAM and controls, we profiled the microbiota of stool samples by amplifying the 
V4 region of the 16S rRNA gene. Two samples did not have enough material for DNA 
extraction, leaving 45 SAM and 11 controls remaining. The fecal microbiota of Nigerian 
children was dominated by Enterobacteraciae, Bifidobacterium, Enterococcus, 
Pediococcus, Lactobacillus and Streptococcus species (Figure 5-2A). There were no 
differences in alpha or beta diversity between SAM and controls (Figure 5-2B,C), nor 
were there any individual taxa that differed significantly between groups (Wilcoxon test, 
FDR corrected P > 0.1, Supplemental Table 5-3). Although there was a trend for lower 
bacterial diversity in children with SAM compared to controls, the difference was not 
significant, even when age was taken into account (Figure 5-2C, ANCOVA P > 0.05).C, 
A > 0.05).   
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Figure 5-2. The stool microbiota does not discriminate SAM from controls.  
(A). Stool microbiota profiled using the V4 region of the 16S rRNA gene. Each bar in 
the barplot represents a single sample from a single child and each color a different 
bacterial taxa (OTU). OTUs present at less than one percent in every sample were placed 
in the remainder displayed in black. Samples are ordered by their WHZ displayed in the 
heatmap above. (B). Principal Coordinate Analysis (PCoA) plot of microbiota profiles 
built from weighted UniFrac distances. Each point represents a single sample from a 
single child. Positions of points display dissimilarities in the microbiota, with points 
further from one another being more dissimilar. (C). Shannon’s diversity of the stool 
microbiota in children with SAM compared with controls. The boxes represent the 25th 
and 75th quartiles, and the line displays the median value within each group. Points 
extending beyond the lines are outliers defined as values greater or less than 1.5 times 
the interquartile range. 
  
 
FIGURE 1: Stool microbiota does not discriminate SAM from controls. (A). Stool microbiota profiled 
using the V4-V5 region of the 16S rRNA gene. Each bar in the barplot represents a single sample 
from a single child and each color a different bact rial taxa (OTU). OTUs present less than one 
percent in every sample were placed in the remainder displayed in black. Samples are ordered by 
their WHZ displayed in the heatmap above. (B). Principal Coordinate Analysis (PCoA) plot of 
microbiota profiles built from weighted UniFrac distances. Each point represents a single sample 
from a single child. Positions of points display dissimilarities in the microbiota, with points further 
from one another being more dissimilar. C. Shannon’s diversity of the stool microbiota in children 
with SAM co pared with controls. The boxes represent the 25th and 75th quartiles, and the line 
displays the median value within each group. Points ext nding beyond t e lines are outliers defined 
as values greater or less an 1.5 time  interquartil  range. 
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28_Bacteria;Firmicutes;Clostridia;Clostridiales;Lachnospiraceae;Blautia;|92
29_Bacteria;Firmicutes;Clostridia;Clostridiales;Peptostreptococcaceae;Incertae_Sedis;|100
30_Bacteria;Firmicutes;Clostridia;Clostridiales;Ruminococcaceae;Faecalibacterium;|100
31_Bacteria;Firmicutes;Erysipelotrichia;Erysipelotrichales;Erysipelotrichaceae;Incertae_Sedis;|100
32_Bacteria;Firmicutes;Erysipelotrichia;Erysipelotrichales;Erysipelotrichaceae;unclassified;|100
34_Bacteria;Firmicutes;Clostridia;Clostridiales;Family_XI;Anaerococcus;|100
35_Bacteria;Firmicutes;Clostridia;Clostridiales;Lachnospiraceae;Incertae_Sedis;|89
36_Bacteria;Proteobacteria;Gammaproteobacteria;Enterobacteriales;Enterobacteriaceae;Yersinia;|100
37_Bacteria;Actinobacteria;Coriobacteriia;Coriobacteriales;Coriobacteriaceae;Eggerthella;|100
38_Bacteria;Firmicutes;Bacilli;Lactobacillales;Lactobacillaceae;Lactobacillus;|99
39_Bacteria;Firmicutes;Erysipelotrichia;Erysipelotrichales;Erysipelotrichaceae;Catenibacterium;|100
41_Bacteria;Firmicutes;Clostridia;Clostridiales;Peptostreptococcaceae;Incertae_Sedis;|100
43_Bacteria;Actinobacteria;Coriobacteriia;Coriobacteriales;Coriobacteriaceae;Olsenella;|95
44_Bacteria;Firmicutes;Clostridia;Clostridiales;Family_XIII;Mogibacterium;|100
45_Bacteria;Actinobacteria;Actinobacteria;Actinomycetales;Actinomycetaceae;Actinomyces;|100
46_Bacteria;Firmicutes;Bacilli;Bacillales;Alicyclobacillaceae;Tumebacillus;|100
47_Bacteria;Actinobacteria;Actinobacteria;Micrococcales;Micrococcaceae;Rothia;|100
48_Bacteria;Firmicutes;Bacilli;Bacillales;Family_XI;Gemella;|100
49_Bacteria;Firmicutes;Clostridia;Clostridiales;Peptostreptococcaceae;Peptostreptococcus;|100
50_Bacteria;Firmicutes;Bacilli;Lactobacillales;Lactobacillaceae;Lactobacillus;|100
51_Bacteria;Firmicutes;Clostridia;Clostridiales;Clostridiaceae_1;Clostridium_sensu_stricto_1;|97
53_Bacteria;Firmicutes;Bacilli;Lactobacillales;Lactobacillaceae;Lactobacillus;|100
54_Bacteria;Actinobacteria;Actinobacteria;Micrococcales;Micrococcaceae;Kocuria;|100
55_Bacteria;Firmicutes;Clostridia;Clostridiales;Lachnospiraceae;Dorea;|100
56_Bacteria;Firmicutes;Bacilli;Lactobacillales;Leuconostocaceae;Leuconostoc;|100
57_Bacteria;Firmicutes;Negativicutes;Selenomonadales;Veillonellaceae;Veillonella;|100
59_Bacteria;Firmicutes;Bacilli;Lactobacillales;Lactobacillaceae;Lactobacillus;|96
60_Bacteria;Firmicutes;Clostridia;Clostridiales;Ruminococcaceae;Butyricicoccus;|70
61_Bacteria;Firmicutes;Clostridia;Clostridiales;Lachnospiraceae;Incertae_Sedis;|98
62_Bacteria;Fusobacteria;Fusobacteriia;Fusobacteriales;Fusobacteriaceae;Fusobacterium;|100
63_Bacteria;Firmicutes;Clostridia;Clostridiales;Lachnospiraceae;Incertae_Sedis;|94
64_Bacteria;Firmicutes;Bacilli;Lactobacillales;Lactobacillaceae;Lactobacillus;|100
65_Bacteria;Firmicutes;Clostridia;Clostridiales;Defluviitaleaceae;Incertae_Sedis;|99
66_Bacteria;Firmicutes;Clostridia;Clostridiales;Family_XIII;Incertae_Sedis;|86
67_Bacteria;Firmicutes;Bacilli;Lactobacillales;Lactobacillaceae;Lactobacillus;|99
68_Bacteria;Firmicutes;Bacilli;Lactobacillales;Streptococcaceae;Lactococcus;|100
71_Bacteria;Firmicutes;Bacilli;Bacillales;unclassified;unclassified;|95
73_Bacteria;Firmicutes;Negativicutes;Selenomonadales;Veillonellaceae;Veillonella;|73
79_Bacteria;Firmicutes;Clostridia;Clostridiales;Ruminococcaceae;Flavonifractor;|100
80_Bacteria;Bact roidetes;Bacteroidia;Bacteroidales;Bacteroidaceae;Bacteroides;|100
84_Bacteria;Actinobacteria;Actinobacteria;Bifidobacteriales;Bifidobacteriaceae;Bifidobacterium;|100
94_Bacteria;Bacteroidetes;Bacteroidia;Bacteroidales;Prevotellaceae;Prevotella;|100
97_Bacteria;Firmicutes;Bacilli;Lactobacillales;Lactobacillaceae;Lactobacillus;|99
99_Bacteria;Actinobacteria;Coriobacteriia;Coriobacteriales;Coriobacteriaceae;Enterorhabdus;|100
138_Bacteria;Actinobacteria;Coriobacteriia;Coriobacteriales;Coriobacteriaceae;Collinsella;|100
174_Bacteria;Firmicutes;Bacilli;Lactobacillales;Streptococcaceae;Streptococcus;|99
182_Bacteria;Firmicutes;Bacilli;Lactobacillales;Streptococcaceae;Streptococcus;|100
228_Bacteria;Firmicutes;Bacilli;Lactobacillales;Carnobacteriaceae;unclassified;|76
271_Bacteria;Firmicutes;Bacilli;Lactobacillales;Lactobacillaceae;Lactobacillus;|98
299_Bacteria;Firmicutes;Clostridia;Clostridiales;Clostridiaceae_1;Clostridium_sensu_stricto_1;|100
302_Bacteria;Firmicutes;Bacilli;Lactobacillales;Lactobacillaceae;Lactobacillus;|92
306_Bacteria;Firmicutes;Bacilli;Lactobacillales;Lactobacillaceae;Lactobacillus;|91
383_Bacteria;Proteobacteria;Alphaproteobacteria;Rhodospirillales;Acetobacteraceae;Gluconobacter;|97
392_Bacteria;Firmicutes;Bacilli;Lactobacillales;Lactobacillaceae;Lactobacillus;|94
418_Bacteria;Firmicutes;Bacilli;Lactobacillales;Lactobacillaceae;Lactobacillus;|96
429_Bacteria;Firmicutes;Erysipelotrichia;Erysipelotrichales;Erysipelotrichaceae;Incertae_Sedis;|99
525_Bacteria;Actinobacteria;Actinobacteria;Bifidobacteriales;Bifidobacteriaceae;Gardnerella;|99
574_Bacteria;Firmicutes;Bacilli;Lactobacillales;Streptococcaceae;Streptococcus;|98
575_Bacteria;Firmicutes;Bacilli;Lactobacillales;Lactobacillaceae;Pediococcus;|78
602_Bacteria;Actinobacteria;Actinobacteria;Bifidobacteriales;Bifidobacteriaceae;Bifidobacterium;|84
610_Bacteria;Actinobacteria;Actinobacteria;Bifidobacteriales;Bifidobacteriaceae;Bifidobacterium;|98
0_Bacteria;Actinobacteria;Actinobacteria;Bifidobacteriales;Bifidobacteriaceae;Bifidobacterium;|100
1_Bacteria;Proteobacteria;Gammaproteobacteria;Enterobacteriales;Enterobacteriaceae;Escherichia-Shigella;|100
2_Bacteria;Firmicutes;Bacilli;Lactobacillales;Enterococcaceae;Enterococcus;|100
3_Bacteria;Firmicutes;Bacilli;Lactobacillales;Lactobacillaceae;Pediococcus;|100
4_Bacteria;Actinobacteria;Coriobacteriia;Coriobacteriales;Coriobacteriaceae;Collinsella;|100
5_Bacteria;Firmicutes;Bacilli;Lactobacillales;Streptococcaceae;Streptococcus;|100
6_Bacteria;Proteobacteria;Gammaproteobacteria;Enterobacteriales;Enterobacteriaceae;unclassified;|100
7_Bacteria;Firmicutes;Bacilli;Lactobacillales;Streptococcaceae;Streptococcus;|100
8_Bacteria;Firmicutes;Bacilli;Lactobacillales;Lactobacillaceae;Lactobacillus;|100
9_Bacteria;Firmicutes;Bacilli;Lactobacillales;Leuconostocaceae;Weissella;|100
10_Bacteria;Firmicutes;Bacilli;Lactobacillales;Lactobacillaceae;Lactobacillus;|100
11_Bacteria;Firmicutes;Bacilli;Lactobacillales;Lactobacillaceae;Lactobacillus;|82
12_Bacteria;Firmicutes;Clostridia;Clostridiales;Lachnospiraceae;Blautia;|82
13_Bacteria;Firmicutes;Bacilli;Lactobacillales;Lactobacillaceae;Lactobacillus;|100
14_Bacteria;Actinobacteria;Actinobacteria;Bifidobacteriales;Bifidobacteriaceae;Gardnerella;|100
15_Bacteria;Firmicutes;Clostridia;Clostridiales;Peptostreptococcaceae;Incertae_Sedis;|100
16_Bacteria;Firmicutes;Clostridia;Clostridiales;Lachnospiraceae;Blautia;|86
17_Bacteria;Firmicutes;Bacilli;Bacillales;Staphylococcaceae;Staphylococcus;|100
18_Bacteria;Proteobacteria;Alphaproteobacteria;Rhodospirillales;Acetobacteraceae;Gluconobacter;|97
19_Bacteria;Firmicutes;Erysipelotrichia;Erysipelotrichales;Erysipelotrichaceae;Incertae_Sedis;|100
20_Bacteria;Firmicutes;Clostridia;Clostridiales;Clostridiaceae_1;Sarcina;|100
21_Bacteria;Firmicutes;Clostridia;Clostridiales;Ruminococcaceae;Subdoligranulum;|100
22_Bacteria;Verrucomicrobia;Verrucomicrobiae;Verrucomicrobiales;Verrucomicrobiaceae;Akkermansia;|100
23_Bacteria;Firmicutes;Clostridia;Clostridiales;Lachnospiraceae;Dorea;|100
24_Bacteria;Firmicutes;Clostridia;Clostridiales;Clostridiaceae_1;Clostridium_sensu_stricto_1;|100
26_Bacteria;Firmicutes;Bacilli;Lactobacillales;Streptococcaceae;Streptococcus;|100
27_Bacteria;Actinobacteria;Coriobacteriia;Coriobacteriales;Coriobacteriaceae;Enterorhabdus;|72
28_Bacteria;Firmicutes;Clostridia;Clostridiales;Lachnospiraceae;Blautia;|92
29_Bacteria;Firmicutes;Clostridia;Clostridiales;Peptostreptococcaceae;Incertae_Sedis;|100
30_Bacteria;Firmicutes;Clostridia;Clostridiales;Ruminococcaceae;Faecalibacterium;|100
31_Bacteria;Firmicutes;Erysipelotrichia;Erysipelotrichales;Erysipelotrichaceae;Incertae_Sedis;|100
32_Bacteria;Firmicutes;Erysipelotrichia;Erysipelotrichales;Erysipelotrichaceae;unclassified;|100
34_Bacteria;Firmicutes;Clostridia;Clostridiales;Family_XI;Anaerococcus;|100
35_Bacteria;Firmicutes;Clostridia;Clostridiales;Lachnospiraceae;Incertae_Sedis;|89
36_Bacteria;Proteobacteria;Gammaproteobacteria;Enterobacteriales;Enterobacteriaceae;Yersinia;|100
37_Bacteria;Actinobacteria;Coriobacteriia;Coriobacteriales;Coriobacteriaceae;Eggerthella;|100
38_Bacteria;Firmicutes;Bacilli;Lactobacillales;Lactobacillaceae;Lactobacillus;|99
39_Bacteria;Firmicutes;Erysipelotrichia;Erysipelotrichales;Erysipelotrichaceae;Catenibacterium;|100
41_Bacteria;Firmicutes;Clostridia;Clostridiales;Peptostreptococcaceae;Incertae_Sedis;|100
43_Bacteria;Actinobacteria;Coriobacteriia;Coriobacteriales;Coriobacteriaceae;Olsenella;|95
44_Bacteria;Firmicutes;Clostridia;Clostridiales;Family_XIII;Mogibacterium;|100
45_Bacteri ;Actinobacteria;Actinobacteria;Actinomycetales;Actinomyc taceae;Actinomyces;|100
46 B illales;Alicyclobacillaceae;Tumebacillus;|100
47 t ri ;Actinobacteria;Actinobacteri ;Micro occ les;Microco caceae;Rothia;|100
48_Bacteria;Fir icutes;Bacilli;Bacillales;Family_XI;Gemella;|100
49_Bacteria;Firmicutes;Clostridia;Clostridiales;Peptostreptococcaceae;Peptostreptococcus;|100
50_Bacteria;Firmicutes;Bacilli;Lactobacillales;Lactobacillaceae;Lactobacillus;|100
51_Bacteria;Firmicutes;Clostridia;Clostridiales;Clostridiaceae_1;Clostridium_sensu_stricto_1;|97
53_Bacteria;Firmicutes;Bacilli;Lactobacillales;Lactobacillaceae;Lactobacillus;|100
54_Bacteria;Actinobacteria;Actinobacteria;Micrococcales;Micrococcaceae;Kocuria;|100
55_Bacteria;Firmicutes;Clostridia;Clostridiales;Lachnospiraceae;Dorea;|100
56_ acteria;Fir icutes;Bacilli;Lactobacillales;Leuconostocaceae;Leuconostoc;|100
57 t i ; i i t ;Negativicutes;Selenomonadales;Veillonellaceae;Veillonella;|
59 Firmicutes;Bacilli;Lactobac llales;Lactoba illaceae;Lactobacillus;|96
60 t i ; i i t ; l t i i ; l t i i l ;Rumi coccaceae;Butyricicoccus;|70
61_ acteria;Fir icutes; lostridia; lostridiales;Lachnospiraceae;Incertae_Sedis;|98
62_Bacteria;Fusobacteria;Fusobacteriia;Fusobacteriales;Fusobacteriaceae;Fusobacterium;|100
63_Bacteria;Firmicutes;Clostridia;Clostridiales;Lachnospiraceae;Incertae_Sedis;|94
64_Bacteria;Firmicutes;Bacilli;Lactobacillales;Lactobacillaceae;Lactobacillus;|100
65_Bacteria;Firmicutes;Clostridia;Clostridiales;Defluviitaleaceae;Incertae_Sedis;|99
66_Bacteria;Firmicutes;Clostridia;Clostridiales;Family_XIII;Incertae_Sedis;|86
67_Bacteria;Firmicutes;Bacilli;Lactobacillales;Lactobacillaceae;Lactobacillus;|99
68_Bacteria;Fir icutes;Bacilli;Lactobacillales;Streptococcaceae;Lactococcus;|100
71 t ri ; ir i t ;Bacilli;B cillales;unclassified;unclassified;|95
73 Firmicutes;Negativicutes;Selenomon dales;Veillonellaceae;Veillonella;|73
79 t i ;Firmicutes;Clostridia;Clostridiales;Ruminococcaceae;Flavonifr ctor;|100
80_ acteria;Bacteroidetes;Bacteroidia;Bacteroidales;Bacteroidaceae;Bacteroides;|100
84_Bacteria;Actinobacteria;Actinobacteria;Bifidobacteriales;Bifidobacteriaceae;Bifidobacterium;|100
94_Bacteria;Bacteroidetes;Bacteroidia;Bacteroidales;Prevotellaceae;Prevotella;|100
97_Bacteria;Firmicutes;Bacilli;Lactobacillales;Lactobacillaceae;Lactobacillus;|99
99_Bacteria;Actinobacteria;Coriobacteriia;Coriobacteriales;Coriobacteriaceae;Enterorhabdus;|100
138_Bacteria;Actinobacteria;Coriobacteriia;Coriobacteriales;Coriobacteriaceae;Collinsella;|100
174_Bacteria;Firmicutes;Bacilli;Lactobacillales;Streptococcaceae;Streptococcus;|99
182_Bacteria;Firmicutes;Bacilli;Lactobacillales;Streptococcaceae;Streptococcus;|100
228_Bacteria;Firmicutes;Bacilli;Lact bacill l ;Carnobacteriaceae;unclassified;|76
271_Bacteria;Firmicutes;Bacilli;Lactobacillales;Lactobacillaceae;Lactobacillus;|98
299_Bacteria;Firmicutes;Clostridia;Clostridiales;Clostridiaceae_1;Clostridium_sensu_stricto_1;|100
302_Bacteria;Firmicutes;Bacilli;Lactobacillales;Lactobacillaceae;Lactobacillus;|92
306_Bacteria;Firmicutes;Bacilli;Lactobacillales;Lactobacillaceae;Lactobacillus;|91
383_Bacteria;Proteobacteria;Alphaproteobacteria;Rhodospirillales;Acetobacteraceae;Gluconobacter;|97
392_Bacteria;Firmicutes;Bacilli;Lactobacillales;Lactobacillaceae;Lactobacillus;|94
418_Bacteria;Firmicutes;Bacilli;Lactobacillales;Lactobacillaceae;Lactobacillus;|96
429_Bacteria;Firmicutes;Erysipelotrichia;Erysipelotrichales;Erysipelotrichaceae;Incertae_Sedis;|99
525_Bacteria;Actinobacteria;Actinobacteria;Bifidobacteriales;Bifidobacteriaceae;Gardnerella;|99
574_Bacteria;Firmicutes;Bacilli;Lactobacillales;Streptococcaceae;Streptococcus;|98
575_Bacteria;Firmicutes;Bacilli;Lact bacill l ; tobacill ;Pediococcus;|78
02_Bacteria;Act nobacteria;Actinobacteria;Bifidobacteri les;Bifidobacteriaceae;Bifidobacterium;|84
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5.3.3 Fecal metabolome and inflammatory markers do not distinguish SAM 
from controls 
To obtain a global view of nutrient deficiency in SAM and gain insight into 
pathophysiology, we performed a comprehensive untargeted analysis of metabolites in 
stool from all 58 children using two different methods; gas chromatography-mass 
spectrometry (GC-MS) and liquid chromatography-mass spectrometry (LC-MS). 
Surprisingly, both methods yielded no metabolites significantly affected by SAM 
(Wilcoxon test, FDR corrected P > 0.1, Figure 5-3, Supplemental Table 5-4). There were 
also no significant differences in the inflammatory proteins calprotectin or lactoferrin, as 
measured by ELISA (Figure 5-4). 
 
	
	
	
SUPPLEMENTAL FIGURE 3. Principal component analysis (PCA) scoreplots of stool metabolome from children with 
SAM and controls as determined by LC-MS using positive (top) and negative (bottom) electrospray ionization (ESI). 
Components 1 and 2 are shown on the left with components 3 and 4 on the right. Each point represents a single sample 
from a single child. Positions of points display dissimilarities in the metabolome, with points furthest from one another 
being most dissimilar.	
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SUPPLEMENTAL FIGURE S2. Principal component analysis (PCA) plots of stool metabolome from children 
with SAM and controls as determined by LC-MS using positive (top) and negative (bottom) electrospray 
ionization (ESI). Components 1 and 2 are shown on the left with components 3 and 4 on the right. Each point 
represents a single sample from a single child. Positions of points display dissimilarities in the metabolome, with 
points furthest from one another being most dissimilar. 
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Figure 5-3. Principal component analysis (PCA) scoreplots of stool metabolome from 
children with SAM and controls as determined by LC-MS using positive (top) and 
negative (bottom) electrospray ionization (ESI).  
Components 1 and 2 are shown on the left with components 3 and 4 on the right. Each 
point represents a single sample from a single child. Positions of points display 
dissimilarities in the metabolome, with points furthest from one another being most 
dissimilar. 
 
Figure 5-4. Concentration of inflammatory proteins in stool of children with SAM 
compared to controls as measured by ELISA. 
 Each point represents a single sample from a single child. The boxes represent the 25th 
and 75th quartiles, and the line displays the median value within each group. Points 
extending beyond the lines are outliers defined as values greater or less than 1.5 times 
the interquartile range. 
5.3.4 Children with SAM have a distinct plasma metabolome 
In contrast to stool results, the abundance of approximately 15% of LC-MS features 
detected in plasma were significantly altered by SAM, where a “feature” represents a 
unique m/z and retention time value (Wilcoxon test, FDR corrected P < 0.1, Supplemental 
Table 5-5). Separation between groups was observed along the 3rd and 4th component of 
principal component analysis (PCA) plots built from LC-MS data (Figure 5-5), 
demonstrating the plasma metabolome of children with SAM is distinct from non-
malnourished children. The vast majority of differential features were detected 
exclusively by LC-MS, with only three metabolites differing significantly by GC-MS 
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SUPPLEMENTAL FIGURE S3. Concentration of inflammatory proteins in stool of children with SAM 
compared to controls as measured by ELISA. Each point represents a single sample from a single 
child. The boxes represent the 25th and 75th quartiles, and the line displays the median value within 
each group. Points extending beyond the lines are outliers defined as values greater or less than 1.5 
times the interquartile range
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(valine, leucine and aspartic acid). There were no metabolites that differed between 
children with non-edematous malnutrition (marasmus, N = 21) or edematous malnutrition 
(kwashiorkor, N = 26), and no significant effect of sex or age was observed (data not 
shown). 
 
Figure 5-5. Principal component analysis (PCA) plots of plasma metabolome from 
children with SAM and controls as determined by LC-MS using positive (top) or 
negative (bottom) electrospray ionization (ESI).  
Only components 3 and 4 are shown. The plots on the left display individual samples 
(scores). Each point represents a single sample from a single child. Positions of points 
display dissimilarities in the metabolome, with points furthest from one another being 
most dissimilar. Plots on the right display individual LC-MS features (loadings). Each 
ray represents a single LC-MS feature, with those significantly elevated in SAM or 
Po
si
tiv
e 
ES
I
Ne
ga
tiv
e 
ES
I
●
−50 0 50
−5
0
0
50
Individuals factor map (PCA)
Dim 3 (6.81%)
Di
m
 4
 (5
.8
8%
)
●
●
●
●
●
●
●
● ●
●
●
●●
●
●
●
●●
●
●
●
● ●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
SAM
Control
●
−1.0 −0.5 0.0 0.5 1.0
−1
.0
−0
.5
0.
0
0.
5
1.
0
Variables factor map (PCA)
Dim 3 (6.81%)
Di
m
 4
 (5
.8
8%
)
●
●
SAM
Control
●
−50 0 50
−5
0
0
50
Individuals factor map (PCA)
Dim 3 (8.45%)
Di
m
 4
 (6
.1
4%
)
●
●
●
●● ● ●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●●
● ●
●
●
●
SAM
Control
●
−1.0 −0.5 0.0 0.5 1.0
−1
.0
−0
.5
0.
0
0.
5
1.
0
Variables factor map (PCA)
Dim 3 (8.45%)
Di
m
 4
 (6
.1
4%
)
●
●
SAM
Control
Samples LC-MS features
●
−50 0 50
−5
0
0
50
Individuals factor map (PCA)
Dim 3 (6.81%)
Di
m
 4
 (5
.8
8%
)
●
●
●
●
●
●
●
● ●
●
●
●●
●
●
●
●●
●
●
●
● ●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
l
●
−1.0 −0.5 0.0 0.5 1.0
−1
.0
−0
.5
0.
0
0.
5
1.
0
Variables factor map (PCA)
Dim 3 (6.81%)
Di
m
 4
 (5
.8
8%
)
●
●
SAM
Control
●
−50 0 50
−5
0
0
50
Individuals factor map (PCA)
Dim 3 (6.81%)
Di
m
 4
 (5
.8
8%
)
●
●
●
●
●
●
●
● ●
●
●
●●
●
●
●
●●
●
●
●
● ●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
t l
●
−1.0 −0.5 0.0 0.5 1.0
−1
.0
−0
.5
0.
0
0.
5
1.
0
Variables factor map (PCA)
Dim 3 (6.81%)
Di
m
 4
 (5
.8
8%
)
●
●
SAM
Control
117 
 
Controls highlighted in black or red respectively (Wilcoxon test, FDR corrected P < 
0.1). 
 
5.3.5 Oxylipins, phospholipids and amino acids are depleted in the plasma 
of children with SAM 
Significant features in LC-MS data with greater than 2-fold change between SAM and 
controls were selected for further identification. As expected, free amino acids and 
dipeptides were lower in the plasma of children with SAM including glutamine, arginine, 
tyrosine, leucine, valine, and the tryptophan metabolite kynurenine (Figure 5-6A). A 
number of ether-linked single chain phospholipids belonging to the phosphatidylcholine 
(PC) and phosphatidylethanolamine (PE) families were also significantly decreased 
(Figure 5-6B). In addition,  there was a marked reduction in a number of oxylipins 
belonging to the eicosanoid and docosanoid family. In depth investigation of 
fragmentation patterns of these lipids revealed that each feature (represented as a single 
boxplot pair in Figure 5-6C) contained at least two different oxylipin species, differing 
only in the location of the hydroxyl group(s) (Figure 5-7). The precise species 
contributing to the differences between SAM and controls could therefore not be 
determined. Arachidonic acid (AA), a precursor to the eicosanoids was also significantly 
lower in children with SAM. While median abundance of docosahexaenoic acid (DHA, 
the precursor to the docosanoids), was lower in children with SAM, the difference was 
not significant (FDR corrected P = 0.2) (Figure 5-6). 
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Figure 5-6. Free amino acids/dipeptides (A), phospholipids (B), and oxylipins (C) 
significantly decreased in children with SAM compared to controls. 
> 2 fold change, Wilcoxon test, FDR corrected P < 0.1, with the exception of DHA 
which was not significant. Panels (A) and (B) were detected by positive ESI LC-MS 
and (C) by negative ESI LC-MS. Each point represents a single sample from a single 
child. The boxes represent the 25th and 75th quartiles, and the line displays the median 
value within each group. Points extending beyond the lines are outliers defined as values 
greater or less than 1.5 times the interquartile range. PC: Phosphatidylcholine, PE: 
Phosphatidylethanolamine. See Supplemental Table 5-5 for phospholipid identities. (*) 
Metabolite ID confirmed by authentic standards.
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FIGURE 3. Free amino acids/dipeptides (A) phospholipids (B) and oxylipins (C) significantly 
decreased in children with SAM compared to controls (> 2 fold change, Wilcox test, FDR corrected 
P < 0.1, with the exception of DHA which was not significant). Panels (A) and (B) were detected by 
positive ESI LC-MS and (C) by negative ESI. Each point represents a single sample from a single 
child. The boxes represent the 25th and 75th quartiles, and the line displays the median value within 
each group. Points extending beyond the lines are outliers defined as values greater or less than 
1.5 times the interquartile range. PC: Phosphatidylcholine, PE: Phosphatidylethanolamine. See 
Supplemental Table 5 for phospholipid identities. (*) Metabolite ID confirmed by authentic 
standards. 
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FIGURE 3. Free amino acids/dipeptides (A) phospholipids (B) and oxylipins (C) ignificantly 
decreased in children with SAM ompared to controls (> 2 fold change, Wilcox test, FDR corrected 
P < 0.1, with the exception of DHA which was not significant). Panels (A) and (B) were detected by 
positive ESI LC-MS and (C) by negative ESI. Each point represents a single sample from  single 
child. The boxes represent the 25th and 75th quartiles, and the line displays the median valu  within 
each group. Points extending beyond the lines are outliers defined as values greater or less tha  
1.5 times the interquartile range. PC: Phosphatidylcholine, PE: Phosphatidylethanolamine. S e 
Supplemental Table 5 for phospholipid identities. (*) Metabolite ID confirmed by authentic 
standards. 
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FIGURE 3. Free amino aci /di eptides (A) phospholipids (B) an  oxyli ins (C) significantly 
de reased in c ildren with SAM compared to controls (> 2 fold change, Wilcox test, FDR corrected
P < 0.1, with the exception of DHA which w s not significant). Panels (A) and (B) ere detected by 
positive ESI LC-MS and (C) by negative ESI. Each oint repre ents a si gle sample from a single 
child. The boxes repr ent the 25th and 75th quartil s, and the line displays the median v lu  within
each group. Points xtending beyond th  lines are outlier  define  as values gr ater or less than 
1.5 times t e interquartile range. PC: Phosphatidylcholine, PE: Phosphatidylethanolamine. See 
Supplemental Tabl  5 for phospholipid identities. (*) M tabolite ID confirmed by authentic 
standards. 
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Figure 5-7. LC-MS/MS spectra examples for oxylpin features containing two or more 
species
C20:4:1OH Eicosanoids M-H
MS/MS A
MS/MS B
C22:6:2OH Docosanoids M-H
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MS/MS B
Dihydroxybutyrates M-H
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MS/MS B
MS/MS C
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5.3.6 Metabolites elevated in plasma of children with SAM 
Unlike metabolites negatively associated with SAM, the classes of metabolites elevated 
in malnourished children were more diverse, and included sugars, peptides, lipids, short 
chain fatty acids and porphyrins, among others. Of interest, we detected a 2C6-
disaccharide by LC-MS in both positive and negative ionization modes that was 
significantly elevated in children with SAM (Wilcoxon test, FDR corrected P < 
0.1,Figure 5-9).  Authentic standards of different 2C6-disaccharides confirmed that our 
LC-MS measurements represented the total 2C6-disaccharides in plasma. Analysis of 
standards by GC-MS, which is able to resolve disaccharides, and LC-MS/MS determined 
that sucrose was the most abundant disaccharide in plasma, with smaller amounts of 
lactose and maltose also present. 
 
Two forms of truncated fibrinopeptide A (FPA) missing 2, or 3 N-terminal amino acids 
were also detected in significantly greater amounts in children with SAM. Specifically, 
des-AD (lacking N-terminal alanine and aspartate) and des-ADS FPA (lacking N-
terminal alanine, aspartate and serine) were both increased approximately 6-fold (Figure 
5-9). Intact FPA was outside the mass range of our initial analysis, and therefore  a 
second analysis was conducted with a larger mass range to include the intact FPA 
peptide. Surprisingly, the abundance of intact FPA was not significantly different 
between SAM and controls (Figure 5-8), indicating that the truncated forms are not 
simply a degradation product of increased intact FPA, but have some other unknown 
origin. 
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Figure 5-8. Comparison of intact fibrinopeptide A (FPA) and B (FPB) in plasma of 
children with SAM compared to controls measured using positive ESI LC-MS.  
Each point represents a single sample from a single child. The boxes represent the 25th 
and 75th quartiles, and the line displays the median value within each group. Points 
extending beyond the lines are outliers defined as values greater or less than 1.5 times 
the interquartile range. P > 0.1 Wilcoxon test, FDR corrected. 
 
Other metabolites of interest elevated in SAM included several acylcarnitines, the 
peptidehormone angiotensin I (Ang I), heme, lactate, oleoyl ethanolamide, 2,4 and 3,4- 
dihyroxybutyrate, an uncharacterized sphingoid base, a hydroxyvitamin D3 derivative 
and several other unknown compounds (Figure 5-9, Supplemental Table 5-5). 
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SUPPLEMENTAL FIGURE S5. Comparison of intact fibrinopeptide A (FPA) and B (FPB) in plasma of 
children with SAM compared to controls as measured by positive ESI LC-MS. Each point represents a 
single sample from a single child. The boxes epresent the 25th and 75th quartiles, and the line displays the 
median value within each group. Points extending beyond the lines are outliers defined as values greater or 
less than 1.5 times the interquartile range. p > 0.1 Wilcox test, FDR correct d. 
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Figure 5-9. Metabolites significantly elevated at least 2-fold in the plasma of children 
with SAM compared to controls (Wilcoxon test, FDR corrected P < 0.1).  
(Left) Metabolites detected using positive ESI LC-MS. (Right) Metabolites detected 
using negative ESI LC-MS. Each point represents a single sample from a single child. 
The boxes represent the 25th and 75th quartiles, and the line displays the median value 
within each group. Points extending beyond the lines are outliers defined as values 
greater or less than 1.5 times the interquartile range. FPA: Fibrinopeptide A, HTD: 3-
Hydroxy-cis-5-tetradecenoyl. (*) Metabolite ID confirmed by authentic standards. 
5.3.7 Assessment of biomarkers to discriminate SAM from controls 
To measure the strength of the association between biomarkers and SAM, the odds ratios 
(OR) was calculated based on conditional logistic regressions of all metabolites elevated 
in children with SAM (Supplemental Table 5-6).  2C6-disaccharides and lactate were 
among the metabolites with the highest OR, ranging from 2.25-2.20 respectively (Figure 
5-10A). ROC curves identified decanoylcarnitine, 2C6-disaccharides, an uncharacterized 
sphingoid base, angiotensin I, and heme as the metabolites that maximized the sensitivity 
and specificity for SAM, as shown by the area under the curve (AUC), which ranged 
 
 
FIGURE 4. Metabolites significantly elevated at least 2-fold in the plasma of children with SAM 
compared to controls (Wilcox test, FDR corrected P < 0.1). (Left) Metabolites detected using positive 
ESI LC-MS. (Right) Metabolites detected using negative ESI LC-MS. Each point represents a single 
sample from a single child. The boxes represent the 25th and 75th quartiles, and the line displays 
the median value within each group. Points extending beyond the lines are outliers defined as 
values greater or less than 1.5 times the interquartile range. FPA: Fibrinopeptide A, HTD: 3-
Hydroxy-cis-5-tetradecenoyl. (*) Metabolite ID confirmed by authentic standards. 
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compared to controls (Wilcox test, FDR corrected P < 0.1). (Left) Metabolites detected using 
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from 0.83- 0.81 for these compounds (Figure 5-10B, Supplemental Table 5-6
 
 43 
 
 
 
FIGURE 5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Decanoylcarnitine
Decanoylcarnitine
Decanoylcarnitine
Dihydroxybutyrates
 The American Journal of Clinical Nutrition AJCN/2016/135962 Version 1
119 
 
 
Figure 5-10. Evaluation of biomarkers to identify SAM from controls.  
(A) Odds Ratios as determined by conditional logistic regressions of all validated 
metabolites positively associated with SAM. Bars represent 95% confidence intervals. 
(B) Receiver Operator Characteristics (ROC) curves. Metabolites with the highest area 
under the curve (AUC) are shown. 
 
5.4 Discussion 
We hereby report the first LC-MS-based untargeted metabolomic study of stool and plasma 
from children with SAM. In contrast to the stool microbiota and metabolome, which did 
not discriminate SAM from controls, approximately 15% of the plasma metabolome, 
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equating to 585 features, were significantly altered by malnutrition. The explanation for 
the lack of differences in stool are likely multifaceted, but may include the large effect of 
diet and inter-individual variation which cannot be accounted for with small cross-sectional 
studies. It is also worth noting that feces represent the net result of nutrient consumption, 
digestion and absorption.  Malabsorption has been widely reported in SAM, and therefore 
it is possible that these children both consume and absorb fewer nutrients compared with 
non-malnourished controls, resulting in little net difference in stool nutrient composition.  
 
The stool microbiota data mirrored the metabolome results as neither the composition or 
diversity were significantly altered by malnutrition, even when children were matched for 
age. This is in contrast to previous studies that have observed differences in the relative 
abundance of specific taxa and diversity for age in twin pairs and unrelated controls 6,7. 
The relatively small number of controls in the study limited our ability to model the 
relationship between microbial diversity and age, and therefore it is possible that a larger 
sample size may have revealed significant differences. Our cohort also tended to be older 
than the children included in the study by Subramanian et al7, which could partially explain 
the lack of differences in the microbiota. As the microbiota has been shown to stabilize by 
around two years of age7, and a large proportion (41%) of the children in our study were 
two years or older, it is possible that the window where microbiota stunting is most 
apparent was not captured by our study. Additionally, none of the plasma metabolites 
affected by SAM were of clear microbial origin, providing further evidence that the 
microbiota may not be playing a major role in this particular cohort. 
 
Among the plasma metabolites discriminating SAM from controls, the total 2C6-
disaccharides had one of the strongest positive associations, as determined by ROC and 
OR analyses, and were detected in both positive and negative ionization modes. Regardless 
of their structure and content in the diet, disaccharides are not readily absorbed, and 
therefore must pass through the intercellular space of the intestinal mucosa to reach 
systemic circulation. For this reason, sucrose, cellobiose, lactulose and other disaccharides 
have been used as indicators of intestinal permeability26,27. Malabsorption and increased 
intestinal permeability are associated with SAM and EED, as measured by dual sugar 
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permeability tests such as the lactulose/mannitol test9. Despite  these tests being fairly 
reliable, the requirement for fasting prior to administration raises ethical concerns for 
children with SAM, and urine must be collected over several hours for accurate results. A 
non-administered permeability test, for which the total disaccharides are an attractive 
candidate, would therefore be highly valuable. 
 
Although elevated disaccharides are suggestive of enteropathy in the SAM group, we did 
not observe any difference in the inflammatory markers calprotectin or lactoferrin in stool. 
These proteins are used as indicators of inflammation in other pathologies such as 
inflammatory bowel disease28, but have not been evaluated as biomarkers of enteropathy 
in SAM. The weak correlation between lactoferrin and calprotectin (Spearman’s R = 0.33, 
P =0.01) limits our ability to make conclusions as to the intestinal inflammatory status of 
these children. Future studies evaluating the association of non-administered disaccharides 
with enteropathy are warranted to determine if they might also be useful in identifying 
EED. 
 
The majority of metabolites discriminating SAM from controls in plasma were nutrients 
depleted due to malnutrition. As expected, a number of amino acids/dipeptides were 
reduced, indicative of protein deficiency. Oxylipins were also significantly decreased, and 
to the best of our knowledge, have not been examined in children with SAM previously.  
Importantly, each oxylipin feature contained at least two different species, and therefore 
the number and diversity of oxylipins altered by SAM may be vastly under-represented by 
our study. Oxylipins are bioactive lipids formed by oxidation of long chain polyunsaturated 
fatty acids (LCPUFA), with the most well studied being the AA-derived eicosanoids 29. 
These bioactive lipids perform a wide array of functions, including tissue repair, blood 
clotting, and regulation of the immune system. Oxylipins within the same family can have 
similar or opposing effects (i.e. pro- or anti-inflammatory), and thus we cannot determine 
the precise biological consequence of reduced oxylipins during SAM29. However, as 
children with SAM exhibit an impaired immune response to a variety of pathogens 30, a 
lack of oxylipin mediators may be a contributing factor and warrants further investigation.  
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Previous studies have confirmed that children with SAM are deficient in LCPUFA31,32, 
including the oxylipin precursors AA and DHA. As a large proportion of LCPUFA are 
stored as acyl-linked phospholipids, which could not detectable by our method, a 
comparison of the total LCPUFA in our cohort was not possible. Nevertheless, the 
significant reduction in free AA, non-significant trend for lower free DHA, and significant 
decreases in multiple phospholipids and oxylipins are suggestive of LCPUFA deficiency 
in our cohort.  
 
Despite previous evidence of LCPUFA deficiency in SAM, the levels of LCPUFA in 
ready-to-use therapeutic food (RUTF) are low33. Recently, a RUTF formulation su-
pplemented with fish oil has been developed, which translated into increased LCPUFA in 
recipient children33. More studies are required to determine if the incorporation of fish oil 
into refeeding programs restores oxylipin levels as well and whether this leads to any 
clinical benefit.  
 
Apart from dietary deficiencies, other factors may also influence LCPUFA and oxylipin 
levels.  Children with SAM have decreased desaturase activity, resulting in decreased 
synthesis of AA and DHA from their precursors34,35. Additionally, a large proportion of 
dietary fatty acids are lost to beta-oxidation, a process that is induced during starvation36,37. 
A number of even-chain acylcarnitines, the bi-products of beta oxidation, were 
significantly elevated in children with SAM in our study. This suggests beta-oxidation of 
lipids may contribute in part to LCPUFA deficiency in SAM. Bartz et al4 found that even-
chain acylcarnitines, including the C10, C8 and C2 species identified in our study, 
decreased significantly upon nutritional intervention in children with SAM from Uganda. 
Acylcarnitines may therefore be useful not only as biomarkers of a malnourished state, but 
also as measures of treatment efficacy. 
 
The truncated FPAs were also biomarkers of interest as they are unique peptides of 
unknown origin and were elevated approximately 6 fold in SAM. The des-ADS form in 
particular has not been reported previously. FPA is a 16 amino acid peptide produced upon 
cleavage of the fibrinogen alpha chain by thrombin during the coagulation cascade. Thus, 
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it is an indicator of thrombosis, and is elevated in plasma during a number of inflammatory 
conditions including Crohn’s disease, gastric cancer, and coronary thrombosis38–40. As the 
intact peptide was not elevated in SAM, these fragments are not simply a result of increased 
inflammation and thrombosis, but have another unknown origin. One hypothesis is that 
they may arise from increased protease activity as proposed by Zhang et al41 who reported 
elevated des-A FPA in gastric cancer with lymph node metastasis. Protease activity is 
increased during starvation to supply the body with additional amino acids42, and therefore 
it is possible that these truncated forms are a consequence of this up-regulation. 
 
Angiotensin I (Ang I) was another peptide elevated in the SAM group. Ang I is the 
precursor to Ang II, a hormone directly involved in vasoconstriction and the renin-
angiotensin system (RAS). Ang II was also detected by our analysis and tended to be higher 
in children with SAM (average 4-fold increase), but did not reach statistical significance 
(FDR corrected P = 0.15). Children with SAM have higher blood pressure compared to 
controls43. In addition, , rats fed low protein diets exhibit increased expression of multiple 
components of the RAS system, including renin, angiotensin I converting enzyme (ACE) 
and angiotensin II type 1 receptors44,45. Together these results suggest increased expression 
of both the angiotensin hormones themselves and their receptors may contribute to 
vasoconstriction and increased blood pressure in SAM. 
 
Lactate was also elevated in the plasma of malnourished children, and was one the 
metabolites with the highest OR for SAM. Lactate is an endproduct of cellular respiration 
under anaerobic conditions, and is elevated in blood due to a number of etiologies, 
including anemia, sepsis, trauma, and malignancy46. In the context of malnutrition, 
elevated lactate may result from insufficient oxygen supply due to the anemia or increased 
infections associated with SAM. Interestingly, several studies have shown blood lactate to 
be a good predictor of mortality due to a variety of illnesses47–49, including a study of 
Tanzanian children with any febrile illness50.  Further research should evaluate lactate as a 
predictor of mortality in SAM. 
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Finally, we observed a significant increase in free iron (III) heme in the plasma of 
malnourished children. Heme is normally bound to hemeproteins, but is released under 
conditions of oxidative stress and as a result of hemolysis. Free heme causes tissue damage, 
systemic inflammation51,52, and exacerbates sepsis and malaria in animal models53,54. In 
humans, malaria severity correlates with the levels of free heme, and sepsis-related 
mortality is associated with decreased levels of the heme binding protein hemopexin54,55. 
These diseases frequently affect children with SAM in the developing world, and malaria 
in particular is significantly associated with malnutrition56,57. Elevated heme during SAM 
may contribute to increased severity of these infections, and therefore treatments targeting 
free heme may be beneficial. 
 
Our study has several limitations. Firstly, reliable information regarding other infections 
and pathologies was not available due to the limited local diagnostic facilities, so their 
possible impact on the microbiota and metabolome remains unknown. Children with 
malnutrition were also more likely to originate from rural settings, and therefore we cannot 
distinguish the role of environment from that of malnutrition. Also, although we identified 
clear differences in the plasma metabolome of children according to nutritional status, this 
was not the only source of variation. We speculate that other unaccounted for sources of 
variation may include time of sample collection as it relates to circadian rhythms58 and 
feeding time, diet and other environmental exposures, and/or the proximity of the plasma 
sampling to the plasma-red blood cell interface. The samples in this study were taken at 
random time points, with no requirements for fasting or feeding prior to collection. This 
may explain why we did not identify some of the classical signs of fasting, such as ketones 
elevated in the SAM group. However, our pragmatic collection method emphasized 
metabolites robust to external factors such as time of day and feeding. This strengthens the 
applicability of our findings to a clinical setting, where controlling for such variables may 
not be feasible. 
 
In conclusion, we have demonstrated that the plasma metabolome discriminates children 
with SAM from controls and identified a number of novel biomarkers of malnutrition, 
providing new insight into disease mechanisms and management. Future studies should 
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monitor these metabolites longitudinally during intervention to identify those most 
correlated with mortality and/or recovery. Validation of such biomarkers may enable better 
identification of children at highest risk of poor outcomes, the interventions they need most, 
and could provide a quantitative measure of treatment efficacy for a leading cause of 
childhood mortality worldwide.  
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Chapter 6 
6 Post-acquisition artifact filtering for LC-MS based human 
metabolomic studies 
McMIllan, A, Renaud, J, Gloor, GB, Reid, G, and MW, Sumarah 
This chapter is based on a manuscript currently under revisions for publication as a 
preliminary communication in The Journal of Cheminformatics. 
Supplemental Tables 6-(1-3) are available for download as additional files (.xlsx) 
6.1 Findings 
Untargeted metabolomics has a wide array of applications, from biomarker discovery to 
elucidating disease mechanisms, and characterizing the function of microbial communities. 
Of all available platforms, liquid chromatography-high resolution mass spectrometry (LC-
MS) is capable of detecting the widest range of metabolites. The resulting data from a 
single untargeted LC-MS experiment contains thousands of “features”, where each 
represents a single mass-to-charge ratio (m/z). Unlike other ‘omics’ fields, annotation of 
the complete metabolome is not realistic, and therefore efforts to identify features are 
focused on those selected via robust statistical approaches. A consequence of selective 
annotation is that the proportion of features originating from true metabolites versus 
background contamination or ionization source-generated artifacts remains unknown.  
Our recent work on the plasma metabolome of children with severe acute malnutrition 
prompted us to address this issue. In this dataset, statistical analysis identified 
approximately 300 features (positive and negative mode combined) which met our pre-
defined P value and fold change cut-offs (Wilcoxon test, FDR corrected P < 0.1, > 2 fold 
change, see Supplemental Table 6-1). However, upon further investigation, we noted that 
a large proportion of significant features were not endogenous metabolites, but rather salt 
clusters composed of potassium and/or sodium, with chloride and/or formate anions. 
Although most of these clusters eluted early in the void volume, their retention times 
overlapped with a number of metabolites of interest, indicating retention time alone is not 
a suitable filter to remove these source-generated artifacts (Figure 6-1). As the masses of 
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these clusters are not consistent across datasets, they cannot be removed based on m/z alone 
(data not shown).   
 
Figure 6-1. Retention time and m/z of plasma metabolites differing significantly 
between children with severe acute malnutrition and controls  
Wilcoxon test, FDR corrected P < 0.1, > 2 fold change. Salt clusters are shown in red, 
with validated metabolites colored according to their charge state. Data was acquired by 
positive ESI. 
Electrospray ionization in particular is a ‘soft’ ionization technique and is known to 
generate non-covalent complexes, including salt clusters, which can occur irrespective of 
the extraction method, solvent, column or platform used1–4. Salt clusters are derived from 
compounds present in the LC buffer and/or compounds present in the sample itself 
therefore, with the most commonly observed clusters consisting of combinations of small 
cations such as Na+ and/or NH4+ with chlorides and/or small organic acids, such has 
formate (HCOO-) and acetate (H3CCOO-)1. These salt clusters have m/z values with 
characteristically high mass defects, which for this work we simply define as the decimal 
numbers after the nominal mass. This is the result of the relatively high ratio of elements 
such as chlorine (34.9688527 Da), sodium (22.9897697 Da), potassium (38.963708 Da), 
and oxygen (15.9949146 Da), compared to hydrogen (1.007825 Da) and nitrogen 
(14.003074 Da). 
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When the mass defect of all endogenous or food-derived metabolites in the human 
metabolome database5 are plotted by m/z (Figure 6-2, Supplemental Table 6-2), only 0.39 
% of endogenous compounds fall within the mass defect space occupied by salt clusters, 
confirming the rarity of human metabolites with such high mass defects. 
Given the ubiquity of salt clusters in LC-MS data1–4, and their predictable mass defect, we 
developed a method to identify and remove salt cluster artifacts from untargeted LC-MS 
data using mass defect filtering. This comprised performing a linear regression of 
compounds with the highest mass defect in the human metabolome database (Figure 6-2), 
then modelling CnHn+2 alkanes, which represent the theoretical maxima mass defect for 
compounds containing only carbon, hydrogen, oxygen, and/or nitrogen. Both methods 
yielded the same linear equation (y=0.00112x + 0.01953). We then applied this equation 
to experimental datasets and removed features with mass defects greater than our model 
equation. Given there are a small number of endogenous metabolites in the human 
metabolome database with high mass defects, such as iodine containing thyroid hormones 
and triphosphates, we also incorporated an “inclusion list” into our model. Features in 
experimental datasets with the same m/z as compounds in this inclusion list (within a pre-
set error range) will be retained; ensuring known endogenous compounds are not removed 
with salt clusters. 
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Figure 6-2. Mass defect as a function of m/z for all endogenous and food-derived 
compounds between 50-750 m/z in the human metabolome database (hmdb, n=17957) 
compared to features detected experimentally in plasma (n=2227).  
The red line depicts the theoretical mass defect maxima for compounds containing only 
C, H, N and/or O (y=0.00112x + 0.01953). Features above this line which are present 
only in the experimental dataset are likely to be salt clusters or multiply charged as 
indicated by the arrows. Hmdb masses are shown as theoretical [M+H]. Experimental 
data was acquired by positive ESI, and contains a variety of adducts including but not 
limited to [M+H], [M+Na], [M+K] and [M+NH4], as well as isotopic peaks. 
 
To test the ability of our method to remove artifacts while retaining validated metabolites, 
we applied this filter to plasma data from the metabolomics study of severe acute 
malnutrition mentioned previously (Supplemental Table 6-1). Importantly, the metabolites 
of interest contained multiply-charged peptides, which were not modelled by the human 
metabolome dataset (Figure 6-2). Some of these peptides occupied the same mass defect 
space as the salt clusters, and therefore would be removed from the analysis by our original, 
‘mass defect only’ method (Figure 6-3A,B). However, using a C18 column, the salt clusters 
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elute in, or shortly after the void volume, while peptides are retained. We therefore 
incorporated retention time into the model as a third variable to further isolate the salt 
clusters. Incorporation of retention time removed all salt clusters while retaining all 
identified metabolites of interest, confirming the validity of the method (Figure 6-3C).  
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Figure 6-3. Significant metabolites (Wilcoxon test, FDR corrected P < 0.1, > 2 fold change) remaining in the malnutrition dataset 
after A. no filter, B. mass defect filter only, C, mass defect filter with retention time.  
Each point represents a single metabolite, colored according to their charge states, with salt clusters shown in red. Data was acquired by 
positive ESI. Singly-charged features encompass a variety of adducts including but not limited to [M+H], [M+Na], [M+K] and [M+NH4]. 
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We next applied the mass defect filter to all features detected in plasma (2227 in positive 
mode, 1742 in negative mode) to determine the percentage of features in the complete 
dataset with mass defects corresponding to salt clusters. This analysis revealed a large 
percentage (15.94% in positive mode, 28.82% in negative mode) of total features were 
likely salt clusters (Table 6-1).  
 
Table 6-1. Percent data reduction after mass defect filtering alone or in combination 
with retention time and hmdb inclusion list. All features detected in plasma in the 
malnutrition dataset are shown in both positive and negative ionization mode. RT: 
retention time, md: mass defect. 
ionization 
mode filter 
features 
remaining 
% features 
removed  
positive none 2227 0.00 
 md 1730 22.32 
 md+RT 1853 16.79 
 md+RT+inclusion 1872 15.94 
negative none 1742 0.00 
 md 1107 36.45 
 md+RT 1225 29.68 
 md+RT+inclusion 1240 28.82 
 
To determine if the proportion of salt clusters could be reduced instrumentally, and if they 
occurred in other biological matrices, we ran a series of tests comparing the effect of sweep 
gas and column type (reverse phase or HILIC) on salt cluster formation in a set of three 
plasma, urine and stool samples. The sweep gas did not significantly reduce the salt cluster 
proportion (Supplemental Table 6-3), although fewer features were detected overall, 
indicating lower sensitivity with this method. Surprisingly, the use of HILIC columns 
consistently increased the proportion of salt clusters (Figure 6-4, Supplemental Table 6-3), 
perhaps due to less ion suppression at later retention times where these salt clusters elute.  
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Figure 6-4. Effect of column type on salt cluster formation in plasma, urine and stool.  
The left and right panels display mass defect as a function of m/z for the same set of 
samples run on reverse phase or HILIC columns respectively. Data was acquired by 
positive ESI. 
 
Although salt clusters were identified in all sample types, they consistently occurred at a 
lower proportion in stool and urine compared to plasma. The use of K2EDTA tubes for 
blood collection in our study may be responsible for this observation. Barri et al.6 
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demonstrated that plasma collected with EDTA tubes had a significantly higher number of 
potassium clusters compared to heparin tubes, while citrate tubes resulted in more sodium 
clusters. These results indicate that salt cluster removal is applicable to stool, urine and 
plasma, but is particularly important for plasma collected with tubes containing salt-based 
anticoagulants. 
It is worth noting that our method was designed for studies pertaining to human physiology, 
and therefore synthetic compounds were not included in the analysis. Synthetic compounds 
such as drugs and pesticides, which are more likely to contain halogens7,8, can occupy the 
salt cluster mass defect space. Investigators concerned with these types of molecules may 
therefore wish to incorporate these masses in the inclusion list or refrain from applying this 
correction to their datasets. 
The advantage of removing artifacts prior to annotation and statistical analyses is three-
fold. Firstly, removing a large number of unknown features will allow for more complete 
annotation of the metabolome, and decreased reporting of false positives. Secondly, feature 
reduction may change the relationship between samples as determined by multivariate 
modelling methods such as principal component analysis. Most importantly, removing 
hundreds of features will affect the distribution of P values generated from univariate 
analyses. This has important implications for multiple testing corrections, such as the false 
discovery rate (FDR) and Bonferroni adjustment, which rely on this distribution (FDR), or 
on the total number of features compared (Bonferroni) for P value adjustment 9,10.  
In conclusion, we propose a method to filter out salt cluster artifacts in untargeted LC-MS 
data using mass defect and retention time. This filter can be easily applied to processed 
data using a set of R functions, and requires only a list of detected m/z and retention time 
values. The code for these analyses as well as example datasets are freely available at 
(https://github.com/amcmil/mz_defect_filter).  
6.2 Materials and Methods 
6.2.1 Metabolite extraction 
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For stool, approximately 250 mg of wet sample was lyophilized overnight. After drying, 
40 mg was weighed into microcentrifuge tubes and extracted with 8:2 methanol:H2O to a 
final concentration of 40 mg/mL. Samples were then vortexed for 30 sec, followed by 
centrifugation for 15 min at 10 000 rpm. Supernatant was then transferred to LC-MS vials 
for with micro-inserts for analysis. 
 
Metabolites were extracted from plasma according to the methods of Dunn et al, 201111. 
Briefly, plasma samples were thawed on ice for 30 min. Once thawed, 805 µL of 8:2 
methanol:H2O was added to 230 µL of plasma to make a 4.5 fold dilution. Samples were 
vortexed for 15 sec and centrifuged at 15 000 rpm for 15 min to pellet precipitated proteins. 
370 µL of supernatant was then transferred to separate vials and dried down for LC-MS 
using a speedvac with no heat. Samples were then reconstituted with 90 µL ddH2O and 
transferred to LC-MS vials with micro-inserts for analysis. 
For urine, 200 µL of sample was extracted with 800 µL 1:9 Acetonitrile:H2O as per the 
methods of Warth et al. 201212. After centrifugation, 500 µL of supernatant was transferred 
to LC-MS vials with micro-inserts for analysis. 
6.2.2 LC-MS analyses 
Samples were analyzed using an Agilent 1290 Infinity HPLC coupled to a Q-Exactive 
Orbitrap mass spectrometer (Thermo Fisher Scientific, Waltham, USA) with a HESI 
(heated electrospray ionization) source. For reverse phase HPLC, 2 µL of each sample was 
injected into a ZORBAX Eclipse plus C18 2.1 x 50mm x 1.8 micron column. Mobile phase 
(A) consisted of 0.1% formic acid in water and mobile phase (B) consisted of 0.1% formic 
acid in acetonitrile. The initial composition of 0% (B) was held constant for 30 s and 
increased to 100% over 3.0 min. Mobile phase B was held at 100% for 2 minutes and 
returned to 0% over 30s for a total run time of 6 min. For normal phase HPLC, 2 µL of 
each sample was injected into a ZORBAX RRHD HILIC plus 2.1 x 50mm x 1.8 micron 
column. Mobile phase (A) consisted of 0.1% formic acid in water and mobile phase (B) 
consisted of 0.1% formic acid in acetonitrile. The initial composition of 95% (B) was held 
constant for 30 s and decreased to 5% over 3.0 min. Mobile phase B was held at 5% for 1 
minute and returned to 95% over 30s and held for 1 minute for a total run time of 6 min. 
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Full MS scanning between the ranges of m/z 50-750 was performed at 140 000 res–olution. 
The HESI source was operated under the following conditions: nitrogen flow of 30 and 8 
arbitrary units for the sheath and auxiliary gas respectively, probe temperature and capillary 
temperature of 450 °C and 250 °C respectively and spray voltage of 3.9 kV and 3.5 kV in 
positive and negative mode respectively. The automatic gain control (AGC) target and 
maximum injection time were 1e6 and 500 ms respectively. For experiments testing the 
affect of sweep gas on cluster formation, sweep gas was set to 2 arbitrary units. Blanks of 
pure methanol were run between every sample to limit carryover. After data acquisition 
Thermo .RAW files were converted to .MZML format and centroided using 
ProteoWizard13. Files were then imported into R using the XCMS package14 for 
chromatogram alignment and deconvolution. Features were detected with the “xcmsSet” 
function using the “centWave” method and a ppm tolerance of 1. Prefilter was set to 3-
5000, noise 1E5, and signal to noise threshold was set to 5. Due to a lower overall noise 
and signal in negative mode, noise was set to 1E3 for this mode. Retention time correction 
was conducted using the “obiwarp” method, grouping included features present in at least 
one samples, allowable retention time deviation was 5 seconds, and m/z width set to 0.015. 
Areas of features below the signal to noise threshold in the data were integrated using the 
“fillPeaks” function with default settings.  
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Chapter 7 
7 General discussion 
The composition of the microbiome has only recently become accessible, resulting from 
advancements in NGS techniques. Due to the infancy of the field, as well as the cost of 
metagenomics/transcriptomics, the majority of microbiome studies to date have been 
limited to “who is there”. Metagenomics has become increasingly more affordable and 
common, but validation of predicted products is still extremely rare, and conclusions are 
usually drawn from metagenomics alone1–3. Our work on BV in Chapters 2 & 3 has 
discovered that many metabolites discriminating BV from health are of unknown origin 
(i.e. 2HV, GHB, 2-hydroxyisocaproate, 2-hydroxyglutarate), with the genes responsible 
for their production either being poorly characterized or completely unknown. Indeed, none 
of the above mentioned metabolites were predicted based on meta-transcriptome analysis4. 
Our work therefore serves as a cautionary tale for those tempted to draw sweeping 
conclusions from metagenomic data alone. As demonstrated by the case of the amines in 
BV, a single metabolite can have a large impact on phenotype5,6. Conversely, it is often 
overlooked that genes and transcripts identified by NGS experiments are merely 
predictions based on sequence similarity to genes whose functions have been proven 
experimentally. In the absence of classical microbiology methods, metabolomics offers 
some confirmation of these predictions. The findings within Chapters 2 & 3 highlight this 
fact, and advocate that a combination of techniques is absolutely necessary to obtain a 
complete picture of the function of microbial communities.  
7.1 The vaginal metabolome in BV 
Despite being the most common vaginal condition, the diagnostics for BV have remained 
stagnant for the past 25 years7. The current methods are time consuming and unreliable, 
prompting the search for new diagnostic biomarkers by our group. Upon commencement 
of my PhD studies there were no metabolomic studies of the vaginal environment. 
Though we were not the first to publish work on the vaginal metabolome8–10, the 
Rwandan study in Chapter 2 represents the largest study to date, and the only one to 
include pregnant women. We were also the first to identify GHB and 2HV as biomarkers 
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of BV11. These biomarkers have since been confirmed in two independent cohorts by 
other groups12, as well as in our own study of Canadian women in Chapter 3. Whether 
these metabolites play any functional role in BV is yet to be determined, however we 
have shown that they do not have any effect on growth of vaginal bacteria, nor do they 
effect cytokine production by vaginal epithelial cell lines stimulated with TNF-alpha 
(data not shown).  
 
Replication is an important aspect of these studies. Validation of biomarkers is 
encouraged in the metabolomics field and is often required by high impact journals13–16. 
This is due in part to the large number of variables analyzed in a single experiment, 
increasing the likelihood of false positives. The same could be said for microbiome data, 
however validation of findings within the same scientific article is extremely rare in this 
field. Given the high degree of irreproducibility among microbiome studies17,18, 
replication would be of enormous benefit, especially when the findings are controversial.  
 
The studies of the vaginal metabolome Chapters 2 & 3 have also allowed direct 
comparison of the three most common metabolomics platforms; NMR, GC-MS and LC-
MS. Although there was some degree of overlap between them, each method identified 
some degree of unique information. There were many metabolites which could be 
detected by all three methods, such was the case with 2HV, cadaverine, succinate, and 
many amino acids. In other cases, only one or two of the methods was able to detect a 
given metabolite. For example, trimethylamine was detected by NMR and LC-MS, but 
not GC-MS. Due to time constraints, the metabolites identified exclusively by LC-MS 
were not investigated for the Rwandan study, however this method would have 
uncovered the largest number of unique metabolites, as detection of large lipids, peptides, 
and poryphrins is possible19,20.  
 
An additional point of interest is the surprising amount of reproducibility in the 
metabolome between ethnicities and geographical locations. This undoubtedly arises 
from the highly conserved nature of the vaginal microbiota. Although the prevalence of 
certain taxa has been shown to differ between ethnicities, with African Americans having 
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a higher prevalence on BV associated bacteria21,22, the core vaginal microbiota is 
remarkably conserved worldwide. Indeed, in every instance, L. iners and L. crispatus 
dominate the microbiota of healthy women21,23–26. The reason for the dominance of these 
two species is still not well understood, but has led to the theory of universality necessary 
for human reproduction27. The findings in Chapter 4 suggest L. iners’ unique ability to 
bind fibronectin may be one of the many factors involved28,29. Interestingly, we found 
that women of African descent from Rwanda had a high prevalence of Lactobacillus 
species. Although recruitment was biased to include an equal number of women with and 
without BV, we were still not able to recruit enough women with BV in the time 
provided. This raises an interesting question as to weather the increased rates of BV in 
African American women are of genetic or environmental origin. Addressing this 
question will require further studies directly comparing African American with African 
women in an unbiased fashion, but could provide novel insight into the factors which 
shape the vaginal microbiota.  
7.2 Integration of metabolite and NGS data 
By marrying the metabolome and microbiome, we have shown in Chapters 2 & 3 that 
these data can identify biologically relevant species-product relationships. A surprising 
finding of this thesis was that correlations between metabolites and taxa and/or transcripts 
are relatively weak. This likely stems from multiple factors, including the high degree of 
co-occurrence between BV associated bacteria, as well as the fact that absolute 
abundance of bacteria and/or transcript cannot be measured by NGS approaches. 
Although we confirmed production of GHB by G. vaginalis in vitro and identified the 
putative enzyme in the transcriptome, the Spearman’s correlation between GHB and G. 
vaginalis was only 0.56 in the Rwandan study and 0.74 in the Canadian study. In the case 
of succinate and L. crisptatus, the relationship is even more convoluted by the fact that 
many organisms other than L. crispatus produce succinate. Despites these obstacles, we 
have shown it is possible to identify meaningful correlations armed with the knowledge 
of the system and data at hand.  
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This work has also highlighted the enormous amount of spurious correlations between 
these data. Conclusions based on these correlations should therefore be made with 
extreme caution. Ideally one would require multiple lines of evidence in addition to in 
vitro validation for confirmation of these species-product relationships. Due to the 
demanding nutritional and growth requirements of many vaginal isolates, the latter may 
not always be possible. This is the case for many environments, including the gut. The 
ability to culture the unculturable is thus an underappreciated yet essential piece to 
understanding the microbiome and its role in health and disease30. 
7.3 The microbiome and metabolome in malnutrition 
The malnutrition study in Chapter 5 created an opportunity to apply the methods 
developed in the earlier chapters to a more complex system. Contrary to previous 
studies31,32, we could not identify any significant differences in the microbiome of 
children with SAM compared to non-malnourished controls. While this could be a result 
of the modest sample size of our study, the lack of metabolites in plasma of clear 
microbial origin differentiating children with SAM from controls argues against this. We 
also explored correlations between the stool microbiome (16S) and stool metabolome in 
this dataset, and found these to be relatively weak (data not shown), consistent with what 
was found in the vaginal environment. This may be due in part to functional overlap 
between taxa, but may also be related to the compositional nature of NGS data as was 
discussed previously.  
 
Finally, this chapter highlighted the usefulness of an untargeted approach. Many of the 
plasma metabolites differentiating children with SAM from controls have not been linked 
to the condition previously (heme, oxylipins, truncated FPA and others), allowing 
generation of new hypotheses regarding the pathology of SAM in humans.  
7.4 Improving upon metabolomics methods 
A major aspect of this thesis was developing workflows for analysis of metabolomic data. 
This involved evaluation of various software available for metabolite integration, 
deconvolution and identification, as well as methods of visualizing these data. Although 
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many more software exist from the ones employed in this thesis, we found these 
(AMDIS33, Spectconnect34, Xcaliber, XCMS35, R36) to be most appropriate for our 
specific needs. In terms of metabolite annotation, we opted for a low throughput 
approach, with each metabolite being manually curated. For LC-MS, annotation is by far 
the most time consuming portion of analysis, creating a push for more automated 
methods. While there are software available which claim accurate annotation based on 
m/z and/or MS/MS (Mummuchog37, CSI-FingerID38, CFM-ID39, LipidBlast40), we found 
none of these to be as accurate as manual annotation. Indeed, in most cases the software 
either could not identify any plausible match, or returned false positives. Thus, although 
significant progress has been made in the area of metabolite annotation, there is much to 
be done before automated annotation is a reality. Despite the fact that automated 
annotation is not reliable in most cases, many studies continue to publish metabolomics 
data without the use of standards or even MS/MS data. This is concerning, especially 
given that many of these studies are multidisciplinary, with many of reader’s having 
expertise outside the chemistry field and therefore unable to critically analyze the work.  
 
As noted in Chapter 6, there is also an enormous amount of noise in LC-MS data, with 
the identity of most features in a given experiment remaining unknown. Separating the 
metabolites of biological origin from the noise is a key first step in making annotation of 
the complete metabolome feasible. We demonstrated in Chapter 6 that by utilizing 
intrinsic properties of salt clusters (mass defect), these artefacts can be easily identified 
and removed. Data reduction methods such as this will decrease reporting of false 
positives, impact multivariate modelling results as well as statistical analysis. 
7.5 Future directions 
There are many aims which could not be addressed during the time span of my PhD. An 
obvious, and I believe feasible goal is to develop a rapid diagnostic test for BV based on 
GHB, 2HV and/or their tyrosine ratios. GHB is a controlled substance41, which has 
driven the development of screening tests for specimens such as urine and hair, making 
this metabolite the most logical choice for BV diagnostics42,43. A rapid diagn–ostic test 
for GHB in urine does exist42, however the limits of detection are not likely within the 
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range of vaginal fluid. We estimate GHB concentrations to be in the range of 2µg/mL in 
women with BV, with currently available tests reporting limits of detection of 10µg/mL. 
Additional method work would therefore be required to produce a test sensitive enough to 
detect BV.  
 
Development of tests specific for an organisms and/or their metabolic by-products such 
as this may lead to more personalized treatments in the future. In the example of GHB 
and G. vaginalis, women with this organism may require an alternative treatment to 
someone dominate by BVAB1 for example. G. vaginalis is thought to be one of the more 
pathogenic organisms in BV due in part to sialidase production which breaks down the 
mucus layer of the vaginal epithelium, potentially contributing to the increased 
susceptibility to HIV44,45. Sialidase levels also predict preterm birth in a dose dependent 
manor in women with BV, and G. vaginalis supernatants directly stimulate HIV-1 
expression in vitro, providing further evidence for the role of this organism in adverse 
outcomes associated with BV46. Despite this knowledge, many clades of G. vaginalis are 
intrinsically resistant to the front-line treatment for BV, metronidazole47. It is therefore 
not surprising that the BV recurrence rates are high, and that alternative treatments are 
needed. Probiotics have been shown to be effective in increasing cure rates when 
combined with antibiotic treatment48,49, perhaps due in part to disruption of G. vaginalis 
biofilms by these organisms50,51. Alternative therapies such as this have yet to make their 
way into common practice, but undoubtedly will in the future given the increasing 
awareness of the benefits of probiotics52. 
 
Longitudinal sampling of the microbiome and metabolome of women with BV would 
also be highly valuable. If metabolic markers can be detected in advance of symptoms, 
treatment before onset may be possible. Further studies are required to determine if early 
treatment translates into reduced risk of co-morbidities associated with BV. At the very 
least, the unpleasant symptoms associated with the condition might be prevented, which 
would benefit those with recurrent BV most. Longitudinal analysis is also needed to 
determine how the metabolome varies with menstrual cycle. Other groups have 
demonstrated that the proportion of G. vaginalis increases significantly during menses53. 
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This observation suggests GHB levels may also increase during this time, creating the 
potential for false positives if diagnostics based on GHB are implemented.   
 
In terms of future directions for the malnutrition study in Chapter 5, replication is a key 
next step. Once metabolic changes due to SAM have been validated in an independent 
cohort, a number of avenues are worth following. The theory of non-administered 
disaccharides being indicative of enteropathy is an intriguing finding, and should be 
validated in animal models and humans by comparison to histology scores and dual sugar 
permeability tests respectively. Confirmation of these associations would be highly 
valuable, allowing children with enteropathy to be rapidly identified. Without such a 
method of identifying children with enteropathy, we cannot determine how this 
contributes to malnutrition, and evaluate treatments effective in reducing it.   
 
The reduction in oxylipins in children with SAM is also worth investigating to determine 
if reductions contribute to an impaired immune response. If oxylipin reduction is shown 
to result mainly from limited availability of long-chain polyunsaturated fatty acids 
(PUFAs) precursors, this would provide evidence for modification of the current 
nutritional interventions include higher levels of PUFAs. 
 
Metabolomics is a rapidly evolving field, and its application to microbiome studies holds 
much promise. This thesis has demonstrated how these data can be integrated to find 
useful information, whether it be in the form of disease biomarkers or improved 
understanding of microbial metabolism. It is my hope that some of these findings will one 
day be translated into clinical practice to improve the diagnosis, management and/or 
treatment of disease as this is the ultimate goal of medical research. 
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